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Adverse outcomes in schizophrenia are driven by physical ill-health, negative symptoms and 
neurocognitive decrements. Obstructive sleep apnoea (OSA) comorbid with schizophrenia 
may worsen these outcomes, because OSA is associated with adverse cardiovascular outcomes 
and cognitive impairment in general populations. High rates of obesity seen in people with 
schizophrenia makes it likely that OSA is highly prevalent in this population. There is minimal 
literature reporting robust prevalence estimates, clinical correlates or treatment outcomes of 
OSA in people with schizophrenia.  
Research addressing these gaps in the literature would be useful to determine the impact OSA 
has on adverse outcomes in schizophrenia, provide evidence to inform enhanced detection of 
OSA at the clinical level and quantify treatment outcomes that may be particularly relevant to 
schizophrenia. The aims of this thesis are to determine the absolute and relative prevalence of 
OSA in a cohort of people with schizophrenia compared to a matched population control group; 
undertake exploratory analysis to determine clinical associations with OSA in people with 
schizophrenia; prospectively determine whether diagnostic tools for OSA are accurate in 
people with schizophrenia; and whether continuous positive airway pressure (CPAP) treatment 
of OSA comorbid with schizophrenia is tolerable and associated with improvement in physical 
health and cognitive outcomes. 
The results of this thesis demonstrate that OSA is highly prevalent in schizophrenia occurring 
at a rate of 40%, which is at the higher end of previous prevalence estimates reported in selected 
populations that were systematically reviewed. Severe OSA was diagnosed in 27% of the 
cohort. In comparison to a general population cohort the relative risk of OSA in schizophrenia 
was 2.9 (95%CI 1.0-8.1, p=0.05). On adjusting for age and BMI the relative risk was reduced 
to 1.7 (95%CI 0.8-3.7, p=0.17), indicating that risk of OSA in schizophrenia is predominantly 
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driven by obesity. Exploratory analysis of clinical factors indicated that OSA was associated 
with reduced odds of employment, increased odds of cardiovascular disease and lower mean 
quality of life, independent living and psychological well-being scores. Diagnosis of OSA was 
not significantly associated with adverse psychopathological or cognitive outcomes. 
Prospective validation of OSA diagnostic tools indicated these had poor discriminatory value. 
In six participants with severe OSA CPAP treatment was well tolerated at six months of follow-
up with mean usage per night adequate for treatment effect. CPAP treatment was associated 
with normalisation of sleep architecture, mean 7.3kg of weight loss and improvement in 
cognition as measured by mean change in BACS total Z-score of 0.59. 
This thesis demonstrates that OSA is highly prevalent in schizophrenia. The main predictor of 
OSA appears to be excess rates of obesity, whilst general population screening tools perform 
poorly and are unlikely to be beneficial for clinical screening. OSA comorbid with 
schizophrenia is associated with adverse physical health and quality of life outcomes. 
Importantly treatment of OSA in people with schizophrenia is tolerable, effective and is 
associated with substantial weight loss and improvement in cognitive measures. These results 
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Key concepts and definitions 
Obstructive sleep apnoea: is a nocturnal breathing disorder characterised by repeated collapse 
and obstruction of the upper airway during sleep resulting in hypoxia, frequent arousal and 
disruption to normal sleep architecture. OSA arises as a combination of reduced muscle tone 
during sleep and extrinsic airway compression due to excessive soft tissue or structural features 
which give rise to a narrowed airway. Obesity, tobacco smoking and the use of alcohol increase 
the risk of OSA (Young et al., 2004). OSA is independently associated with a number of 
adverse physical health outcomes including hypertension, insulin resistance, ischaemic stroke, 
heart failure and cardiovascular disease (Epstein et al., 2009). Similarly, due to sleep 
fragmentation OSA is also associated with impaired neurocognitive function (Fulda et al., 
2001). OSA is diagnosed on the basis of demonstrating an apnoea hypopnoea index (AHI) of 
greater than ten events per hour using polysomnography (PSG). Severity of OSA is stratified 
based on AHI cut-offs: mild AHI 10-20 events/hr, moderate 20-30 events/hr and severe >30 
events/hr (Epstein et al., 2009). 
Multi-channel polysomnography (PSG): is a multi-parametric study that allows for 
comprehensive recording of physiological changes that occur during sleep and is the standard 
diagnostic measure for OSA (Epstein et al., 2009). PSG is recorded during sleep and can be 
performed in a sleep laboratory attended and monitored by a sleep technician or performed at 
home using portable equipment. Both methods have similar diagnostic accuracy for OSA 
(Gagnadoux et al., 2002). At a minimum PSG consists of twelve channels that record 
electroencephalogram (EEG), respiratory airflow, chin muscle tone, leg movements, eye 
movements using an electroocculogram (EOG), electrocardiogram (ECG) for heart rate and 
rhythm, oxygen saturation and abdominal/chest wall belts to measure inspiratory effort. 
Assessment of these combined parameters allow assessment of sleep architecture, 
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identification of apnoeas and hypopnoeas, body position during sleep, abnormal leg 
movements and scoring of sleep related parameters including an apnoea hypopnoea index 
(AHI) which defines the number of partial or complete apnoeas per hour of sleep. AHI is the 
diagnostic measure used to define OSA. Scoring and interpretation of PSG data is performed 
manually by sleep technicians and sleep physicians using standardised criteria published by the 
American Academy of Sleep Medicine (AASM) (Berry et al., 2015).  
Continuous positive airway pressure (CPAP): is a medical device that provides positive 
pressure ventilation throughout the respiratory cycle. CPAP consists of a mechanical flow 
generator, pressure hosing and a tight-fitting mask that delivers a constant supply of air above 
atmospheric pressure during sleep. Masks can be designed to fit over the nose or face to deliver 
air to the respiratory tract. By providing positive pressure during inspiration CPAP 
pneumatically splints the airway open, overcomes tissue forces that cause airway collapse and 
prevents the occurrence of obstructive apnoeas (Sullivan et al., 1981). CPAP is an effective 
treatment for OSA (Epstein et al., 2009). Use of CPAP is associated with reversal of daytime 
somnolence and improvement of sleep quality (Patel et al., 2003); improvement of 
hypertension and hyperglycaemia (Bratton et al., 2015; Iftikhar et al., 2013); and improvements 
in vigilance and related occupational outcomes (Pan et al., 2015). The pressure required to be 
delivered by CPAP is determined using a titration study which can either be performed in a 
monitored sleep laboratory or automated using at-home equipment. Titration studies monitor 
apnoea events at increasing CPAP pressures to determine the optimal pressure setting at which 
apnoea and hyponoea events are prevented during sleep. 
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Chapter 1: Literature review and rationale for subsequent 
chapters 
Introduction 
Schizophrenia is a chronic psychotic illness associated with devastating socio-occupational 
outcomes and severe physical health comorbidity. Adverse socio-occupational outcomes are 
driven primarily by negative and cognitive symptoms (apathy, cognitive impairment and social 
withdrawal) of schizophrenia that despite a plethora of antipsychotic drug options, remain 
resistant to treatment and represent a significant barrier to functional recovery (Fusar-Poli et 
al., 2015). Physical health comorbidity arises primarily due to the cardiometabolic side-effects 
of antipsychotic drugs (Correll et al., 2015), high rates of tobacco smoking (Myles et al., 2012) 
and poor lifestyle (unhealthy diet and lack of exercise) resulting in a 16-18 year reduction in 
life-expectancy due predominantly to an excess of cardiovascular disease (Laursen, 2011). 
Both outcomes represent an area of unmet clinical need. 
It is likely that obstructive sleep apnoea (OSA) is prevalent in schizophrenia because of high 
rates of the causative risk factors such as obesity and tobacco smoking. OSA may be relevant 
in schizophrenia because it both contributes to poorer physical health outcomes and cognitive 
decrements, and can result in symptoms arising from poor sleep which overlap with the 
negative symptoms of schizophrenia. Furthermore, OSA has a validated treatment, nocturnal 
continuous positive airway pressure (CPAP), which mitigates adverse outcomes of the illness. 
As such the link between OSA and schizophrenia represents a novel and interesting avenue for 
further research, especially considering the current dearth of evidence in this area. 
Currently there is minimal literature reporting on OSA in schizophrenia. Prevalence estimates 
are limited to small convenience samples using non-standard diagnostic measures. On the other 
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hand, there is no literature reporting on the physical health and psychiatric correlates of OSA 
comorbid with schizophrenia nor is there any evidence on the outcomes of OSA treatment in 
this population. Given these gaps in the literature the overall aims of this thesis are three-fold: 
firstly, to develop more robust estimates of OSA prevalence in schizophrenia; secondly to 
explore clinical and psychiatric correlates in this population to informs means of enhanced 
screening and detection; and thirdly to determine what impact treatment of OSA comorbid with 
schizophrenia has on physical health and psychiatric outcomes. 
Because of the cross-disciplinary nature of this thesis it is pertinent to first background some 
of the general concepts that form the basis of my thesis. Whilst schizophrenia, it’s 
symptomatology and adverse cardiometabolic outcomes are familiar to the majority of 
psychiatrists, the pathobiology, diagnostic nuances and management of sleep apnoea are 
unlikely to be familiar subject matter. In reference to cardiometabolic disease this lack of 
knowledge is likely to be particularly acute given that prior to beginning this thesis OSA was 
not mentioned in any clinical guidelines for the prevention of physical health morbidity in 
people with schizophrenia. Similarly, it is reasonable to assume that whilst sleep physicians 
are well acquainted with OSA and its management, they are unlikely to appreciate the unique 
symptomatic impact that OSA may have on psychiatric and physical health outcomes in people 
with schizophrenia. 
In one sense a key aim of this thesis is to bridge a knowledge gap between two seemingly 
unrelated disciplines in an attempt to inform novel strategies to improve functional recovery 
and the physical health of people with schizophrenia. This thesis follows in the footsteps of a 
wealth of recent literature addressing the physical health inequalities of people with 
schizophrenia and the responsibility psychiatrists have in managing risk factors for preventable 
cardiometabolic disease once considered outside of their field of practice (Lambert et al., 
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2009). In this context it is pertinent to recognise that siloing of expertise is likely to result in 
misconceptions or deficiencies in the literature or a lack of research translation between 
specialties. This is particularly relevant in mental health where treatment nihilism abounds and 
a psychiatric diagnosis has, and remains a barrier to effective medical care (Knaak et al., 2017). 
This literature review will first background the key concepts of schizophrenia and its 
relationship with cardiometabolic morbidity and negative symptoms. Subsequently OSA and 
its relationship with physical health morbidity and cognitive decrements will be discussed. 
Finally, a mechanistic relationship between schizophrenia and OSA will be discussed and 
recent literature reviewed. 
Schizophrenia and poor physical health 
Schizophrenia is a highly disabling psychotic illness that has an approximate 0.4% lifetime 
prevalence in the general population (Saha et al., 2005). It is a clinical diagnosis codified by 
the DSM-V and is defined by the presence of positive symptoms (delusions, hallucinations, 
disorganised speech and/or catatonia) with or without negative symptoms (social withdrawal, 
diminished emotional expression, apathy and poverty of speech) that have been present for 
greater than six months and result in socio-occupational impairment. Peak incidence occurs in 
adolescence and early adulthood (McGrath et al., 2008) with some suffering a chronic and 
relapsing course with incomplete remissions. People living with schizophrenia experience high 
levels of unemployment (Evensen et al., 2016), poor quality of life (Eack et al., 2007) and have 
a life expectancy 10-15 years less than the general population (Laursen, 2011). 
Apart from psychiatric symptoms, people with schizophrenia have mortality rates substantially 
higher than the general population. This differential mortality gap was first demonstrated by 
Saha and colleagues (2007) in a systematic review that demonstrated a standardised mortality 
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ratio (SMR) of 2.58 indicating that a person with schizophrenia has more than a doubling in 
risk of death compared to age and sex matched people in the general population. Further 
analysis indicates this differential mortality is driven by an excess of cardiovascular disease 
(SMR 1.79) and endocrine disease such as diabetes (SMR 2.63); and has worsened over time 
given higher SMRs reported over successive decades. Other literature has confirmed an excess 
of metabolic syndrome and cardiovascular risk factors in people with schizophrenia which is 
the primary driver of cardiovascular morbidity and mortality in this population. The metabolic 
syndrome refers to a cluster of related risk factors comprising abdominal obesity, hypertension, 
impaired insulin sensitivity, elevated triglycerides and reduced high density lipoprotein (HDL) 
cholesterol that promote cardiovascular disease. Data from the US CATIE study demonstrated 
that 42.7% of subjects met criteria for metabolic syndrome which equated to a relative risk of 
1.38 for men and 2.51 for women in comparison to the age-matched general population  
(McEvoy et al., 2005). Australian data has similarly indicated a prevalence of metabolic 
syndrome in people with psychotic illness of 54.8% (Galletly et al., 2012). Epidemiological 
evidence also demonstrates increased odds of hard cardiovascular endpoints in people with 
schizophrenia compared to the general population including diabetes, heart failure and stroke, 
and death from these outcomes (Curkendall et al., 2004). As such, people with schizophrenia 
have metabolic profiles similar to that seen in people 10-15 years older in the general 
population (Bobes et al., 2007). 
Lifestyle and medication drive cardiovascular disease in schizophrenia 
The determinants of increased cardiometabolic risk in people with schizophrenia are likely to 
be multifactorial. Firstly, traditional lifestyle factors play an important role. There is extensive 
evidence that people with schizophrenia engage in low rates of physical activity (Stubbs, Firth, 
et al., 2016) and have poor cardiorespiratory fitness compared to healthy controls 
(Vancampfort et al., 2017). Meta-analytic estimates suggest people with psychotic illness 
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spend up to eleven hours of their waking day undertaking no physical activity at all (Stubbs, 
Williams, et al., 2016). The determinants of physical inactivity are poorly understood but may 
correlate with lower socioeconomic status and the negative symptoms of psychotic illness 
(Vancampfort et al., 2017). Similarly, rates of smoking are extremely high in people with 
psychotic illness (Myles et al., 2012) and are up to three times that seen in the general 
population (Newcomer, 2007). Theories to account for this association include the lower 
socioeconomic status of people with schizophrenia, neurobiological vulnerabilities to nicotine 
dependence and use of nicotine as self-treatment for medication side-effects or symptoms of 
psychosis (de Leon et al., 2005). Some authors have noted an excess prevalence of family 
history of diabetes and cardiovascular disease in people with schizophrenia (Holt et al., 2006). 
Whilst this association may support shared genetic risk factors for schizophrenia and poor 
physical health it may also implicate intergenerational environmental factors.  
Aside from traditional lifestyle factors, a unique determinant of risk for cardiovascular disease 
in people with schizophrenia is long term treatment with antipsychotic medications that are 
known to promote weight gain and metabolic syndrome. Meta-analysis of data from 
randomised-controlled trials (RCTs) of 15 antipsychotic drugs found both first generation 
(FGA) and second generation (SGA) agents, apart from haloperidol, ziprasidone and 
lurasidone, were independently associated with weight gain to a varying extent (Leucht et al., 
2013). Subsequent analysis indicates that this effect is dose dependent and has a linear 
relationship with duration of exposure (Spertus et al., 2018). Various mechanisms have been 
posited to explain antipsychotic-induced weight gain. There is empirical evidence that 
olanzapine and clozapine alter leptin and ghrelin levels centrally resulting in a direct orexigenic 
effect (Lu et al., 2015), whilst antagonism of central 5-HT2C and H1 receptors correlate with 
increased weight gain due to direct orexigenic effects and sedation respectively (Henderson et 
al., 2015).  Antipsychotic drugs have also been demonstrated to directly dysregulate lipid and 
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glucose metabolism further compounding their effect on promoting impaired glucose tolerance 
and hyperlipidaemia independent of weight gain alone (Goncalves et al., 2015; Skrede et al., 
2012). 
Physical health comorbidity in schizophrenia is under-recognised and under-treated 
Despite overwhelming evidence of a disproportionate burden of cardiovascular risk factors, 
cardiometabolic disease and premature mortality, people with schizophrenia have historically 
accessed preventative health care and management of established disease at lower rates than 
the general population. There is an abundance of data indicating that the detection of physical 
health comorbidity is poor. One early US study that screened 2,090 inpatients with major 
mental illness indicated that 43% suffered one or more physical illnesses and that half of these 
diagnoses had not been contemporaneously identified in the primary healthcare or mental 
healthcare setting (Koranyi, 1979). Evidence of under-recognition is also reflected in more 
recent case-controlled primary care data from the UK (Smith et al., 2013) and the US (Carney 
et al., 2006) demonstrating people with schizophrenia have lower odds of diagnosis with 
ischaemic heart disease, hypertension, cardiac failure and peripheral vascular disease than the 
general population despite clear evidence of an excess prevalence of these diseases in screened 
populations. Interestingly registry data from Sweden (Crump et al., 2013) (where free universal 
access to healthcare reduces confounding influences) indicates that whilst people with 
schizophrenia had double the number of healthcare contacts and mortality from ischaemic heart 
disease, they were less likely than the general population to have a diagnosis of ischaemic heart 
disease prior to death. As such it can be inferred that people with schizophrenia are prone to 
inefficient and poor-quality preventative management of cardiovascular disease despite a clear 
preponderance of risk factors. This assumption also holds true for the management of 
established disease. One large US cohort study of people undergoing treatment for confirmed 
myocardial infarction demonstrated that schizophrenia conferred a 34% increase in twelve-
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month mortality, an association that became insignificant when the statistical model was 
adjusted for five quality indicators (Druss et al., 2001). Longitudinal Australian data also 
confirms an excess of cardiovascular morbidity in people with schizophrenia and demonstrates 
that hospitalisation, mortality and revascularisation rates for comorbid ischaemic heart disease 
had not diminished over time (Lawrence et al., 2003). The unfortunate healthcare experience 
for a person with schizophrenia has thus been the neglect of early detection and intervention 
followed by inequitable access to management of acute illness when severe symptomatology 
or life-threatening disease supervenes (Muck-Jorgensen et al., 2000). 
Cardiometabolic disease is ultimately preventable and thus it is unsurprising that access to 
primary prevention through management of risk factors has also been poorly available to 
people suffering schizophrenia. Data from a number of countries indicate that simple clinical 
measures are often neglected in the routine clinical care of people with psychotic illness. One 
large survey in the US noted that BMI and waist circumference were not recorded in 95% of 
patients with psychotic illness under routine primary care and mental health assessment 
(Buckley et al., 2005). Similarly, blood pressure was not routinely recorded in 45-65% of 
outpatients chronically treated with antipsychotic medications, whilst glucose and lipid 
monitoring were not performed in 60-65% and 70-75% respectively in the same population 
despite clinician awareness of risk (Barnes et al., 2007; Buckley et al., 2005; Newcomer et al., 
2004). A controlled study comparing metabolic monitoring between people prescribed 
antipsychotic medications for psychotic illness and antiretroviral medications for HIV (which 
have an analogous cardiometabolic side-effect profile) demonstrated similar figures for 
subjects with psychosis. Conversely this study reported over 90% compliance with monitoring 
for people on antiretroviral medications (Jennex et al., 2008) which highlights both the 
achievability of preventative monitoring and the inadequacy of simple medical care that people 
with schizophrenia encounter. Once cardiovascular risk factors have been established, people 
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with schizophrenia also experience significant under-prescribing as a means of secondary 
prevention. As an example, a large survey of people with psychosis in Australia reported that 
only 40% of people with established type two diabetes were prescribed hypoglycaemic 
medication, 52% with hypertension were prescribed blood pressure lowering medication and 
39% with hypercholesterolaemia were prescribed statins (Galletly et al., 2012).  
In regard to OSA more specifically, there may be unique barriers to both preventing risk factors 
for the development of OSA and accessing treatment for people with schizophrenia. Hesitancy of 
mental health clinicians to participate in physical health assessment in people with major mental 
illness may result in lack of detection or management of risk factors for OSA. Lack of integration 
between physical health and psychiatric services plays into this possible deficit and is an area of 
substantial need. Furthermore, in this setting there may be significant diagnostic overshadowing 
that further impairs recognition of physical health comorbidity. Unique to people with 
schizophrenia cognitive and psychosocial deficits arising from negative symptoms make it difficult 
to establish and maintain the lifestyle changes necessary to prevent OSA. In addition, psychiatrists 
may not see themselves as responsible for the institution of treatment for OSA nor be aware of 
evidence-based diagnosis and management pathways. 
Physical health guidelines in schizophrenia neglect OSA 
Recognition of the disproportionate burden of cardiometabolic risk and morbidity has led to an 
increasing concern amongst mental health clinicians in regard to physical health comorbidity 
(Correll, 2007), numerous editorialised calls to action (Crompton et al., 2010; Langan et al., 
2013) and an explosion of literature informing systematic and protocolised strategies for 
screening and preventative management at the clinical level. A large number of major society 
guidelines (American Diabetes Association, 2004; De Hert et al., 2009; National Institute for 
Health and Care Excellence, 2014) have been published describing specific monitoring 
protocols which have been systematically reviewed (De Hert et al., 2011). Generally, all of 
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these address identification and management of obesity, diabetes and hyperglycaemia, 
hyperlipidaemia, cardiovascular disease and hyperprolactinaemia. As a result, standardised 
protocols for anthropometric, glycaemic and lipid monitoring have been implemented widely 
in mental health services across Australia and internationally. Furthermore, these guidelines 
also provide evidence-based lifestyle and pharmacological strategies that are safe and effective 
at preventing cardiometabolic morbidity in this population (M et al., 2009). Although uptake 
of such strategies has been variable at a clinical and population level (Mitchell et al., 2012; 
Moeller et al., 2011; Morrato et al., 2010) there is at least an abundance of literature which has 
established a broad evidence base and translational research emphasis on recognition and 
management of these common risk factors in people with schizophrenia. 
Whilst the monitoring and management of weight gain, diabetes, hypertension and 
hyperlipidaemia have been extensively described in physical health guidelines for 
schizophrenia, strategies regarding OSA are neglected. At the time of writing this literature 
review, OSA had not been included in any major guidelines for the management of physical 
comorbidity in schizophrenia. This is despite risk factors such as obesity (Mitchell et al., 2013), 
tobacco smoking (Myles et al., 2012) and alcohol consumption (Moore et al., 2012), which are 
directly causative of OSA, being highly prevalent in people with schizophrenia. As discussed 
further below OSA is associated with secondary physical health morbidity, poor quality of life 
and neurocognitive changes that may remain under-recognised and unaddressed given the 
presumptive prevalence of OSA in people with schizophrenia. Further research is required to 
effectively incorporate OSA screening and management into schizophrenia management 
guidelines to further optimise preventive metabolic management of this population. 
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Sleep and its measurement 
In humans sleep-wake cycles are controlled by the circadian clock, which is a complex 
neurohormonal system that generates a 24-hour rhythm which is the primary regulator of sleep 
and wakefulness. Melatonin, secreted by the pineal gland, is the major signalling molecule that 
entrains an individual’s circadian rhythm. Secretion of melatonin is regulated by the sensory 
input of light from the suprachiasmatic nucleus and to a lesser extent other physiological and 
genetic factors (Farhud et al., 2018). The circadian rhythm influences the ideal timing of 
restorative sleep and is disrupted by non-environmental light (Schomerus et al., 2005) and 
unsynchronised socio-occupational behaviour such as shift-work (James et al., 2017). 
Disruption to circadian rhythms has a detrimental effect on physical and mental health being 
associated with an increase in depressive symptoms, cognitive impairment and increased risk 
of cardiovascular disease (Bedrosian et al., 2017; Ortiz-Tudela et al., 2014).  
Sleep is a highly regulated process that can be divided into various phases, based on 
electroencephalogram (EEG), electromyogram (EMG) and electrooculogram (EOG) data, 
which cycle in a normal pattern throughout a period of sleep. Broadly sleep can be divided into 
rapid eye movement (REM) and non-REM (NREM) sleep. In an awake alert individual EEG 
demonstrates a low-amplitude low frequency pattern defined as alpha waves. Initiation of sleep 
results in the establishment of NREM stage 1 (N1) sleep resulting in the loss of alpha rhythm 
and the development of lower frequency delta waves. Individuals awakened from N1 sleep are 
subjectively unaware of being asleep. N1 sleep quickly transitions to NREM stage 2 sleep (N2) 
characterised by persistence of delta waves interrupted by sleep spindles and K-complexes. 
Sleep spindles denote burst-like episodes of oscillatory activity lasting greater than 0.5 seconds 
which presumably function in the consolidation of long-term memory through the integration 
of new information into existing knowledge (Tamminen et al., 2010) and the directed retention 
or discarding of existing memory (Saletin et al., 2011). K-complexes consist of a brief high 
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voltage biphasic waves recorded predominantly over the frontal cortex; these are proposed as 
a mechanism to prevent cortical arousal (and wakefulness) during sleep and also to strengthen 
synaptic pathways established during the preceding period of wakefulness (Cash et al., 2009). 
N2 sleep is followed by NREM stage 3 (N3) sleep (also termed slow wave sleep (SWS)) 
characterised by high voltage low amplitude waves termed delta waves. The N3 stage may be 
associated with dreaming and functions as the restorative period of sleep that may also promote 
the consolidation of long-term memory. Generally skeletal muscle tone reduces progressively 
throughout subsequent phases of NREM sleep. REM sleep is a unique phase of sleep 
characterised by random or rapid movement of the eyes (detected by EOG) with complete 
skeletal muscle paralysis accompanied by alpha waves on EEG. The function of REM sleep is 
poorly understood (Shrivastava et al., 2014), but is associated with vivid dreaming and a 
propensity to brief waking with lucid recall of dream subject matter (Hobson et al., 2000). 
Normal sleep undergoes ultradian cycling with initial descent from N1 to N3 sleep followed 
by alteration between NREM and REM sleep every 60-90 minutes for the duration of sleep. 
Generally, the bulk of N3 sleep occurs during the early period of sleep with REM sleep 
occurring during the later period of sleep. The biological relevance of this ultradian rhythm is 
unknown. A pictorial representation of sleep phases in comparison to EEG data is presented in 
figure 1. 
Clinical and symptomatic measurement of sleep 
Self-reported questionnaires are frequently used to measure subjective quality of sleep with the 
most commonly used tools being the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 
1989) and Epworth Sleepiness Scale (ESS) (Johns, 1991). Importantly these tools are not a 
screening test for clinical diagnosis of a sleep disorder, but are rather designed as research, 
population health or clinical tools for identification of sleep disturbance or daytime somnolence 
that deviates from the normal population.  
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Figure 1: EEG sleep data in comparison to sleep stages (Carley, D.W. and Farabi, S.S., 
2016) American Diabetes Association (2020) with permission. 
The PSQI is the most widely used measure in clinical and research settings (Mollayeva et al., 
2016) and was originally developed in 1988 in a cohort of patients with major depression as a 
standardised method of differentiating those with good and poor-quality sleep. It applies to 
sleep symptoms in the last month and consists of nine questions that are summated into seven 
subscale scores and an overall score between 0-21. The subscale scores individually assess 
sleep duration, latency, disturbance, efficiency, quality; daytime impairment and use of 
hypnotic medication. A total score of greater than five defines poor sleep quality. The PSQI is 
useful in that it has been validated across a number of clinical and non-clinical populations 
(Mollayeva et al., 2016), including cohorts with schizophrenia (Ritsner et al., 2004). However, 
there is some evidence that subscale scores may be of more relevance in the assessment of 
people with schizophrenia (Faulkner et al., 2019) rather than the total score due to the 
prominence of circadian rhythm disturbance in this population (Pritchett et al., 2012) and 
differences in aligning sleep with socio-occupational expectations between the general 
population and people with schizophrenia (Faulkner et al., 2017).  
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The ESS is another widely used questionnaire which was first described in 1990 and developed 
as a means of identifying abnormal daytime sleepiness. It was developed in a group of 150 
people with a variety of diagnosed sleep disorders and compared to a control group of 30 
(Johns, 1991). It consists of eight questions with a score greater than ten being indicative of 
excessive daytime sleepiness. The ESS has been validated across a large number of populations 
(Chan et al., 2009; Izci et al., 2008; Manni et al., 1999), but has not been specifically validated 
in populations with schizophrenia. In terms of external validity the ESS is shown to have 
moderate correlation with measures of psychological symptom severity (Olson et al., 1998), is 
moderately predictive of a diagnosis of OSA (Manni et al., 1999), and is strongly predictive of 
a diagnosis of narcolepsy (Parkes et al., 1998) but correlates poorly with objective measures of 
daytime sleepiness such as the median sleep latency time (MSLT) (Chervin et al., 1997; Johns, 
1992). In schizophrenia the questions used in the ESS may lack internal validity given that 
people with schizophrenia may not partake in the activities queried due to low rates of 
employment and socio-occupational disadvantage. As such it is important that sleep symptom 
scores reported in people with schizophrenia be interpreted in this context and with a broader 
caveat that these scores correlate poorly with more objective measures of architectural sleep 
disturbance. 
Scoring systems also exist for the purpose of determining risk or as a surrogate diagnostic tool 
for various sleep disorders. There are a large number of screening tools developed to diagnose 
OSA – these include the Berlin (Netzer et al., 1999), OSA50 (Chai-Coetzer et al., 2011), STOP-
BANG (Chung, Subramanyam, et al., 2012) and Wisconsin Sleep (Young et al., 1993) 
questionnaires. Generally, these questionnaires utilise combinations of self-reported and 
partner-reported snoring or apnoeas, obesity or increased neck circumference and symptoms 
of daytime sleepiness as criteria to generate a score which is then dichotomised to a binary 
diagnostic outcome. These tools have been recently systematically reviewed by the US 
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Preventative Services Task Force, which concluded that currently there is insufficient evidence 
that any published tool has sufficient accuracy to be of benefit in screening general populations 
for OSA (Gamaldo et al., 2018). As such these tools are useful only for the identification of 
subjects in selected groups who would benefit from further diagnostic assessment, not as a 
measure of diagnosis alone. Of relevance to this thesis, no published diagnostic tool has been 
validated in cohorts of people with schizophrenia, making their clinical value in this situation 
even less clear and their use for population estimates of OSA prevalence unreliable. 
Objective measurement of sleep 
The most objective measure for assessment of sleep is multichannel PSG and actigraphy which 
allow for unambiguous quantitative measures of sleep architecture and circadian rhythm. The 
commonly reported parameters for PSG are outlined in table 1. PSG involves the measurement 
of oxygen saturation, EEG, EOG, ECG, body position, nasal air flow, limb movement and 
abdominal and thoracic inspiratory effort and allows for the objective measurement of sleep 
architecture and respiratory parameters during sleep. EEG data collected during PSG also 
allows for the measurement of various parameters, that whilst not diagnostic of a sleep disorder, 
are associated with a variety of cognitive and psychological outcomes in health and disease. 
Actigraphy involves use of a wearable accelerometer to record movement over 24 hours 
periods and derive periods of activity versus inactivity based on sustained acceleration above 
a threshold. These periods, or epochs, reliably correlate with physical activity/inactivity, onset 
of sleep and onset of wakefulness with the generated data able to report parameters such as 
total sleep time, sleep efficiency, number of nocturnal awakenings, sleep latency and sleep-
wake cycling. Whilst actigraphy measurements are moderately correlated with diagnosis of a 
sleep-disorder, they are not a substitute for PSG and have most benefit in objectively assessing 
insomnia, circadian rhythm dysregulation and side-effects of hypnotic or sedative drugs 
(Ancoli-Israel et al., 2003). Furthermore, there is moderate quality evidence that sleep 
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disturbance as measured by actigraphy in populations with psychiatric illness correlates with 
psychiatric outcomes (Ancoli-Israel et al., 2003). As an example, one cohort study of 28 people 
with schizophrenia demonstrated that circadian rhythm, mean daytime activity levels and 
nocturnal awakening were significantly disrupted in comparison to a control cohort. Similarly, 
day-time napping, poor sleep efficiency and mean nocturnal awakenings correlated strongly 
with overall neuropsychological function in those with schizophrenia (Martin et al., 2001). 
Sleep in schizophrenia 
Before discussing the pathophysiology of OSA and its possible relationship to schizophrenia, 
it is first pertinent to review the sleep symptoms and architectural changes in sleep experienced 
by people with schizophrenia more generally. Mechanistically objective alterations in sleep or 
the subjective experience of sleep symptoms may be driven by both neurobiological changes 
intrinsic to schizophrenia and the pharmacodynamic effects of antipsychotic medications. As 
such it is important to consider the sleep outcomes experienced by people with untreated 
schizophrenia in comparison to those with established disease who are taking antipsychotic 
medications.  
It is likely that the relationship between sleep disturbance and psychotic symptoms is 
bidirectional. There is good quality evidence that sleep deprivation and disturbance provokes 
subclinical psychotic symptoms in normal populations (Hennig et al., 2018; Scott et al., 2017). 
Similarly, actigraphic measures of sleep disturbance and circadian rhythm disturbance have 
been demonstrated to predict the development of positive symptoms and overt psychosis in 
adolescent populations at ultra-high risk of psychosis (Lunsford-Avery et al., 2017; Lunsford-
Avery et al., 2015). In established disease, measures of sleep disturbance are also shown to 
worsen after antipsychotic drug withdrawal and predate overt psychotic relapse (Chemerinski 
et al., 2002). As a corollary objective PSG measures of REM sleep disruption correlate with 
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longitudinal psychiatric outcomes and global functioning after one year of treatment for 
recently diagnosed schizophrenia (Goldman et al., 1996). Similarly, treatment of sleep 
disturbance is effective at reducing psychotic symptomatology of paranoia and hallucinations 
as demonstrated in a large randomised controlled trial (RCT) of cognitive behavioural therapy 
for treatment of insomnia (Freeman et al., 2017). Taken as a whole these observations suggest 
that sleep disturbance is a core feature of schizophrenia and mirrors current psychosis 
symptomatology, whilst also being a risk factor itself for the development or worsening of 
psychotic symptomatology.  
Whilst not a diagnostic criterion per se, sleep disturbance in schizophrenia is consistently 
reported with subjective sleep symptoms being highly prevalent. One cohort study of 214 men 
with treatment naïve schizophrenia reported that 63% described persistent ‘sleep loss 
symptoms’ which included difficulty maintaining sleep, early waking and trouble initiating 
sleep (Sweetwood et al., 1976). Other cohort studies of patients treated with antipsychotic 
drugs have reported lower rates of sleep disturbance of between 32-37%  (Haffmans et al., 
1994; Serretti et al., 2004), which may reflect an effect of antipsychotic treatment in 
ameliorating positive symptoms that contribute to sleep disruption (Krystal et al., 2008). 
Standardised measurement of sleep in people with schizophrenia also demonstrates significant 
sleep disturbance in this population. Royuela et al. (Royuela et al., 2002) assessed 
 
 
Table 1: Common PSG parameters, definition according to AASM criteria and clinical or diagnostic relevance (Berry et al., 2015) 
Sleep parameter Definition Clinical relevance 
Sleep measures 
Sleep onset latency (SOL) Time from lights off to 10 consecutive minutes 
of stage 2 sleep (in minutes) 
Measure of vigilance or degree of day-time sleepiness. Repeated testing is termed 
median sleep latency time (MSLT) which is gold-standard diagnostic tool for 
narcolepsy and idiopathic hypersomnia. Sleep latency is reduced when a subject is 
increasingly sleepy. 
Total sleep time (TST) Minutes of sleep during recorded period of sleep May be reduced or prolonged by variety of pathological factors. Differing normal 
ranges for ages, total sleep time reduces with increasing age. 
Sleep efficiency index (SEI) Total time spent asleep per time period of 
recording (expressed as percentage) 
Normal sleep efficiency index is >80%. Reduced with frequent awakenings during 
the night. Reduced sleep efficiency is an indicator of non-restorative sleep. 
Arousal index (AI) Number of arousals or awakenings per hour Arousals are caused by disruption to sleep may be due to primary sleep fragmentation 
or because of apnoeas causing arousal due to hypoxia. 
N1 Time (in minutes) or percentage of total sleep 
time in stage 1 sleep 
Transition between wakefulness and sleep. Reduced with excessive sleepiness. 
Normal range in adults is ~5% of total sleep. 
N2 Time (in minutes) or percentage of total sleep 
time in stage 2 sleep 
First stage of true sleep. Accounts for ~50% of total sleep in adults. Increasing N2 is 
an age-related change and also seen with some medications. Reduced due to sleep 
fragmentation or increased N3 or REM sleep. 
N3 (also termed slow wave sleep 
(SWS)) 
Time (in minutes) or percentage of total sleep 
time in stage 3 sleep 
Deep restorative sleep. Accounts for ~20% of total sleep in adults. Predominates in 
first third of the night. Increases after sleep deprivation and with hypnotic/sedative 
medications. 
REM Time (in minutes) or percentage of total sleep 
time in REM sleep 
Function of REM sleep uncertain. Accounts for ~25% of total sleep in adults. 
Suppressed by alcohol, tricyclic antidepressants and amphetamines. Increased REM 
occurs during treatment of OSA. 
REML Time (in minutes) from initiation of N1 to first 
REM epoch 
Reduced REML is seen in withdrawal from antidepressant drugs and alcohol, clinical 




Sleep parameter Definition Clinical relevance 
Respiratory measures 
Hypopnoea 10 seconds of reduced nasal airflow with 
accompanying oxygen desaturation 
Seen in OSA and central causes of sleep apnoea (i.e. reduced central nervous 
respiratory drive) 
Apnoea 10 seconds of complete cessation of nasal 
airflow 
Seen in OSA and central causes of sleep apnoea (i.e. reduced central nervous 
respiratory drive) 
Apnoea hyponoea index (AHI) Number of apnoeas and hypopnoeas during each 
hour of PSG recording 
Diagnostic measure of OSA 
Respiratory effort related arousal 
(RERA) 
Reduction in nasal airflow with increased 
respiratory effort and arousal without oxygen 
desaturation 
Seen in OSA 
Respiratory disturbance index 
(RDI) 
Number of apnoeas, hypopnoeas and RERAs 
per hour of PSG recording 
Alternative diagnostic measure of OSA 
Oxygen desaturation index (ODI) Number of 3% oxygen desaturation events per 
hour of PSG recording 
Indicator of apnoea or hypopnoea, but unable to differentiate central versus 
obstructive causes. May be used as a screening test for OSA. 
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44 people with treated schizophrenia with the PSQI in comparison to a general population 
control group. Mean PSQI was elevated in the schizophrenia group compared to the control 
group (mean PSQI 6.6 versus 4.5, p<0.01) which was accounted for by significant elevation of 
sleep latency, sleep duration and hypnotic drug use subscales. Interestingly, sleep disturbance 
was not significantly elevated in the schizophrenia group. These findings suggest that people 
with schizophrenia spend more time in bed and have poor sleep efficiency, but do not 
subjectively recognise nocturnal interruption to sleep or report excessive daytime somnolence. 
A similar cohort study in a mixed first episode psychosis (FEP) and chronic schizophrenia 
cohort of 100 people reported ESS and PSQI with comparisons across the two groups (Sharma 
et al., 2016). PSQI aggregate scores were elevated in 83% of the total cohort, whilst ESS scores 
were only elevated in 32%. In contrast with previous studies, elevated PSQI scores were 
significantly higher in the chronic cohort compared to the FEP cohort whilst mean duration of 
illness was significantly higher in those with an elevated PSQI compared to those without 
across the entire cohort. These findings were not replicated with the ESS data.  
On the whole, the literature reporting symptom data indicates that sleep disturbance, as 
measured by difficulty initiating efficient sleep, is highly prevalent in people with 
schizophrenia. However, there are inconsistencies in whether these symptoms improve or 
worsen with duration of illness or initiation of antipsychotic treatment. Interestingly, whilst 
sleep disturbance is common this does not necessarily translate into a measurable signal on 
standardised assessment of daytime somnolence using PSQI subscales or the ESS which may 
reflect a lack of symptomatic awareness of these symptoms by people with schizophrenia or 
alternatively that these tools perform poorly in this population. 
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Objective sleep disturbance in schizophrenia  
The clinical observation of sleep symptoms in schizophrenia has led to the development of 
extensive literature reporting PSG data in people with schizophrenia compared to healthy 
controls. This literature has been extensively reviewed with three meta-analyses published 
reporting architectural sleep alterations in newly diagnosed, medication-withdrawn and 
medication treated patients with schizophrenia  (Benca et al., 1992; Chan et al., 2017; 
Chouinard et al., 2004).  In summary these meta-analyses have some broadly comparable 
findings but also key differences as a result of inclusion criteria, specifically whether 
schizophrenia cohorts were antipsychotic naïve or exposed, and statistical heterogeneity across 
the included studies. The most recently published meta-analysis (Chan et al., 2017) reported 
aggregate effect size data indicating prolonged sleep onset latency and N1, and reduced N3, 
REM sleep latency, total sleep time and sleep efficiency index in cohorts with schizophrenia. 
Restriction of analysis to medication naïve patients indicated that whilst differences in sleep 
onset latency, total sleep time and sleep efficiency index remained similar, there was no 
detectable difference in effect size of sleep architecture (i.e. reduced N3 and REM sleep 
latency). These findings are consistent with an earlier meta-analysis (Chouinard et al., 2004) 
which included only medication naïve cohorts. Restriction of analysis to medication-
withdrawn cohorts demonstrated a consistent reduction in total sleep time, sleep efficiency 
index, REM sleep latency and N3 with a concomitant increase in sleep onset latency. Analysis 
of medicated cohorts indicated significantly prolonged sleep onset latency and N2 with a 
concomitant reduction in REM duration. In an older meta-analysis of predominantly medicated 
cohorts effect size was significantly higher for sleep onset latency and reduced for total sleep 
time and sleep efficiency index (Benca et al., 1992). Interestingly moderator analysis of 
duration of illness indicated that longer duration of illness correlated with a progressive 
reduction in N3 and normalisation in REM sleep latency.  
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These meta-analytic findings suggest that sleep disturbance in schizophrenia is a dynamic 
process dependent on and modified by both the duration of illness and exposure to 
antipsychotic medication. Consistent findings are that sleep disruption (as measured by total 
sleep time, sleep efficiency index and sleep onset latency) is a pervasive feature of 
schizophrenia both early and late in disease. This observation is unsurprising given evidence 
of severe circadian rhythm disturbance in schizophrenia which has been replicated across 
multiple studies using actigraphic measures, sleep diaries and serial melatonin measurement 
(Afonso et al., 2014; Martin et al., 2001; Poulin et al., 2010; Wulff et al., 2012). Furthermore, 
some authors have reported neurochemical data demonstrating objective changes in regulatory 
pathways indicative of a biological basis to circadian rhythm disruption in this population (Rao 
et al., 1994; Wulff et al., 2012). On the other hand, changes to sleep architecture in 
schizophrenia (as measured by REM and non-REM sleep duration, and REM sleep latency) 
are more inconsistent and appear to depend more on medication exposure and duration of 
illness. As such it is difficult to definitively determine whether single architectural parameters 
are pathobiologically related to schizophrenia or whether they represent a surrogate of response 
to treatment or marker of long-term outcome. 
The major confounding effect of PSG data in schizophrenia is the impact that antipsychotic 
drugs may play in altering normal sleep architecture. There is extensive data reporting the effect 
of antipsychotic drugs on sleep architecture in both normal volunteers and people with 
schizophrenia, the bulk of which has been extensively reviewed (Cohrs, 2008). FGAs on the 
whole appear to consistently prolong total sleep time and improve sleep efficiency in people 
with schizophrenia but have an inconsistent effect on these parameters in healthy controls. 
Exposure also prolongs N3 sleep, however this impact is variable with low potency, more 
sedating drugs (e.g. chlorpromazine) exerting a significant influence and high potency, less 
sedating drugs (e.g. haloperidol) having minimal effect. Similarly, the impact of FGAs on REM 
 
35 
sleep duration appears to be agent specific. Of note, withdrawal effects have more consistent 
effects on sleep architecture. Abrupt drug withdrawal of haloperidol results in reduction of total 
sleep time, N3 sleep, REM duration and sleep efficiency with relative increase in N2 sleep 
(Neylan et al., 1992; Nofzinger et al., 1993; Thaker et al., 1989). Evidence also suggests that 
the degree of reduction in total sleep time and sleep efficiency after antipsychotic withdrawal 
were strongly correlated with risk of psychosis relapse, whilst degree of increase in N3 sleep 
was inversely correlated (Chemerinski et al., 2002; Neylan et al., 1992). 
In regard to SGAs their effect on sleep varies considerably based on the individual agent, 
reflecting the diverse receptor profile of these drugs. Most SGAs, with the exception of 
risperidone, increase total sleep time and sleep efficiency, whilst their effects on REM and non-
REM sleep are variable. Olanzapine and ziprasidone are consistently reported to prolong N3 
sleep in people with schizophrenia, clozapine is associated with a reduction in N3 sleep, whilst 
other individual drugs have minimal effect. Similarly, REM sleep duration is variably 
impacted; clozapine and paliperidone are reported to prolong REM sleep, risperidone and 
ziprasidone are reported to reduce REM sleep, whilst olanzapine and quetiapine have 
inconsistent or clinically meaningless effects. As such it is difficult to generalise an effect of 
all antipsychotic drugs on sleep architecture, beyond a relatively consistent effect on 
prolonging total sleep time and sleep efficiency which is likely a function of their ability to 
ameliorate positive symptoms which impact directly on sleep quality (Cohrs, 2008). 
The effect of sleep on symptomatology in schizophrenia 
It is likely that changes in sleep architecture are associated with clinical outcomes in 
schizophrenia, particularly neurocognitive performance. There is a preponderance of PSG data 
that indicates abnormalities in REM sleep are a predictor of more severe symptomatology, 
using general rating scales such as the positive and negative symptom scale (PANSS) and brief 
 
36 
psychiatric rating scale (BPRS). As an example, reduction in REM latency is consistently 
reported to be strongly correlated to BPRS scores in untreated schizophrenia (Poulin et al., 
2003; Tandon et al., 1992) and is responsive to antipsychotic drug treatment (Taylor et al., 
1991). REM sleep density (the frequency of eye movements during REM sleep) is also reported 
to be reduced in schizophrenia compared to general populations and is inversely correlated 
with BPRS (Poulin et al., 2003) and total PANSS scores (Yang et al., 2006). The effect of REM 
sleep disturbance is most pronounced in its association with positive symptomatology. Severity 
of positive symptoms is inversely correlated with REM density (Benson et al., 1993; Rotenberg 
et al., 1997) which is independent of antipsychotic medication effects (Yang et al., 2006). 
Similarly, reductions in REM sleep latency (the time between onset of sleep and the first 
episode of REM) are predictive of more severe positive symptomatology both in drug naïve 
cohorts (Lauer et al., 1997; Poulin et al., 2003) and in treated cohorts recently withdrawn from 
antipsychotic medications (Tandon et al., 1992; Taylor et al., 1991; Thaker et al., 1989). Whilst 
beyond the scope of this thesis, some authors suggest these associations indicate the physiology 
of REM sleep shares a common biological basis with the symptomatology of schizophrenia 
(Poulin et al., 2003). 
Conversely the main PSG measure associated with negative symptomatology is alterations in 
slow wave sleep (SWS). Findings across multiple studies of treatment naïve (Ganguli et al., 
1987; Keshavan, Miewald, et al., 1995; Keshavan, Pettegrew, et al., 1995; van Kammen et al., 
1988) and antipsychotic medicated (Kajimura et al., 1996; Kato et al., 1999; Tandon et al., 
2000) cohorts consistently demonstrate an inverse relationship between slow wave sleep 
duration and negative symptoms throughout all phases of illness. This finding is independent 
of age and depressive symptomatology (which can also be associated with reduced slow wave 
sleep) (Ganguli et al., 1987). Some studies also suggest that reduction in delta wave activity 
(defined as reduction in voltage and frequency of delta waves) is also correlated with negative 
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symptoms independent of absolute slow wave sleep duration (Ganguli et al., 1987; Kato et al., 
1999; Keshavan, Miewald, et al., 1995). These findings are indicative of a direct 
neurobiological link between sleep and functional outcomes in schizophrenia. As such, 
treatment directed at normalising slow wave sleep in schizophrenia may represent a novel 
means of modifying negative symptoms of schizophrenia, which often remain resistant to 
antipsychotic treatment. 
It is perhaps unsurprising that alterations in sleep architecture are also associated with cognitive 
deficits in schizophrenia. Cognition encompasses multiple aspects of intellectual functions 
including working, short-term and long-term memory, judgement, reasoning, procedural 
learning, attention, comprehension and language. As such, comparability of literature reporting 
the effect of sleep on cognition in schizophrenia is impacted on by the variety of outcomes that 
can be measured. Decrements in gross measures of vigilance as measured by reaction time 
were shown to be correlated with reduction in slow wave sleep duration and sleep spindle 
density in a small cohort of drug-naïve patients with schizophrenia (Forest et al., 2007). Other 
lines of research support the role of disordered sleep architecture as playing a role in sleep-
dependent memory consolidation. In cohorts of treated patients with schizophrenia reductions 
in slow wave sleep and sleep spindle density have been correlated with measures of 
visuospatial memory (Goder et al., 2004), declarative memory (Goder et al., 2008) and 
procedural learning (Goder et al., 2006), however results were inconsistent across these studies, 
possibly as a result of the different antipsychotic treatments that the cohorts were prescribed 
(Manoach et al., 2009).  
Whilst the absolute amount of time spent in various phases of sleep correlates with outcomes 
in individual cognitive domains, there is evidence that global measures of complex cognitive 
processes are more dependent on dynamic aspects of sleep architecture. In healthy people this 
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can be thought of as a multi-step process whereby consolidation of declarative memory is 
achieved predominantly through the effects of early slow wave sleep with subsequent 
integration and enhancement of these memories into larger integrative networks dependent on 
later N2 and REM sleep. As such higher level or abstract cognitive processes such as 
procedural learning, emotional memory and judgement are likely to be more dependent on the 
normal progression throughout sleep stages (i.e. predominant slow wave sleep early in the night 
followed by later N2 and REM sleep) than on absolute or relative changes in the amount of 
time spent in slow wave sleep, REM or N2 sleep (Manoach et al., 2009). Empirical evidence 
for this assertion is supported by two studies in normal populations. One study demonstrated 
that overnight improvement in visio-perceptual learning correlated strongly with absolute slow 
wave sleep early in the night and REM sleep late in the night, and that this correlation was 
strengthened by a regression model combining these two parameters (Stickgold et al., 2000). 
Another study of day-time napping on visio-perceptual learning indicated that deterioration in 
performance was reduced with naps containing slow wave sleep, but was improved with naps 
that contained slow wave sleep followed by periods of REM (Mednick et al., 2002). In 
schizophrenia there is evidence that disruptions in this multi-step process similarly drive 
deficits in procedural memory learning. One polysomnographic study demonstrated that in 
comparison to healthy controls, people with schizophrenia spent a significantly shorter period 
of time in N2 in the last quarter of sleep and had significantly reduced sleep spindle density. 
The motor sequence task was used as measure of procedural learning and was measured before 
and after a night of sleep. Quantity of N2 sleep in the last quarter of sleep and early slow wave 
sleep duration were predictive of improvement, a correlation that was strengthened when these 
two parameters were combined in a logistic regression model (Manoach et al., 2010).  
Impairment across a variety of cognitive domains is a central feature of schizophrenia and 
persists throughout all phases of the disease (Rund, 1998). Furthermore, cognitive deficits 
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remain stable over the course of disease independent of acute change in positive symptoms 
(Harvey et al., 1990) and are a strong predictor of functional outcome (Green et al., 2000). 
Disappointingly, antipsychotic agents have only modest effect on cognitive measures in 
schizophrenia with FGAs having no measurable impact and SGAs having statistically 
significant but clinically meaningless effects in comparison to placebo (Bowie et al., 2006). It 
is likely that sleep disruption is intrinsic to schizophrenia and plays a complex role in driving 
cognitive deficits and negative symptoms. As such modification of the architectural changes 
and disruption of sleep in schizophrenia may represent a novel means of improving treatment-
resistant symptoms and functional outcomes. However as yet there is almost no literature 
describing specific interventions to achieve this or outcomes of such a therapeutic approach. 
How might OSA and its treatment be relevant in schizophrenia 
There is a wealth of evidence indicating that sleep disturbance and sleep architecture is 
disrupted in schizophrenia, however there is comparatively little high-quality literature 
describing what role comorbid OSA plays in driving sleep disturbance in schizophrenia. As 
previously discussed, it is probable that OSA is prevalent in schizophrenia due to shared risk 
factors. As a corollary, it is plausible that sleep disturbance described in schizophrenia may 
therefore be driven or exacerbated by OSA. Unsurprisingly, many of the sleep symptoms and 
architectural changes in sleep described in schizophrenia are analogous to those seen with 
OSA. It is important therefore to consider the pathophysiology, symptomatology and treatment 
outcomes of OSA and how these may be aetiologically linked to schizophrenia. 
OSA is the most common of the diagnosable sleep disordered breathing syndromes. OSA 
results from repeated collapse or obstruction of the pharyngeal airway during sleep resulting 
in hypoxia and frequent arousals that cause sleep fragmentation and disruption to normal sleep 
architecture (Osman et al., 2018). The pathophysiology of OSA is driven by excessive soft 
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tissue surrounding the upper airway, negative intraluminal pressure generated by inspiratory 
effort and a failure of pharyngeal dilator muscles to counterbalance these opposing forces and 
maintain airway patency. During wakefulness people with OSA are able to maintain adequate 
tone to preserve airway patency, however during sleep physiological reduction in muscle tone 
can result in collapse of the airway with resultant hypoxia, then arousal, to normalise airway 
tone. Dilator muscle tone and reflex responsiveness to negative airway pressure is most ablated 
during transition of N1 to N2 sleep and during REM sleep and therefore apnoeas are most 
common during these phases of sleep (Eckert et al., 2008). 
The major risk factors for OSA are obesity, male sex, increasing age and tobacco smoking, all 
of which mediate risk mainly through mechanical effects. Deposition of fat around the pharynx 
in obesity increases collapsibility of the airway (Horner et al., 1989)  and also has direct effects 
on pharyngeal dilator muscle function resulting in increased fatigability (Carrera et al., 2004). 
Compared to women, men demonstrate sex-related propensity for fat distribution around the 
pharyngeal airway (Whittle et al., 1999) and a longer pharynx length (Malhotra et al., 2002) – 
both factors promote airway collapsibility. Similarly increasing age is associated with 
preferential deposition of pharyngeal fat, independent of total body fat, whilst muscular 
reflexes to negative airway pressure also deteriorate with age (Malhotra et al., 2006). Tobacco 
smoking is reversibly associated with an increased risk of OSA as a result of pharyngeal lymph-
adenoid hyperplasia in response to particulate irritants, and nicotine withdrawal during sleep 
can result in a reduced arousal threshold to hypoxia (Young et al., 2004). Obesity (Mitchell et 
al., 2013) and tobacco smoking (Myles et al., 2012) are highly prevalent in schizophrenia 
making it likely that OSA is therefore over-represented in this population. 
Various classes of drugs are also associated with increased risk or exacerbation of underlying 
OSA, generally mediated by reduction in muscle tone or a central reduction in respiratory drive 
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during sleep. Meta-analysis has demonstrated alcohol is strongly associated with risk and 
severity of OSA, an effect that is independent of obesity (Simou et al., 2018). Mechanistically, 
there is evidence that alcohol both reduces pharyngeal muscle tone and increases upper airway 
resistance predisposing to airway collapse (Krol et al., 1984). Alcohol use may be a significant 
factor in driving OSA risk in people with schizophrenia, given that alcohol use disorders are 
over-represented in this population (Moore et al., 2012). Historically benzodiazepines have 
also been implicated in increasing risk of OSA through the purported mechanism of reducing 
muscle tone. However, this association has not survived recent meta-analysis which 
demonstrates that benzodiazepines do not objectively worsen apnoeas or hypopnoeas, but do 
have a significant effect on worsening nocturnal hypoxia associated with apnoeas likely as a 
result of an increased arousal threshold (Mason et al., 2015).  
Of particular relevance to schizophrenia, there is emerging evidence that SGA medications are 
another drug-related risk factor for OSA. Chronic SGA use induces significant weight gain and 
pharmacodynamically interact with a receptor profile that may have effects on central 
respiratory drive and airway muscle tone providing a mechanistic link with OSA. There is 
minimal empirical evidence, but some authors suggest that serotonergic antagonism of SGAs 
may ablate central nervous system control of airway patency and resistance during sleep 
(Kanamaru et al., 2007). One retrospective cohort study of patients referred to a sleep disorders 
clinic reported mean apnoea hyponoea index as a measure of OSA severity between patients 
exposed and unexposed to SGAs. This study reported a significantly higher apnoea hyponoea 
index in those exposed to SGA agents which remained significant when controlling for BMI, 
age, sex and benzodiazepine use (Rishi et al., 2010). Another single-arm intervention study 
reported change in apnoea hyponoea index after eight weeks of treatment with olanzapine, 
risperidone and quetiapine initiated as treatment in otherwise healthy patients for insomnia. At 
follow-up there was a substantial and statistically significant increase in apnoea hyponoea 
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index from pre-treatment values, which occurred despite no acute change in BMI or neck 
circumference during the treatment period (Khazaie et al., 2018). Another retrospective cohort 
study of patients exposed to SGAs using a control group of people with depression not exposed 
to SGAs, demonstrated that whilst apnoea hyponoea index was elevated in the schizophrenia 
group, this effect became non-significant on a regression model incorporating age, sex and 
BMI (Shirani et al., 2011). Together these studies suggest that SGAs may contribute to an 
increased risk of OSA, however it is unclear whether or not this risk is attributable to off-target 
pharmacodynamic properties or reflects a secondary effect from antipsychotic-induced weight 
gain. Certainly, the literature specifically examining effect of SGA in schizophrenia is limited 
by retrospective methodology, and the literature more generally suffers from small sample size 
that may be insufficiently powered to detect an effect independent of obesity. Larger 
prospective studies using unselected populations are required to definitively determine whether 
SGAs have an independent effect on increasing risk of OSA. 
The symptomatic impact of OSA relevant to schizophrenia 
The main symptomatic outcome of OSA is excessive daytime sleepiness, fatigue and non-
restorative sleep as a result of nocturnal sleep fragmentation. These symptoms are associated 
with reduced socio-occupational performance (Omachi et al., 2009), increased risk of motor 
vehicle accidents (Teran-Santos et al., 1999) and reduced quality of life (Lacasse et al., 2002). 
Beyond subjective symptoms, untreated OSA is also associated with significant neurocognitive 
and affective dysfunction. Case-controlled studies have demonstrated an excess of diagnosable 
depressive disorders in people with OSA compared to general population controls (Aikens et 
al., 1999; Ramos-Platon et al., 1992), an association which has also been demonstrated in larger 
epidemiological cohorts (Ohayon, 2003) and confirmed on meta-analysis (Garbarino et al., 
2018). Whilst the relationship between affective symptoms and OSA is likely to be bi-
directional, OSA is probably in part aetiological given that CPAP treatment is demonstrated to 
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normalise affective symptoms (Giles et al., 2006). Similarly, there is extensive evidence 
describing cognitive decrements in people with OSA compared to the general population, an 
association that appears to affect subdomains selectively. Reviews and meta-analyses of case-
controlled data (Beebe et al., 2003; Bucks et al., 2013; Olaithe et al., 2013; Wallace et al., 2013) 
indicate that vigilance, long-term episodic memory and executive functioning (which includes 
shifting between tasks, efficiently accessing semantic memory, fluid reasoning and problem 
solving) are the predominant cognitive domains affected. Cognitive outcomes also appear to 
occur as a threshold effect of OSA, evidenced by a lack of conclusive evidence demonstrating 
a liner correlation between severity of cognitive symptoms and apnoea hyponoea index 
(Wallace et al., 2013). Importantly, CPAP treatment is associated with an improvement in 
cognitive outcomes in OSA, particularly vigilance and executive functioning (Olaithe et al., 
2013). 
Neurocognitive and affective symptoms of OSA may be particularly relevant in schizophrenia 
where they may compound negative symptoms and pre-existing cognitive decrements related 
to the schizophrenia. Negative symptoms are generally considered to encompass five primary 
domains: blunted affect, alogia, asociality, anhedonia and avolition (Kirkpatrick et al., 2006). 
They are highly predictive of real-world functioning (Harvey et al., 2012) and are poorly 
responsive to antipsychotic treatment (Galderisi et al., 2018). Cognitive decrements in 
schizophrenia are also highly prevalent, stable over the course of illness and considered to be 
a trait marker (Rund, 1998). Affected cognitive domains are broad, but predominantly include 
attention, vigilance, executive functioning and verbal memory (Heinrichs et al., 1998). Similar 
to negative symptoms, severity of cognitive decrements corelate strongly with functional 
outcomes and are resistant to antipsychotic treatment (Fett et al., 2011). Whilst cognitive 
symptoms are distinct from negative symptoms in schizophrenia, there is likely to be some 
degree of overlap. For example, some authors (Marder et al., 2017) have suggested that 
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paradigms of attention and vigilance share commonality with standardised measures of 
negative symptoms; impairment of executive function is a key factor in avolition; and poor 
verbal fluency underlies alogia to a significant extent.  
It is clear that the adverse neurocognitive outcomes of schizophrenia and OSA overlap 
considerably, particularly in the cognitive domains of attention, vigilance and executive 
functioning. It follows therefore that because of pre-existing neurocognitive decrements, 
people with schizophrenia are likely to be particularly vulnerable to the adverse cognitive and 
affective outcomes of comorbid OSA which in turn may indirectly exacerbate negative 
symptoms and functional outcomes intrinsic to psychiatric disease. Given that CPAP is 
validated to improve cognitive outcomes of OSA in the general population, treatment of OSA 
comorbid with schizophrenia may offer a means of improving functional recovery in a subset 
of patients. As yet there is no published evidence to support this assumption. 
Possible effects of treatment of OSA comorbid with schizophrenia 
As previously discussed, disruption of sleep architecture is a pervasive feature of 
schizophrenia, which may be exacerbated by comorbid OSA. In general populations with OSA, 
frequent arousal due to hypoxia results in significant sleep fragmentation and an overall 
reduction in sleep efficiency. Improvements in sleep efficiency after treatment of OSA with 
CPAP therapy are a strong predictor of improvement in vigilance (Conradt et al., 1998). 
Similarly, sleep architecture is grossly disrupted by OSA with consistent reports of reduced 
slow wave sleep, reduction in REM and increase in N1 sleep which are normalised by CPAP 
treatment (Bonsignore et al., 1987; Collard et al., 1996; Fietze et al., 1997; Lamphere et al., 
1989). CPAP treatment has also been reported to normalise sleep spindle density in OSA, 
which is another strong predictor of improvement in vigilance (Yetkin et al., 2018). Of note 
decreases in slow wave sleep and sleep spindle density seen in OSA mirror those described in 
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schizophrenia and as such may compound the associated neurocognitive decrements in 
comorbid disease. There is a preponderance of data demonstrating that CPAP normalises sleep 
architecture in general populations with OSA, but to what extent this occurs in people with 
schizophrenia is yet to be determined. 
Finally, it is possible that treatment of comorbid OSA could improve cardiometabolic 
parameters and quality of life in people with schizophrenia, which as previously discussed is 
an area of unmet clinical need. CPAP treatment has been consistently shown to improve blood 
pressure control and quality of life in people with OSA (Jonas et al., 2017). Whilst large 
randomised studies have not demonstrated an effect of CPAP in the secondary prevention of 
cardiovascular end-points such as stroke or myocardial infarction (McEvoy et al., 2016), there 
is evidence that CPAP does improve recurrence of atrial fibrillation (Kanagala et al., 2003), 
reduces mortality associated with heart failure (Kasai et al., 2008; Wang et al., 2007) and results 
in increased rates of physical activity (Jean et al., 2017).  
Perhaps the largest caveat in interpreting outcomes related to CPAP is that the magnitude of 
treatment effect is dependent on adequate adherence. A therapeutic threshold of CPAP is 
generally considered to be between 5-6 hours per night (Rotenberg et al., 2016), whilst 
improvements in physical health outcomes appear to occur with 4 hours of use per night (Barbe 
et al., 2012; Peker et al., 2016). Disappointingly, general population estimates of adherence are 
between 30-40% with up to 10% of people unable to undertake CPAP at all (Rotenberg et al., 
2016). Although no empirical evidence exists, it is possible that people with schizophrenia may 
undertake CPAP even less than general populations due to changes in mental state. There is 
data in people with major depression and comorbid OSA that CPAP adherence is poorer than 
the general population (Law et al., 2014). As such, despite the theoretical benefit of ideal CPAP 
usage in improving cognitive symptoms, quality of life and physical health outcomes in people 
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with schizophrenia, it is important also to determine whether the treatment is acceptable as an 
indicator of its real-world benefit. 
Prevalence and identification of OSA in schizophrenia 
In general populations identification of OSA is typically based on the symptomatic complaint 
of poor sleep quality or daytime somnolence, which may be objectively assessed using scoring 
systems such as the ESS and PSQI. Similarly, a number of diagnostic scoring systems are 
available that may be useful in identifying high risk groups where PSG assessment is warranted 
to further investigate for OSA. As previously discussed, these clinical measures of OSA 
symptoms are likely to perform poorly in people with schizophrenia. It is plausible that 
diagnostic overshadowing may obscure detection of OSA in people with schizophrenia as both 
patient and clinicians may attribute sleep symptoms, cognitive impairment and daytime 
somnolence to sleep disruption intrinsic to psychotic illness or to the sedating effects of 
antipsychotic medications. Diagnostic tools for OSA and objective measures of sleep 
symptoms or daytime sleepiness are also likely to perform poorly, especially as none have been 
validated in people with schizophrenia. As previously discussed sleep symptoms related to 
socio-occupational activities assessed in these tools may not be particularly relevant to people 
with schizophrenia given socioeconomic deprivation in this population and pervasive negative 
symptoms of apathy and avolition. Similarly, a number of tools rely on bed-partner reported 
snoring or pausing during sleep, which is likely to be insensitive to the detection of symptoms 
given the majority of people with schizophrenia lack a bed partner (Morgan et al., 2011). 
One cohort study (Anderson et al., 2012) of people with schizophrenia undergoing PSG 
assessment for OSA indicated that mean ESS and PSQI were not significantly elevated in those 
subjects who were diagnosed with sleep apnoea using PSG. Whilst this study did not attempt 
to specifically validate these symptom tools, it is pertinent to note that mean PSQI and ESS 
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scores across the entire cohort were only 6.5 and 5.6 respectively despite 52% of the cohort 
having a diagnosis of OSA. These scores are lower than means reported in general population 
controls (Johns, 1991) which is indicative of how poorly sensitive these measures may be. 
Apart from this single study there is no other literature reporting the validity of sleep symptom 
scores or diagnostic questionnaires in schizophrenia and as such minimal evidence to guide 
clinicians on how best to identify OSA at the clinical level. Poor clinical awareness of OSA 
may lead to the under-provision of sleep services to people with schizophrenia and a missed 
opportunity to intervene in a reversible condition that may aggravate cognitive deficits, 
impaired quality of life and adverse physical health outcomes. 
It is important then to interpret published estimates of OSA in this context. There are three 
main methods for reporting prevalence of OSA: estimates based on diagnostic screening tools, 
estimates based on healthcare registry data and estimates based on diagnostic tools such as 
PSG. Two studies have reported estimates based on screening tools. The first study (Alam et 
al., 2012) utilised the STOP-BANG questionnaire (Chung, Subramanyam, et al., 2012) in a 
cohort of 100 subjects comprised mainly of people with schizophrenia or schizoaffective 
disorder and reported a 69% prevalence of OSA. Of the entire cohort 16% had a prior diagnosis 
of OSA confirmed by PSG and of those considered to have OSA based on STOP-BANG scores 
only 32% had OSA previously mentioned as a diagnostic possibility by their treating doctors. 
A second study (Annamalai et al., 2015) reported on a cohort of 175 patients with schizophrenia 
or schizoaffective disorder being assessed for insomnia and utilised a simplified STOP 
questionnaire (Chung et al., 2008)  as a measure of OSA. 57.7% of subjects were considered 
to have OSA based on the STOP questionnaire and similarly only 14.9% of the total cohort 
had a previous diagnosis of OSA. Given the limitations of diagnostic screening tools, it is 
unlikely that these prevalence estimates are accurate. However, the results do suggest that 
clinical recognition and detection of OSA risk is low in people with schizophrenia. One large 
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data linkage study using outpatient data from the US Veterans Health Database reported 
prevalence of OSA in people with a current diagnosis of psychosis based on ICD-10 codes 
(Sharafkhaneh et al., 2005). This large study reported a prevalence rate of OSA of 1.6%, which 
is likely to be a gross underestimation given this rate is much lower than that seen in the general 
population (Heinzer et al., 2015). These results thus only provide further evidence that OSA 
comorbid with schizophrenia is likely to be significantly under-recognised at the clinical level. 
To date there are only four cohort studies that provide estimates of OSA in schizophrenia using 
objective diagnostic measures and from which clinical associations can be determined. The 
details of each study, their inclusion criteria, diagnostic measures and prevalence estimates are 
outlined in table 2. On the whole all of these studies have limitations in methodology which 
limit their extrapolation to populations with schizophrenia more generally. Of note only one 
study (Anderson et al., 2012) utilised the gold-standard measure of apnoea hyponoea index >5 
on overnight PSG as a threshold for diagnosis. Two other studies (Ancoli-Israel et al., 1999; 
Winkelman, 2001) defined respiratory disturbance index (RDI) >10 on overnight PSG as the 
threshold for diagnosis of OSA, which is not recommended in preference to the apnoea 
hyponoea index by the American Academy of Sleep Medicine (AASM) (Berry et al., 2015). 
The final study (Takahashi et al., 1998) utilised overnight oximetry and desaturation index 
(DI), defined as the mean number of desaturation episodes of >4% per hour of sleep, as the 
diagnostic measure of OSA. Whilst desaturation index does correlate with apnoea hyponoea 
index, it does not reliably differentiate obstructive from central apnoeic episodes (Chung, Liao, 
et al., 2012).  
Similarly, variation in populations recruited across these studies is likely to have substantial 
impact on the reported estimates of OSA prevalence, limits comparability of the literature and 
precludes generalisation of results to broader populations of people affected by schizophrenia. 
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As an example, two studies (Takahashi et al., 1998; Winkelman, 2001) screened inpatients with 
schizophrenia; inpatients are likely to have acute changes in mental state and antipsychotic or 
sedative medication usage that may have impacted on sleep quality and confounded sleep study 
results. Similarly, differences in risk factors present in reported populations are also likely to 
have impacted on the reported prevalence estimates. The rates reported in one study (Ancoli-
Israel et al., 1999) of older patients with schizophrenia may not be generalisable to younger 
groups of people because age is a risk factor for OSA. Another study (Winkelman, 2001) 
probably suffers from a positive selection bias because it only included participants referred to 
a sleep disorders clinic based on clinical suspicion of OSA, whilst another study (Anderson et 
al., 2012) is confounded by heterogeneity of psychiatric diagnosis with only 48% of 
participants having a diagnosis of schizophrenia. Ethnic differences may also be at play in the 
final study which reported the lowest prevalence of OSA across the literature (Takahashi et al., 
1998). The mean BMI of 23.9 across this cohort of Japanese patients were in the normal range 
which is atypical of people with schizophrenia generally and is likely the reason why rates were 
not substantially elevated in comparison to a cohort of general population controls.  
Despite these limitations these studies indicate that OSA is likely to be prevalent in 
schizophrenia with rates of between 14-57%. These studies also reported that age, male sex,
 
 
Table 2: Comparison of studies reporting prevalence of OSA in cohorts of people with schizophrenia using diagnostic measures 
 
 
Study Population Methods  OSA diagnostic criteria OSA prevalence  
Ancoli-Israel (1999)  Older (mean age 60 years) outpatients with 
schizophrenia or schizoaffective disorder 
Polysomnography Respiratory disturbance index 
>10 
48% 
Anderson (2012) Group of patients with major mental illness, 48% 
had schizophrenia or schizoaffective disorder 
Polysomnography Apnoea hyponoea index >5 52% 
Takahashi (1998) Inpatients with schizophrenia Overnight oximetry Desaturation index >5 21.9% in men 13.5% 
in women 
Winkelman (2001) Inpatients with schizophrenia referred to a sleep 
disorders clinic for clinical suspicion of OSA 
Polysomnography Respiratory disturbance index 
>10 




BMI and increased neck circumference were associated with a diagnosis of OSA. Beyond these 
traditional risk factors, these studies were not able to provide information as to whether 
antipsychotic medications or psychiatric symptoms were associated with a diagnosis of OSA. 
In light of the existing literature it is clear that further research is required to determine robust 
prevalence estimates of OSA in schizophrenia that are not confounded by acute changes in 
mental state or selection bias due to convenience sampling. Similarly, more detailed datasets 
are also required to determine whether there are psychiatric disease specific predictors of OSA, 
beyond traditional risk factors, that may enhance recognition of OSA or facilitate targeted 
diagnostic screening at the clinical level. 
Overview and approach of subsequent chapters 
As outlined, it is likely that OSA is prevalent in schizophrenia and may have an adverse impact 
on quality of life, physical health morbidity and psychiatric outcomes, particularly negative 
symptoms and cognitive function. OSA has a validated treatment and it is possible that CPAP 
may provide a novel means of improving these adverse outcomes in people with schizophrenia 
and comorbid OSA. Whilst these assertions can be indirectly inferred from existing literature, 
there is a dearth of evidence reporting robust estimates of OSA in unselected cohorts, physical 
health and psychiatric outcomes associated with OSA, and treatment outcomes with CPAP in 
schizophrenia. Of concern, it is likely that OSA in under-recognised and under-treated at the 
clinical level. Further research is also required to identify population-specific clinical factors 
that are predictive of diagnosis to facilitate improved recognition at a clinical level. 
In the context of these gaps in the existing literature the aims of this thesis are firstly to 
determine more accurate and generalisable estimates of OSA prevalence in schizophrenia; 
secondly to investigate physical health and psychiatric disease correlates in this population to 
enhance clinical detection of OSA; and thirdly to determine the impact that CPAP treatment of 
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severe OSA comorbid with schizophrenia has on physical health and psychiatric measures. To 
achieve these aims I present five manuscripts, all published or accepted for publication in peer-
reviewed journals, with each manuscript forming a substantive chapter of this thesis. Each 
manuscript is presented in the format and referencing style as required by the publishing 
journal. This exegesis reviews each of the five manuscripts, why the research was warranted, 
and the specific research aim it addresses. 
Three datasets reporting original data were analysed to provide results in this thesis. The first 
was data derived from the Survey of High Impact Psychosis (SHIP), the second was the 
Assessing Sleep in Schizophrenia and Evaluating Treatment (ASSET) dataset and the third was 
data derived from the Men Androgen Inflammation Lifestyle Environment and Stress 
(MAILES) study. The SHIP dataset is derived from a survey of people in contact with mental 
health services across five Australian states conducted in 2010. This survey included people 
aged 18-64 years and covered a catchment area including approximately 10% of the Australian 
population. The survey was conducted using a two-phase methodology whereby a brief 
screening tool was first used to identify a cohort of 7,955 people with psychotic illness. Of this 
cohort 1,825 were subsequently interviewed, had diagnosis of a psychotic illness confirmed 
using the Diagnostic Interview for Psychosis (DIP) and underwent a battery of assessments 
covering psychopathology, cognitive ability, physical health, medication use and 
socioeconomic measures. Assessments included measures of OSA based on the University of 
Maryland Medical Centre Questionnaire for Sleep Apnea and severity of sleep disruption using 
the Assessment of Quality of Life Questionnaire. The full study methodology has been reported 
previously (Morgan et al., 2011). This dataset allows for the exploratory analysis of 
associations between OSA symptoms and psychiatric outcomes in people with schizophrenia, 
it forms the experimental basis of the manuscript presented in chapter 3. 
 
53 
The ASSET dataset was developed as an independent experiment of this thesis and had not 
previously been published. Briefly, the dataset was developed in two phases. The first phase 
involved prospective recruitment of a population of outpatients in the Northern Adelaide Local 
Health Network aged 18-64 years with a current diagnosis of schizophrenia, who were 
prescribed clozapine. These participants underwent baseline assessment of anthropometric 
measures, physical health screening, psychopathological measures, cognition using the Brief 
Assessment of Cognition in Schizophrenia (BACS), sleep symptoms using the ESS, PSQI, 
Insomnia Severity Index (ISI) and OSA screening tools OSA50 and STOP-BANG. Following 
baseline assessment subjects undertook diagnostic at-home PSG with OSA defined by apnoea 
hyponoea index >10. In the second phase subjects with severe OSA (defined as apnoea 
hyponoea index >30) were commenced on CPAP and were followed up at six months of 
treatment with repeat assessment of anthropometric, psychopathological, cognitive and sleep 
symptoms measures. This data set allows for estimation of OSA prevalence, prospective 
validation of sleep symptoms and OSA diagnostic scores and follow-up data to assess the 
impact of CPAP treatment on physical health measures, psychosis symptoms and cognitive 
outcomes, it forms the experimental basis of the manuscript presented in chapter 5 and 6. 
The MAILES dataset is composed of an observational cohort of randomly selected community 
dwelling males in metropolitan Adelaide recruited between 2000 and 2010. The cohort has 
been prospectively followed with a variety of physical health, laboratory and 
sociodemographic measures occurring at various time points of follow-up. A subset of this 
cohort underwent at-home PSG to screen for OSA based on an apnoea hyponoea index >10. 
The full study methodology has been reported previously (Grant et al., 2014). This dataset 
provides a male general population control group for the ASSET study to determine relative 
prevalence of OSA and explore factors independently associated with OSA in the 
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schizophrenia cohort. In conjunction with the ASSET dataset it forms the experimental basis 
of the manuscript presented in chapter 4. 
Chapter 2 (paper 1) 
The purpose of this first paper was to undertake a systematic review of literature reporting 
diagnostic measures of OSA in cohorts of people with a diagnosis of schizophrenia. In regard 
to the narrative of this thesis the rational for this paper is two-fold. Firstly, this manuscript 
allows me to critically examine the literature to determine what is already known in regard to 
the aim of this thesis, namely prevalence, predictors and outcomes of OSA comorbid with 
schizophrenia. Primarily the results of this manuscript will establish a baseline estimate of 
prevalence to which primary data reported in later chapters of this thesis can be compared, but 
also allows for deficiencies in the literature to be identified, where original research would be 
informative and offer the greatest impact. Secondly, this manuscript aimed to provide a 
synthesis of the literature to inform improved detection of OSA at the clinical level which is 
the overarching aim of this thesis. 
As discussed above there is a paucity of literature reporting diagnostic measures of OSA in 
cohorts with schizophrenia, with existing literature confounded by convenience sampling and 
recruitment bias. As such it is anticipated that existing literature will only provide limited 
information on the aims of this thesis. The pre-specified outcomes of this systematic review 
are to determine the prevalence of OSA, relative prevalence of OSA in comparison to general 
population control groups, the physical health and psychiatric correlates of OSA, the utility of 
OSA screening tools and outcomes of OSA treatment on physical health and psychiatric 
outcomes.  
This systematic review builds on and provides novel information in comparison to existing 
literature. As an example, previous narrative reviews have been published (Cohrs, 2008; 
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Kaskie et al., 2017) but only provide a description of prevalence without critical analysis of 
confounding factors and how this might influence estimates in more representative populations 
of people with schizophrenia. As a corollary these reviews also report minimal analysis of 
factors predictive for diagnosis. Similarly, a meta-analysis reporting prevalence of OSA in 
schizophrenia has also been published (Stubbs, Vancampfort, et al., 2016). However, because 
of variability in recruitment strategies in the existing literature there was significant 
heterogeneity in the effect size reported in this meta-analysis which was not explained by 
subgroup analysis. As such it was felt that systematic review was of more relevance in 
determining prevalence and predictors of OSA in light of these methodological limitations, 
rather than replication meta-analysis. On the whole the existing literature does not adequately 
address any of the aims of this thesis which justifies further original research reported in 
subsequent chapters. 
*The systematic review was published in Schizophrenia Research as a brief report. The 
submission was originally made as a full-length paper and was recommended for publication 
by peer review. An editorial decision was made to reduce the paper significantly in length, for 
the purposes of this thesis the original submission is available in appendix one.  
Chapter 3 (paper 2) 
This paper is a prospective cohort study using data from the SHIP study to determine 
prevalence of OSA related sleep symptoms in a cohort of people with psychotic illness.  The 
study performs exploratory analysis of the association between sleep symptoms and physical 
health, psychopathological and quality of life outcomes. The results of this paper will inform 
the narrative arc of my thesis by providing inferential evidence of the symptomatic burden that 
people with schizophrenia experience as a result of OSA and determine what impact these 
symptoms have on physical health and psychiatric outcomes. Specifically, this paper defines 
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sleep symptoms using criteria from the University of Maryland Medical Centre Questionnaire 
for Sleep Apnoea which quantifies the frequency and severity of snoring and witnessed apnoea 
during sleep over the preceding 12 months; and sleep disturbance using a criterion in the 
Assessment of Quality of Life Questionnaire which quantifies the subjective quality of sleep 
into various categories of severity. The SHIP dataset reports an extensive range of physical 
health, psychiatric, sociodemographic and medication data, and as such allows for broad 
exploratory analysis of associations and multivariate analysis. 
Whilst existing literature has reported on sleep disturbance in schizophrenia (Haffmans et al., 
1994; Serretti et al., 2004; Sweetwood et al., 1976), indicating that it is highly prevalent, there 
is minimal literature that reports sleep disturbance specific to OSA. This chapter builds in this 
evidence base by specifically examining to what extent OSA is likely to drive sleep disturbance 
in people with schizophrenia. The SHIP dataset also has a substantially larger sample size than 
that of existing literature and as such is likely to provide much more robust prevalence 
estimates across a more generalisable cohort of people with psychotic illness. The size of the 
SHIP dataset also allows for extensive exploration of how sleep disturbance and OSA 
symptomatology impacts or is impacted on by a broad array of factors. This is particularly 
important in regard to the second aim of this thesis, because little is currently known in regard 
to the physical health and psychiatric correlates of OSA. Importantly, the SHIP dataset allows 
for multivariate analysis to control for factors such as obesity, age and sex which confound 
these associations, providing a clearer picture of independent associations that may be 
modifiable with CPAP treatment. The results of this paper will help to substantiate, or refute, 
the hypothesis that OSA is associated with poorer psychiatric outcomes and clarify specific 
associations that will be further explored in subsequent chapters reporting more robust 
diagnostic measures of OSA using PSG. 
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Chapter 4 (paper 3) 
Building on the evidence generated in chapter 3, the paper presented in chapter 4 aims to 
determine whether there are increased odds of OSA in people with schizophrenia compared to 
general population controls. In regard to the narrative of this thesis, this paper is directly 
relevant to the investigation of prevalence (in providing evidence that OSA occurs more 
frequently in schizophrenia) and predictive factors (by exploring whether the relative odds of 
OSA is explained by an excess of the traditional risk factors of age and obesity). This paper 
reports a matched cohort study of people screened for OSA using diagnostic PSG. The 
schizophrenia cohort is derived from the ASSET trial which consecutively screened a group of 
people with schizophrenia who were prescribed clozapine, whilst the control cohort is derived 
from a randomly selected population of men screened with PSG as part of the MAILES study. 
Because the comparator cohort is composed completely of men, only the male subjects of the 
ASSET study were analysed. This study will report the odds of severe OSA (apnoea hyponoea 
index >30) in the schizophrenia cohort compared to the control cohort and allow for logistic 
regression analysis using models matching for age and BMI to determine to what extent these 
factors explain an excess of OSA in the schizophrenia cohort. 
Whilst there are a number of cohort studies that report the prevalence of OSA in schizophrenia, 
this paper will be the first to determine whether this prevalence is significantly higher than the 
general population using a matched cohort. One previous study has reported no increased odds 
of OSA in people with schizophrenia compared to a control cohort (Takahashi et al., 1998). 
However, this study did not use PSG for diagnosis of OSA, reported an unusually low mean 
BMI in the schizophrenia cohort and performed measures on inpatients with schizophrenia 
where sleep measures may have been confounded by acute changes in mental state. The paper 
in this chapter avoids these factors and will provide the only current evidence that robustly 
demonstrates or refutes an increased risk of OSA in schizophrenia. The overarching importance 
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of demonstrating increased odds of OSA in schizophrenia validates the importance of enhanced 
screening for OSA in this population. As such the secondary aim of this paper, that is exploring 
to what extent obesity and age drive risk of OSA, is also important because it provides evidence 
on how best to identify people who should undergo screening for OSA at the clinical level. 
Alternatively, if age and BMI do not explain risk of OSA, this result would generate the 
hypothesis that medication or psychiatric disease specific factors may play an aetiological role 
in OSA. As yet there is no literature reporting what clinical factors drive risk of OSA in 
schizophrenia. 
Chapter 5 (paper 4) 
This paper reports the main observational results of the ASSET dataset and addresses the aims 
of determining a robust prevalence estimate of OSA in schizophrenia and how diagnosis of 
OSA is associated with physical health, cognitive, psychiatric and functional outcomes, and 
objective sleep quality using the ESS and PSQI. Furthermore, this paper also prospectively 
determines the diagnostic efficacy of OSA screening tools previously validated in general 
populations. Briefly, this paper reports a prospective cohort study of stable community 
dwelling people with schizophrenia recruited from a clozapine clinic. Diagnosis is based on at-
home PSG with OSA defined by apnoea hyponoea index >10.  
This paper reports the first study to determine prevalence of OSA using gold standard 
diagnostic measures in a cohort composed completely of people with schizophrenia and avoids 
biases in recruitment to which previous literature is liable. As such the results generated will 
be comparatively more generalisable and accurate. Similarly, it will allow for the exploratory 
analysis of a large variety of factors that may be associated with a diagnosis of OSA and offers 
an opportunity to empirically validate associations identified in chapter 4 of this thesis. This 
paper will also determine mean PSQI and ESS scores across the cohort and determine whether 
 
59 
these are increased in those with a diagnosis of OSA. Previous literature has reported these 
scores in cohorts of people with schizophrenia generally (Royuela et al., 2002; Sharma et al., 
2016), however this paper will be the first to determine whether comorbid OSA is responsible 
for these sleep symptoms and whether or not they are predictive of diagnosis of OSA. Similarly, 
this paper will be the first to prospectively validate diagnostic screening tools for OSA in 
people with schizophrenia, which has not been previously reported and will provide an 
evidence base as to whether these questionnaires are useful at the clinical level. 
Chapter 6 (paper 5) 
This chapter addresses the final aim of this thesis which is to investigate the acceptability of 
CPAP treatment for severe OSA and to determine the effect CPAP has on physical health, sleep 
architecture, psychiatric measures and cognitive outcomes. The paper constituting this chapter 
reports on subjects in the ASSET trial with a diagnosis of severe OSA based on apnoea 
hyponoea index >30. These subjects were commenced on CPAP treatment and underwent 
assessment of sleep architecture (using PSG), CPAP usage, physical health measures, 
psychiatric symptoms scales, sleep quality measures and cognitive measures at baseline and at 
six months of treatment.  
To date this is the only study that reports on CPAP treatment of comorbid OSA in 
schizophrenia and is novel in many aspects. Firstly, it allows for the robust assessment of CPAP 
acceptability. As previously discussed, people with schizophrenia access physical healthcare 
at a substantially lower rate than the general population. One factor contributing to this may be 
treatment nihilism. Objectively demonstrating CPAP acceptability would go some way to 
refuting this perception in the minds of clinicians. Secondly, this is the only study which 
provides evidence as to whether treatment of OSA with CPAP modifies negative and cognitive 
symptoms in people with schizophrenia. This outcome is of particular importance, because 
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these symptoms are treatment resistant and a significant barrier to functional recovery. On the 
basis that as OSA is prevalent in schizophrenia, a positive finding would indicate that CPAP 
treatment is a feasible means of improving functional outcomes in a highly disadvantaged 
population. Thirdly, optimisation of physical health is a priority for people with schizophrenia, 
given that cardiovascular morbidity is the primary determinant of reduced life-expectancy in 
this population. This paper provides evidence as to whether treatment of OSA comorbid with 
schizophrenia is able to modify cardiovascular risk factors as a novel means of addressing 
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Background: Risk factors for obstructive sleep apnea (OSA) are common in people with 
schizophrenia. Identification and treatment of OSA may improve physical health in this 
population; however there are no guidelines to inform screening and management. 
Objectives: Systematic review to determine, in people with schizophrenia and related 
disorders: the prevalence of OSA; the prevalence of OSA compared to general population 
controls; the physical and psychiatric correlates of OSA, associations between antipsychotic 
medications and OSA; the impact of treatment of OSA on psychiatric and physical health; and 
the diagnostic validity of OSA screening tools.  
Data sources: Medline, EMBASE, ISI Web of Science and PsycINFO electronic databases. 
Cohort, case–control and cross-sectional studies and RCTs reporting on prevalence of OSA in 
subjects with schizophrenia and related disorders were reviewed. 
Results: The prevalence of OSA varied between 1.6% and 52%. The prevalence of OSA was 
similar between people with schizophrenia and population controls in two studies. Diagnosis 
of OSA was associated with larger neck circumference, BMI N 25, male sex and age N 50 
years. There were no data on physical or psychiatric outcomes following treatment of OSA. 
The diagnostic utility of OSA screening tools had not been investigated.  
Conclusion: OSA may be prevalent and potentially under-recognized in people with 
schizophrenia. Further research is required to determine utility of OSA screening tools, the 
relationships between antipsychotic medications and OSA and any benefits of treating OSA. 




1. Introduction  
Cardiovascular disease causes a 16–18 year reduction in life- expectancy in people with 
schizophrenia (Laursen, 2011). Obstructive sleep apnea (OSA) may contribute to this disease 
burden as it is associated with heightened risk of hypertension, diabetes, stroke and heart failure 
(Epstein et al., 2009). High rates of obesity (Galletly et al., 2012; Mitchell et al., 2013), tobacco 
smoking (Myles et al., 2012), alcohol consumption (Moore et al., 2012), and sedative 
medication use (Al Lawati et al., 2009; Galletly et al., 2012) may increase risk of OSA in 
people with schizophrenia. Whilst diagnosis may go unrecognized when sleep disturbance, 
daytime somnolence and cognitive impairment are mistaken for negative symptoms or 
medication side effects. Recent reviews on OSA in schizophrenia (Alam and Chengappa, 2011; 
Gupta and Simpson, 2015; Kalucy et al., 2013) and physical health guidelines do not provide 
recommendations on screening for OSA in schizophrenia.  
2. Methods  
A systematic review was undertaken of English language publications in peer-reviewed 
journals. We searched Medline, EMBASE, PsycINFO, and ISI Web of Science using: 
(psychosis or schizophrenia) and (obstructive sleep apnea or obstructive sleep apnoea or sleep 
disordered breathing). 148 papers were identified and examined; five original articles reporting 
applicable data were identified (see Table 1).  
Papers were included if they reported: prevalence of OSA in a psychosis cohort alone or 
compared to a matched general population cohort; psychiatric, physical health or 
anthropometric measures and quantitative assessment of how these related to a current 
diagnosis of OSA; prospective assessment of OSA or daytime sleepiness screening tools and; 
physical health or psychiatric disease measures before and after treatment of OSA.  
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We included studies that specified the proportion of participants with a diagnosis of 
schizophrenia, schizoaffective disorder, or schizophreniform disorder in each cohort. 
Overnight multichannel polysomnography (PSG) is the gold standard for diagnosis of OSA 
(Epstein et al., 2009), however we included broader diagnostic definitions including modified 
PSG, and overnight oximetry.  
3. Results  
3.1. Prevalence of OSA  
OSA prevalence varied between 13.5% and 57.1% across four cohort studies screening subjects 
using overnight multichannel PSG, modified PSG or overnight oximetry. These studies varied 
in diagnostic criteria and no study reported on a generalizable psychosis cohort. Winkelman 
(2001) was prone to selection bias as subject recruitment was based on suspicion of OSA. 
Anderson et al. (2012) excluded subjects with previous OSA diagnosis, potentially reducing 
prevalence estimates. Ancoli- Israel et al. (1999) studied an older age group (mean 59.6 years), 
whilst low rates reported by Takahashi et al. (1998) may result from the cohorts' low mean 
BMI (23.9).  
3.2. Relative prevalence of OSA  
Takahashi et al. (1998) reported a non-significant comparison of OSA in inpatients with 
schizophrenia (18.8%) matched to controls recruited from hospital staff (22%). Sharafkhaneh 
et al. (2005) compared prevalence of OSA in subjects with schizophrenia (1.2%) to subjects 
without schizophrenia (1.6%) through retrospective review of 4,060,504 veteran case records, 
reporting an unadjusted odds ratio of 1.49 (95% CI 1.05–1.92). This study potentially under-
estimates the prevalence of OSA due to opportunistic methodology, non-standardized 
diagnostic criteria and lack of data on non-VHA health contact.  
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3.3. Physical and psychiatric correlates of OSA  
Anderson et al. (2012) reported that age (r = 0.47, p = 0.001) and neck circumference (r = 
0.311, p = 0.028) were positively correlated with apnea–hypopnea index (AHI). Multivariate 
analysis revealed male sex (OR = 21.9, 95%CI 1.3–370.3) and BMI >25 (OR 36.1, 95%CI 
1.3–990.1) as significant predictors of OSA using AHI >5 as the dependent variable. Using 
multivariate analysis, Winkelman (2001) reported significant associations for male sex (OR = 
5.76, 95%CI 2.08–15.27), age (OR = 1.03, 95%CI 1.00–1.06) and BMI (OR = 1.14, 95%CI 
1.08–1.21) with RDI >10 as the dependent variable.  
Takahashi et al. (1998) reported no significant correlation between dose of antipsychotic 
medication (mg equivalent dose of haloperidol) and oxygen desaturation index (ODI), but 
reported a positive correlation with hypnotic medication (number of pills per day) in the 
subgroup of women. Winkelman (2001) demonstrated no significant association between 
categorical antipsychotic use and an RDI >10 on multivariate analysis. However, the 
association was significant at an RDI threshold of >20 (OR = 5.02, 95% CI 1.44–17.56). 
Anderson et al. (2012) reported a negative correlation between quantitative measures of 
antipsychotic use (percentage of maximum dose) and AHI >5 (r = −0.382, p = 0.014) on 
univariate analysis, but no significant interaction between categorical benzodiazepine use and 
AHI on multivariate analysis.  
No studies report on measures of quality of life, psychiatric symptoms, cognitive function, or 
social and occupational function.  
3.4. Utility of OSA screening tools  
Anderson et al. (2012), examined measures of daytime sleepiness and sleep disturbance with 
the Epworth Sleepiness Score (ESS) (Johns, 1991) and the Pittsburgh Sleep Quality Index 
(PSQI) (Buysse et al., 1989). The mean ESS was 5.6 (SD = 5.04) and the mean PSQI was 6.5 
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(SD = 3.5), lower than general population controls (Johns, 1991). Sensitivity and specificity 
were not reported.  
3.5. OSA treatment  
No study reported acceptability of CPAP treatment; or measures of physical health, 
psychopathology or social functioning before and after treatment.  
4. Discussion  
OSA is common in people with psychotic illness with rates in screened populations between 
13.5–57.1%. This is comparatively higher than general population estimates between 2%–4% 
(Young et al., 2008). Variations in age, degree of obesity, patient selection and diagnostic 
measures however, make no single study widely generalizable to psychiatric populations. 
Unfortunately, one large case–control study potentially underestimates both general and 
relative prevalence of OSA due to its opportunistic methodology given 80% of OSA remains 
undiagnosed despite access to healthcare (Kapur et al., 2002; Young et al., 1997) and that 
people with psychotic illness have reduced access to healthcare reducing diagnosis in this 
group further. Prevalence of OSA in stable community patients and the impact of shared risk 
factors including obesity, sedative medication use and alcohol abuse remain to be determined.  
The significant association of age, BMI >25 and male sex in two studies (Anderson et al., 2012; 
Winkelman, 2001) and neck circumference in one (Anderson et al., 2012) are consistent with 
the American Academy of Sleep Medicine general population guidelines (Epstein et al., 2009) 
that identify BMI and neck circumference as primary predictors of OSA. Similarly, the STOP-
BANG questionnaire validated in general populations (Chung et al., 2008) utilizes criteria of 
BMI >35, age >50 years, neck circumference >40 cm and male sex; along with observed 
apneas, hypertension, snoring, and symptoms of daytime sleepiness. This provides indirect 
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evidence that the STOP-BANG could identify at-risk patients, with the caveat that it has not 
been specifically validated and a lower BMI of >25 constitutes a risk factor in people with 
psychosis.  
The low mean scores of the ESS and PSQI reported in one study (Anderson et al., 2012) is 
consistent with other literature (Rishi et al., 2010) indicating a minority of patients with 
schizophrenia and comorbid OSA report sleeping difficulties or snoring at diagnosis. High 
rates of unemployment (Waghorn et al., 2012) and low rates of de facto relationships (Morgan 
et al., 2011) may limit observation of daytime and nocturnal symptoms in people with 
schizophrenia. Furthermore, sleep symptoms may be mistaken for antipsychotic side effects or 
negative symptoms. These findings suggest OSA may be under-recognized in schizophrenia, 
with available evidence emphasizing physical risk factors over sleep symptoms as a means of 
identifying OSA.  
Inconsistent associations between OSA and antipsychotic and hypnotic medications were 
reported in available studies and potentially arise from variation in medication use measures. 
Other literature reports higher prevalence (Shirani et al., 2011) and severity of OSA (Rishi et 
al., 2010) in people taking antipsychotic medications. Similarly, there is a recognized 
association between benzodiazepine use and OSA in the general population (Dolly and Block, 
1982; Hanly and Powels, 1993). Whilst both drug classes are potentially implicated their 
specific etiological role in OSA is as yet unclear and requires further evaluation.  
No study assessed patients before and after treatment of OSA to determine impact on physical 
health, psychopathology or other functional domains in people with psychosis. In the general 
population OSA is associated with depression, anxiety, reduced quality of life and decrements 
in daytime work performance (Lal et al., 2012; Patil et al., 2007); whilst treatment of OSA can 
improve quality of life (Rizzi et al., 2014). OSA could potentially compound the negative 
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symptoms of amotivation, apathy and social withdrawal in schizophrenia. The degree to which 
OSA contributes to these symptoms is unclear and should be a research priority.  
We suggest that OSA screening be considered as part of the physical health assessment of 
people with schizophrenia. OSA is prevalent, potentially under-recognized and a risk factor for 
poor physical health, whilst treatment may potentially improve cardio-vascular risk and quality 
of life. OSA screening should be conducted with emphasis on neck circumference >40 cm, 
BMI >25, male sex, age >50, and witnessed apneas or loud snoring. The OSA50 (Chai-Coetzer 
et al., 2011) is an appropriate tool for this purpose validated in a primary care setting. An 
OSA50 score ≥ 5 should prompt referral for PSG as the preferred diagnostic test. We propose 
sleep symptoms as a subordinate criterion for considering PSG referral, given patients with 
schizophrenia are unlikely to report symptoms of daytime sleepiness, these symptoms may be 
confounded by medication side effects or psychiatric symptoms, and most lack partners to 
report snoring or nocturnal apneas.  
Further research should be directed towards estimates of OSA prevalence in community 
samples with stable schizophrenia, validation of population-specific screening tools and 




Table 1: Studies reporting prevalence of OSA in populations with schizophrenia 
Study Population Diagnostic measure OSA criteria Prevalence 
Anderson et al. 2012 52 outpatients with major 
mental illness, of which 25 
(48%) had a diagnosis of 
schizophrenia or 
schizoaffective disorder  
Polysomnography  
 
Severity based on AHI Mild — 
AHI 5–15 Moderate — AHI 
15–30 Severe — AHI >30  
 
52% prevalence  
32% mild 
14% moderate  
6% severe  
Sharafkhaneh et al. 2005 4,060,504 outpatients identified 
through retrospective review of 
case notes in the Veteran's 
Health Database, patients with 
psychosis compared to general 
population 
Previous diagnosis of OSA 
documented in database, 
diagnostic measures not 
specified  
 
ICD-10 codes, AHI cut-off not 
defined  
 
1.6% prevalence  
 
Winkleman 2001 46 inpatients with 
schizophrenia or 
schizoaffective disorder 
considered at high risk of OSA 






57.1% in males  
46.2% in females  
 
Ancoli-Israel et al. 1999 52 geriatric outpatients (mean 
age 59.6 years) with 
schizophrenia or 
schizoaffective disorder  
Modified polysomnography  
 
RDI >10  
 
48% prevalence  
 
Takehashi et al. 1998 101 inpatients with 
schizophrenia 
Overnight oximetry DI 21.9% in males 
13.5% in females 
Abbreviations: AHI apnea–hypopnea index as defined by AASM (Kushida et al., 2005); RDI respiratory desaturation index as defined by the ASDA criteria (ASDA, 1992; 
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Background: Obstructive sleep apnea (OSA) in the general community is associated with 
obesity, smoking, alcohol, and sedative medication use and contributes to depressed mood, 
daytime sedation, and sudden cardiovascular deaths. Poor cardiovascular health, impaired 
social functioning, and negative and cognitive symptoms are also among the common clinical 
features of psychotic disorders. People with psychosis have higher rates of sleep disturbance; 
however, OSA has not been extensively investigated in this population.  
Aims: This study aimed to determine the prevalence of OSA and general sleep disruption 
symptoms in a representative Australian sample of people with psychosis. We investigated the 
prevalence of potential risk factors for OSA, including obesity, psychotropic medications, and 
substance abuse in this population. Finally, we evaluated associations between symptoms of 
OSA, symptoms of general sleep disruption, and various clinical features in people with 
psychosis.  
Methods: Participants took part in the Second National Australian Survey of Psychosis, a 
population-based survey of Australians with a psychotic disorder aged 18–64 years. Symptoms 
associated with OSA (snoring and breathing pauses during sleep) in the past year were assessed 
using questions from the University of Maryland Medical Centre Questionnaire and symptoms 
associated with general sleep disruption in the past week using the Assessment of Quality of 
Life Questionnaire. Data collected included psychiatric diagnosis and symptoms, education, 
employment, medications, smoking status, physical activity, drug and alcohol use, and 
cognitive function. Physical health measures included body mass index, waist circumference, 
blood pressure, fasting blood glucose, and lipids.  
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Results: Snoring was reported by 41.9%; 7% stating they frequently stopped breathing 
(pauses) during sleep. Univariate logistic regressions show OSA symptoms (pauses and 
snoring) were associated with older age, female gender, lower levels of social participation or 
employment, cardiovascular risk factors, sedentary lifestyle, and poorer quality of life, while 
symptoms of general sleep disruption were more likely in people with depressive symptoms.  
Conclusion: Australians with psychosis have high levels of sleep disturbance, including OSA. 
OSA symptoms were associated with cardiovascular disease risk factors, reduced social 
participation and employment, and poorer quality of life. Whether correction of OSA can 
improve these factors in people with psychosis remains to be determined.  





Obstructive sleep apnea (OSA) affects 2–4% of the general adult population (1). OSA is 
characterized by repeated pharyngeal obstructions during sleep, resulting in airflow cessation 
(apnea) or reduction (hypopnea), frequent disruption of sleep, and hypoxic episodes. While 
obesity is the most significant risk factor, other risk factors, including smoking and use of 
sedative medications, have been found to play a significant role in OSA (2–4). OSA is 
associated with poor cardiometabolic outcome (5), increased risk of depression and anxiety, 
and impaired neurocognitive function (6).  
People living with psychosis experience poor physical health and shortened life expectancy, 
with high prevalence of cardiometabolic risk factors, including obesity, hypertension, and 
diabetes (7, 8); impaired social and occupational function (9–11); and cognitive impairment 
(11, 12). Although OSA and psychotic disorders have many risk factors and poor clinical 
outcomes in common, few studies have focused on OSA in people with psychosis (13, 14). 
Several small studies have found a high prevalence of OSA in people with schizophrenia (15–
18). High rates of obesity and smoking and frequent use of sedative medications observed in 
people with psychotic illnesses may con- tribute to the development of OSA. Alternatively, the 
pathological sequelae of OSA, including repeated episodes of hypoxia, sleep fragmentation, 
and oxidative stress, may precipitate or perpetuate psychopathological symptoms, metabolic 
disturbance, and impairment of neurocognitive and social functions in people with psychotic 
illness.  
Aims  
Our primary aim was to examine the prevalence of OSA symptoms in a large representative 
sample of people with psychosis. Secondary aims included exploring the associations between 
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OSA symptoms and variety of clinical outcomes, including physical health, risk factors for 
cardiovascular diseases, quality of life, social functioning, cognitive functioning, vocational 
engagement, and psychiatric symptoms. Finally, we examined the association between OSA 
symptoms in this population and known risk factors for OSA (e.g., obesity, alcohol and tobacco 
consumption, and sedative medication).  
Our hypothesis was that clinical symptoms of OSA would be highly prevalent in people with 
psychosis and that clinical symptoms of OSA would correlate with increased cardiometabolic 
risk, poor cognitive and social functioning, and poor quality of life. Clinical symptoms of OSA 
would be associated with obesity, substance abuse, and the use of antipsychotic medications in 
a representative sample of people with psychotic disorders.  
Material and methods 
Sample  
The 2010 Survey of High Impact Psychosis (SHIP) was the second Australian National survey 
of psychotic disorders. The survey catchment covered a population of 1.5 million people aged 
18–64 years, approximately 10% of the Australian population in this age group. A two-phase 
design was used. In Phase 1, screening for psychosis took place in public mental health services 
and in non-governmental organizations supporting people with a mental illness. In Phase 2, 
people who screened positive for psychosis in Phase 1 were randomly selected and stratified 
by age group (18–34 years and 35–64 years) for interview and assessment. This process 
identified 7955 people who were screened positive for psychosis and eligible for interview. 
Potential participants were randomly selected and approached for participation in the study; 
1825 participants who screened positive for psychosis were included and interviewed in Phase 
2 of the study. The study was approved by the human research ethics committees at each of the 
 
109 
seven study sites, and all participants provided written informed consent. Full details of the 
survey methodology are described elsewhere (10, 12).  
Demographics and social participation  
Gender, age, marital status, formal study educational level, and current employment were 
recorded. Item to assess the participant’s involvement in meaningful activity was extracted 
from the main interview schedule to assess: 0 = employed in any job in last 12 months; 1 = 
home duties/caring for own children; 2 = caring for relatives; 3 = retired; 4 = volunteer/unpaid 
work; 5 = student; and 6 = no formal activity. Participants were divided into two groups: no 
formal activity and others. Diagnostic assessment was based on a semi-structured clinical 
research interview, the Diagnostic Interview for Psychosis (DIP) (19). Diagnoses were made 
according to the ICD-10 classification system (20).  
Sleep apnea risk assessment  
Questions assessing sleep apnea were taken from the University of Maryland Medical Centre 
Questionnaire for Sleep Apnea. These were self-rated assessments of the frequency and 
severity of snoring and pauses in breathing during sleep (a more severe symptom of OSA) over 
the previous 12 months. To assess the severity of the snoring, the following question was asked: 
“In the last 12 months, how frequently do you experience or have you been told about snoring 
loud enough to disturb the sleep of others?” [0 = never; 1 = rarely (less than once a week); 2 = 
occasionally (1–3 times a week); 3 = frequently (>3 times a week)]. To assess the severity of 
pauses, the following question was asked: “In the last 12 months, how often have you been 
told that you have “pauses” in breathing or stop breathing during sleep?” [0 = never; 1 = rarely 
(less than once a week); 2 = occasionally (1–3 times a week); 3 = frequently (>3 times a week)].  
The assessment of the severity of disrupted sleep in the past week was made using Question 
13 from the Assessment of Quality of Life (AQoL) Questionnaire-4D (21). The severity of 
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disrupted sleep was rated as 1 = “I am able to sleep without difficulty most of the time”; 2 = 
“My sleep is interrupted some of the time, but I am usually able to go back to sleep without 
difficulty”; 3 = “My sleep is interrupted most nights, but I am usually able to go back to sleep 
without difficulty”; 4 = “I sleep in short bursts only. I am awake most of the night.” 
Dichotomous categories for sleep measurement were created as follows: snoring (yes = 
reported snoring, no = no snoring); pauses (yes = reported pauses, no = no pauses); disrupted 
sleep (yes = at least some of the time, no = rarely).  
Physical activities and physical health  
Physical activity in the past 7 days was assessed using the International Physical Activity 
Questionnaire (IPAQ) short form (22). Electronic scales measuring up to 200 kg were used to 
assess weight (kilograms); height (metres) was taken against a measure on a wall. Body Mass 
Index (BMI) was calculated as weight/height2. Participants were categorized according to 
WHO criteria (23) as underweight (BMI < 18.5), normal (BMI 18.5–24.99), overweight (BMI 
25–29.99) or obese (BMI ≥ 30). Participants’ absolute 5-year cardiovascular disease risk was 
determined by Framingham risk equation (24). Participants’ history of diagnosed 
cardiovascular disease was ascertained by asking participants if they had ever been told by a 
doctor that they had any of the following: heart attack, angina, stroke/ transient ischemic attack 
(TIA), or other heart disease, e.g., arrhythmias. They were asked to bring all medications to the 
interview, and those relevant to cardiometabolic conditions were identified. Details of all 
medication used in the 4 weeks prior to interview was recorded; this was based on self-report 
or review of medication charts (25).  
Participants were also asked to provide a fasting blood sample for analysis of high-density 
lipoprotein cholesterol, triglyceride, and plasma glucose levels. Metabolic syndrome was 
defined using the harmonized criteria developed by the International Diabetes Federation Task 
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Force on Epidemiology and Prevention and related expert organizations (26). These criteria for 
metabolic syndrome require three of the following five risk factors to make the diagnosis: 
abdominal obesity (at-risk waist circumference ≥94 cm for men and ≥80 cm for women); at-
risk diastolic and/ or systolic blood pressure (systolic blood pressure ≥130 mmHg and/or a 
diastolic pressure ≥85 mmHg); at-risk levels of fasting blood glucose (≥5.6 mmol/L), 
triglycerides (≥1.7 mmol/L), or HDL-C (<1.0 mmol/L for men and <1.3 mmol/L for women). 
Abdominal obesity was defined as a waist circumference ≥94 cm for men and ≥80 cm for 
women. Hypertension was diagnosed if the person had a systolic blood pressure ≥130 mmHg 
and/or a diastolic pressure ≥85 mmHg. The thresholds for blood glucose, triglycerides, and 
lipids were: glucose ≥5.6 mmol/L; triglycerides ≥1.7 mmol/; HDL-C <1.0 mmol/L for men and 
<1.3 mmol/L for women. People receiving medications for hypertension, hyperlipidemia, or 
hyperglycemia were considered to meet the relevant criterion.  
The IPAQ short form (22) was used to assess the amount of time participants spent in both 
vigorous and moderate exercise, and the amount of time they spent sitting on a typical weekday, 
during the last 7 days. The total time spent in various activities over the previous 7 days was 
classified according to Australian Bureau of Statistics criteria as applied in the National Survey 
of Mental Health and Wellbeing (27) into four levels of activity: very low, low, moderate, and 
high.  
Psychotropic medications  
Information about antipsychotics, mood stabilizers, antidepressants, and other sedative 
medications taken in the 4 weeks prior to the interview was collected. Outpatients were asked 
to bring their medications to the interview, and for inpatients, the drug charts were reviewed. 




Substance use  
Respondents were asked how often they had used alcohol, cannabis, amphetamines, and other 
drugs in the previous year, and were classified as: 1 = not used; 2 = monthly or less than 
monthly; 3 = weekly/daily (19). Alcohol dependence and risk categories were measured using 
the Alcohol Use Disorders Identification Test (AUDIT) (28). Lifetime diagnoses of alcohol, 
cannabis, and other substance abuse/dependence were assessed using the DIP (19). Caffeine 
consumption was quantified based on amount per day on average in the previous 4 weeks.  
Diagnosis, psychopathology, and cognitive function assessment  
Diagnostic assessment was based on a semi-structured clinical research interview, the DIP (19). 
Diagnoses were made according to the ICD-10 classification system (20). Psychiatric 
symptoms were systematically interrogated using the DIP. Symptoms of hallucinations, 
delusions, or subjective thought disorder in the past 1 month and symptoms of anxiety, 
including worry, panic, anxiety, and obsession over the past 12 months were recorded. A brief 
cognitive assessment tool was employed. This comprised the: (i) National Adult Reading Test 
(NART) Revised (29) and (ii) Digit-Symbol Coding Test (DSCT) from the RBANS battery 
(30). Participants’ subjective experience of forgetfulness over the past 12 months prior to the 
interview was assessed and the results were classified as: 1 = able to remember most things; 2 
= somewhat forgetful; 3 = very forgetful.  
Quality of life assessment  
The quality of life in the past week was assessed using The AQoL-4D 12-item instrument (21). 
The AQoL-4D independently models all the sub-dimensions of health (independent living, 
social relationships, physical senses, psychological well-being, and illness) and combines sub-
models to obtain a multi-attribute utility score. Scores from the first four dimensions form the 
multi-attribute utility score. Algorithms for AQoL scoring were obtained from 
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http://www.aqol.com.au/index.php/scoring-algorithms?id=82. Where negatively skewed 
(AQoL utility scores), data were trans- formed using the appropriate log transformations.  
Statistical analyses  
Descriptive statistics were reported as means and SDs. Dichotomous categories were created: 
age (18–34 vs. 35–64); obesity – BMI ≥ 30 (no vs. yes); absolute 5-year cardiovascular disease 
risk by Framingham risk equation (low vs. high = medium risk or high risk); any formal 
activity, including paid or unpaid work, or study (no vs. yes); subjective memory forgetfulness 
(no = able to remember most things vs. yes = somewhat forgetful or very forgetful); Fagerstrom 
nicotine dependence categories (low = low or very low vs. high = moderate, high, or very high); 
AUDIT risk (low vs. high = hazardous, harmful, or dependent). Univariate logistic regression 
was performed to explore associations between and among potential risk factors (independent 
variables) and the dependent variables (sleep apnea – snore, sleep apnea – pause, and disrupted 
sleep). Independent samples t-test was used to compare the mean scores for the AQoL. A binary 
logistic regression analysis was conducted to explore potential predictors of OSA symptoms. 
Variables were divided into four categories (cardiovascular risks; physical activity; social 
function; and substance abuse) and were entered into the model to estimate multivariate 
associations, with and without adjusting for age, gender, and BMI. Variables were included in 
the regression analyses, if they demonstrated significant association with OSA symptoms in 
the univariate analyses. All statistical analyses were performed with SPSS 22.0. The α value 
taken to indicate statistical significance was adjusted using Bonferroni correction for multiple 




Sociodemographic data  
The study sample comprised 1825 participants. Their mean age was 38.4 ± 11.2 years, and 
59.6% were male. Most participants were single (61.2%); only 17% were married or in de facto 
relationships. More than half (53.2%) of the participants were not currently engaged in any 
meaningful activity such as paid or unpaid employment, volunteer job, career, home duty, or 
study. Most did not engage with any vigorous or moderate physical activity (76.9 and 69.2%, 
respectively); around half (48.5%) had engaged in any form of physical activity for less than 2 
h per week. Nearly all participants (96.7%) had very low to low levels of exercise, according 
to ABS classification (31). The majority of participants were overweight, with 46.4% being 
obese (BMI ≥ 30), and the mean BMI was in the obese range (30.5 ± 7.5 SD) (Table 1).  
Prevalence of symptoms of sleep disturbance  
Nearly half of participants reported snoring during sleep (41.9%), while 17.4% reported that 
they stopped breathing during sleep and 7% reported frequent (>3 times per week) episodes of 
stopping breathing during sleep. Over half of participants reported disrupted sleep at least some 
of the night (Table 2).  
The association between symptoms of sleep disturbance and sociodemographic 
characteristics  
Women reported snoring more frequently than men (p < 0.001). Individuals aged 35–64 years 
had significantly higher odds of snoring (p < 0.001), pauses (stopped breathing during sleep) 
(p < 0.05), and disrupted sleep (p < 0.05), compared with those aged 18–34 years. People 
reporting pauses in breathing during sleep were less likely to have any formal work or study 
activity (p < 0.05), be in paid employment in the previous year (p < 0.01), or be in paid 
employment in the previous week (p < 0.001) (Table 3).  
 
115 
Associations between cardiovascular risks and symptoms of sleep disturbance  
People who reported snoring or pause had 1.5–3 times odds than those who did not to meet at-
risk criteria for most key cardiometabolic risk factors, including elevated plasma triglycerides 
and fasting glucose, low HDL cholesterol, and hypertension. Participants reported snoring had 
odds ratio (OR) of 1.84 [confidence interval (CI) 1.46, 2.32], while those reported pause had 
OR of 2.26 (CI 1.66, 3.08) to meet criteria for metabolic syndrome and they had a higher 5-
year risk of cardiovascular disease [snore OR 1.56 (CI 1.23, 1.98); pause OD 1.65 (CI 1.23, 
2.22), respectively]. Snorers were more likely to have reported a history of cardiovascular 
disease, including angina, heart attack, other heart disease, e.g., arrhythmias, hypertension, and 
stoke/TIA [OR 2.03 (CI 1.64, 2.52)], as did those who reported pauses in breathing during 
sleep [OR 2.19 (CI 1.69, 2.84)]. Participants with disrupted sleep were more likely to meet the 
at-risk criteria for triglyceride levels, but not for other cardiovascular risk factors. Those with 
disrupted sleep were more likely to have a history of cardiovascular disease [OR 1.47 (CI 1.19, 
1.82)] (Table 4).  
Associations between level of physical activities, quality of life, psychopathology, and 
symptoms of sleep disturbance  
Participants with pauses in breathing during sleep, but not snoring or interrupted, had higher 
odds of not to engage in any vigorous activity [OR 1.6 (CI 1.14, 2.26)] or total physical activity 
[OR 1.53 (CI 1.09, 2.16)]. Participants reporting pauses in breathing during sleep had lower 
scores on measures of total quality of life (p < 0.001), independent living (p < 0.05), and 
psychological wellbeing (p < 0.001) when compared with those without pauses (Table 5).  
Participants with disrupted sleep but not snoring or pauses in breathing during sleep had higher 
odds of experiencing hallucinations, delusions or subjective thought disorder (p < 0.001), 
depressive symptoms (p < 0.001), and manic symptoms (p < 0.001) in the past month. Anxiety 
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symptoms were more likely to occur in those whose sleep was characterized by snoring (p < 
0.01), pauses (p < 0.001), and disruption (p < 0.001) (Table 6).  
Associations between psychotropic medications and symptoms of sleep disturbance  
Participants taking atypical antipsychotic medications (including clozapine) had lower odds of 
reporting disrupted sleep than those not taking atypical antipsychotics (p < 0.001, respectively). 
Atypical antipsychotics were not associated with snoring or pauses in breathing during sleep. 
Mood stabilizers were associated with increased odds of snoring (p < 0.001) and pauses in 
breathing during sleep (p < 0.05), but there was no association with disrupted sleep. Taking an 
antidepressant was associated with an increased likelihood of snoring (p < 0.001) and a reduced 
likelihood of disrupted sleep (p < 0.001) but had no significant association with pauses in 
breathing during sleep (Table 7).  
Associations between substance use and symptoms of sleep disturbance  
People who were at risk of hazardous/harmful/dependent drinking or who were current 
smokers were more likely to have pauses in breathing during sleep and disrupted sleep, while 
those who used cannabis or tranquilizers monthly or more frequently were more likely to have 
disrupted sleep. Monthly or more frequent amphetamine use was associated with lower 
incidence of pauses. Caffeine intake of <200 mg/day was associated with a lower incidence of 
snoring and pauses in breathing during sleep (Table 8).  
Multiple logistic regression models adjusting for multiple confounders  
After adjusting for gender, age, and BMI in multiple logistic regression models, the odds of 
pauses in breathing during sleep in participants with a positive history of cardiovascular disease 
remained 1.96 times (95% CI, 1.19, 3.48) higher than those with- out the history of 
cardiovascular disease. Participants who were at high risk of hazardous/harmful/dependent 
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drinking had odds ratio of snoring 1.59 times (CI 1.07, 2.38) and pause in breathing during 
sleep 1.882 times (CI 1.15, 3.09) in low risk participants (Table 9).  
Discussion 
In this representative sample of people with psychotic illness, symptoms of OSA were highly 
prevalent, with rates of pauses in breathing during sleep and snoring 17.4 and 41.9%, 
respectively. However, these results are likely to be underestimates given that 83% of patients 
were neither married or in a de facto relationship and, thus, likely had no regular bed partner 
to notice these symptoms during sleep. Our results confirm and add precision to findings from 
previous studies with small samples of selected patients with schizophrenia (15–18). Further, 
the prevalence of OSA in our study sample was much higher than the prevalence of OSA in 
general population, which is estimated to be 3–5% (1, 32–36).  
Our study has demonstrated that symptoms of OSA (snoring and pauses in breathing during 
sleep) were associated with higher likelihood of meeting at-risk criteria for key cardiometabolic 
risk factors. Symptoms of OSA were associated with a higher rate of a reported history of 
cardiovascular diseases. The association between pause in breathing during sleep and reported 
history of cardiovascular disease remained significant after adjusting for BMI, age, and gender. 
Previous studies in the general population have found that OSA is a significant independent 
risk factor for CVD-related mortality and a composite endpoint of all-cause mortality and 
incident stroke (37). Additionally, obesity, male gender, older age, and increased neck 
circumference are the most significant risk factors for OSA. Thus, it is likely that OSA and 
obesity may impact on each other to set up a vicious cycle, thereby creating severe 
cardiometabolic disease.  
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We found that OSA symptoms, such as snoring and pauses in breathing during sleep, did not 
impact on the severity of psychopathology, including depressive, psychotic, and manic 
symptoms, except anxiety symptoms. Disrupted sleep was associated with more severe 
symptoms in all domains measured. We are not aware of any previous studies examining the 
associations between OSA and psychopathology in people with psychosis; however, a number 
of case studies have reported a reduction in positive and negative symptoms of psychosis when 
Continuous Positive Airway Pressure (CPAP) treatment was initiated (38–41).  
Our results revealed an unexpected finding. People prescribed with more obesogenic and 
sedative atypical antipsychotics were less likely to report subjective sleep disturbances, than 
those who were prescribed other psychotropic drugs. This contradicts an earlier retrospective 
study, which found that atypical antipsychotic medications were independently associated with 
OSA, and that individuals taking atypical antipsychotics had more severe sleep apnea when 
adjusted for BMI, sex, and use of benzodiazepines and sleeping aids (42). It has been suggested 
that the sedative actions of atypical antipsychotics may reduce activity of the hypoglossal and 
recurrent laryngeal nerve on upper airway musculature; however, this is not reflected in our 
data. The finding that the use of atypical antipsychotics is associated with reduced odds of 
disrupted sleep could be explained by the hypnotic effects of these medications, which could 
possibly cause a reduction in reported sleep symptoms. Another explanation for the difference 
between our results and Rishi et al. (42) is that Rishi compared people taking atypical 
antipsychotics with participants who were not taking any hypnotic medication, whereas we 
have compared people with psychotic illnesses on a variety of typical antipsychotics, atypical 
antipsychotics, mood stabilizers, and benzodiazepines. Interestingly, our study showed that the 
use of mood stabilizers and antidepressants was associated with symptoms of OSA. As mood 
stabilizers and antidepressants are commonly used as adjunctive medications in psychosis, this 
finding suggests that the prescribing of these drugs may increase the risk of OSA. Another 
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possible explanation for this new finding is, people with OSA may be more depressed and 
fatigued and, therefore, more likely to be prescribed antidepressants and mood stabilizers.  
Pauses in breathing during sleep, indicating the more severe form of OSA, were associated 
with lower rates of employment or study. Evaluation of health-related quality of life showed 
that our participants reporting more severe form of symptoms of OSA had significant 
impairments in the domains of independent living and psychological well-being. It is possible 
that current sleep symptoms may negatively impact on social participation; alternatively, 
people who are disengaged from social activity may also sleep poorly, perhaps as a result of 
depression or poor physical health. However, if sleep disorders do cause a reduction in social 
function, treatment of these disorders could be associated with improved function and 
productivity. This hypothesis could be tested in clinical trials.  
In this study, we found that symptoms of sleep apnea and symptoms of disrupted sleep impact 
on different clinical domains in people with psychosis. Symptoms of sleep apnea are more 
likely to have negative relationship with people’s cardiometabolic risk, social participation, 
and physical activity, while disrupted sleep has stronger association with active psychiatric 
symptoms. This suggests that the mechanism of the effect of sleep apnea on patients’ clinical 
outcomes is different from sleep deprivation alone.  
In conclusion, this study provides robust evidence that sleep disorders are prevalent in people 
with psychotic illness and may contribute a further risk factor for cardiovascular disease. The 
disease-specific determinants of OSA in people with psychosis should be elucidated in future 
studies. Further investigation and treatment of OSA in people with psychosis may be beneficial 




This study had several limitations: The inherent biases of observational data without clear 
objectives apply to this study. The measures of symptoms of sleep apnea are indirect and self-
reported. This study did not specifically examine the polypharmacy interaction or the 
medication compliance. Due to the nature of cross-sectional study, we can only identify 
associations in the data.  
Ethics statement 
This study was approved by the appropriate institutional human research ethics committees at 
each of the study sites and have therefore been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments. All 




Table 1: Social demographics 
 N % Mean ± SD 
Gender    
 Men 1039 59.3  
 Women 714 40.7  
Age   38.4 ± 11.2 
 18-34 773 42.4  
 35-64 1052 57.6  
Marital status    
 Single, never married 1117 61.2  
 Married/de facto 312 17.0  
 Separated 376 20.6  
 Widowed 20 1.1  
Education level    
 Complete year 9 410 22.5  
 Complete year 10 535 29.3  
 Complete year 11 283 15.5  
 Complete year 12 574 31.5  
Physical activity     
 Vigorous (none) 1448 79.6  
 Moderate (none) 1255 69.2  
 Walking (≤ 2hr/wk) 942 52.3  
 Total activity (≤2 hr/wk) 881 48.5  
 Sitting (hrs/week)   45.7 ± 23.2 
Level of exercise (ABS Classification)    
 Very low 611 33.6  
 Low 1148 63.1  
 Moderate 54 3  
 High 6 0.3  
Meaningful activity (paid or unpaid work, or study)    
 Yes 854 46.8  
 No 971 53.2  
Difficulty reading, writing or both    
 Yes 335 18.4  





 N % Mean ± SD 
BMI - criteria from Wold Health Organization   30.5  ± 7.5 
 Underweight 26 1.5  
 Normal 409 23.1  
 Overweight 516 29.1  
 Obese 823 46.4  
Any history of cardiovascular disease   
(including hypertension and stroke) 
505 28.5  
Diagnosis    
 Schizophrenia 857 47.0  
 Schizoaffective disorder 293 16.1  
 Bipolar disorder with psychotic features  319 17.5  
 
Depression with psychosis 81 4.4  
 Delusional disorder 92 5.0  
 Major depression without psychosis 158 8.7  





Table 2: Sleep data of the study population (present state) 
 N % 
Sleep apnoea snoring   
 Never 1018 58.1 
 Rarely 185 10.6 
 Occasionally 213 12.2 
 Frequently 337 19.2 
Sleep apnoea (pause)   
 Never 1418 82.6 
 Rarely 100 5.8 
 
Occasionally 78 4.5 
 Frequently 121 7.0 
Disrupted sleep                 
 Rarely 837 46.3 
 Some of the night 415 23.0 
 Most of the night 318 17.6 






Table 3: Univariate associations between participant characteristics and symptoms of sleep disturbance 
 Snore Pause Disruptive sleep 
N % X2   (p) OR (95%CI) N % X2   (p) OR (95%CI) N % X2   (p) OR (95%CI) 
Gender             
Men  399 38.4 13  *** 1.43 
(1.18, 1.73) 
117 17.4 0.01 1.01 
(0.78, 1.30) 
557 51.8 3.6 1.20 
(0.99, 1.45) 
Women  336 47.1 122 17.5 412 56.4 
Age             
18-34  259 34.1 33.5 *** 1.77 
(1.46, 2.16) 
110 14.9 5.8 * 1.37 
(1.06, 1.77) 
390 50.7 4.7 * 1.23 
(1.02, 1.48) 35-64  476 47.9 189 19.3 579 55.8 
Lives alone             
Yes  208 39.4 2.3 0.85 
(0.69, 1.05) 
82 15.9 1.2 0.86 
(0.65, 1.13) 
314 56 1.5 1.13 
(0.93, 1.39) No  514 43.3 210 18.1 637 52.8  
Formal activity (paid or unpaid work, or study)         
Yes  345 41.5 0.14 0.97 
(0.8, 1.17) 
122 15 6.5 * 0.72 
(0.56, 0.93) 
450 52.9 0.39 0.94 
(0.78, 1.15) 
No  390 42.3 177 19.6 519 54.3  
Paid employment - past year           
Yes  232 39.9 1.4 0.88 
(0.72, 108) 
75 13.2 10.7 ** 0.62 
(0.47, 0.83) 
308 51.9 1.2 0.9 
(0.74, 1.09) 
No  503 42.9 224 19.5 661 54.5  
Paid employment - past week           
Yes  156 40.9 0.2 0.95 
(0.75, 1.2) 
43 11.4 12.1 *** 0.55 
(0.39, 0.77) 
194 49.6 3.3 0.81 
(0.65, 1.12) 
No  579 42.2 256 19.1 775 54.8   
OR – odds ratio; CI; confidence interval; *, p<0.05; **, p<0.01; ***, p<0.001   
 
 
Table 4: Univariate associations between participant cardiovascular risk factors and symptoms of sleep disturbance 
 Snore Pause Disruptive sleep 
N % X2   (p) OR (95% CI) N % X2   (p) OR (95%CI) N % X2   (p) OR (95%CI) 
Triglycerides level - criteria from IDF criteria         








350 57.3 6.5 
 
1.33 
(1.07, 1.66) Not at risk  247 38.2 73 11.6 333 50.2 
Fasting Plasma Glucose level -criteria from IDF criteria         








205 56 1.2 1.15 
(0.9, 1.47) Not at risk  357 40.3 139 16 478 52.6 
Blood Pressure Systolic and diastolic - IDF criteria         








465 54.5 0.6 1.08 
(0.89, 1.3) Not at risk  310 35.5 125 14.6 474 52.7 
BMI: overweight - IDF criteria           








701 52.8 0.8 0.91 
(0.73, 1.13) No  122 28.7 32 7.7 240 55.3 
HDL level - IDF criteria           








343 54.5 0.4 1.08 
(0.86, 1.34) Not at risk  244 39.5 82 13.6 336 52.7 
Metabolic syndrome - IDF criteria           








347 55.6 1.7 1.16 





 Snore Pause Disruptive sleep 
N % X2   (p) OR (95% CI) N % X2   (p) OR (95%CI) N % X2   (p) OR (95%CI) 
Absolute cardiovascular disease 5 year risk - Framingham risk equation        












Low  361 41 138 16 461 51.2 
Any history of cardiovascular disease  (including hypertension and stroke)      
Yes  263 54.6 43.2 *** 2.03 
(1.64, 2.52) 




300 60.4 12.9 *** 1.47 
(1.19, 1.82) No  459 37.1 170 14.0 644 50.9 





Table 5: Univariate associations between participant physical activities, quality of life and symptoms of sleep disturbance 
 Snore Pause Disruptive sleep 
N % X2  (p) OR (95% CI) N % X2   (p) OR (95% CI) N % X2   (p) OR (95% CI) 
Vigorous activity (hr/week)         
0  598 43.2 3.8 1.27 
(1.0, 1.6) 
254 18.7 7.5 ** 1.6 
(1.14, 2.26) 
770 53.7 0.0 1.0 
(0.8, 1.27) >0  137 37.5 45 12.6 198 53.5 
Moderate activity (hr/week)         
0  493 41.2 1.0 0.9 
(0.74, 1.11) 
207 17.6 0.9 1.03 
(0.79, 1.36) 
664 53.3 0.2 0.96 
(0.78, 1.17) >0  239 43.7 91 17.1 301 54.4 
Walk (hr/week)         
≤ 2  389 43.4 2.0 1.15 
(0.95, 1.39) 
169 19.3 4.2 1.3 
(1.0, 1.68) 
510 54.6 0.8 1.1 
(0.9, 1.31) >2  336 40.1 128 15.5 449 52.5 
Total activity (hr/week)         
0  105 47.7 3.4 1.3 
(0.98, 1.73) 
50 23.4 6.0 * 1.53 
(1.09, 2.16) 
122 54.2 0.0 1.03 





 Snore Pause Disruptive sleep 
N % X2  (p) OR (95% CI) N % X2   (p) OR (95% CI) N % X2   (p) OR (95% CI) 
   Mean SD   Mean SD      
AQol (log) No 985 -0.39 0.38 NS 1377 -0.37 0.35 P <0.001     
  Yes 713 -0.40 0.36 NS 285 -0.47 0.41      
Indep living (log) No 1008 -0.07 0.14 NS 1407 -0.07 0.14 P<0.05     
 Yes 728 -0.08 0.14  293 -0.09 0.15      
Social rel (log) No 991 -0.26 0.32 NS 1389 -0.25 0.31 NS     
 Yes 718 -0.24 0.29  287 -0.26 0.30      
Physic sense (log) No 1012 -0.03 0.06 NS 1412 -0.03 0.05 NS     
 Yes 732 -0.03 0.05  296 -0.03 0.06      
Psy wellbeing (log) No 1009 -0.09 0.15 NS 1409 -0.09 0.14 P = 0.000     
 Yes 730 -0.10 0.14  294 -0.13 0.18      
OR – odds ratio; CI - confidence interval; AQol (log): algorithms for the Assessment of Quality of Life-4D multiattribute utility score; Indep living (log): algorithms for 
independent living; Social rel (log): algorithms for social relationships; Phsic sense (log); algorithms for physical senses; Psy wellbeing (log); algorithms for psychological 
well-being ; *, p<0.05; **, p<0.01; ***, p<0.001   
 
 
Table 6: Univariate associations between subjects’ psychopathology at present state and symptoms of sleep disturbance 
 Snore Pause Disruptive sleep 
N % X2 (p) OR (95% CI) N % X2 (p) OR (95% CI) N % X2 (p) OR (95% CI) 
Hallucinations, delusions or subjective thought disorder in the past one month      
Yes  404 41.0 0.1 1.02 
(0.85, 1.24) 
182 19.1 4.4 1.28 
(0.99, 1.64) 
576 57.4% 12.9 *** 1.41 
(1.17, 1.7) No  331 42.4 117 15.3 393 48.9% 
Any depressive symptoms  in the past one month         
Yes  210 41.5 0.1 0.98 
(0.79, 1.2) 
97 19.8 2.7 1.25 
(0.96, 1.64) 
366 70.2% 81.1 *** 2.67 
(2.15, 3.32) No  525 42.1 202 16.5 603 46.9% 
Screen for mania over the past one month         
Yes  75 48.4 2.9 1.33 
(0.96, 1.85) 
23 15.4 0.4 0.85 
(0.54, 1.36) 
114 72.2% 23.8 *** 2.4 
(1.68, 3.45) No  660 41.3 276 17.6 855 51.9% 
Positive general rating of anxiety or phobia in the past 12 months          
Yes  466 44.6 7.8 ** 1.32 
(1.09, 1.6) 
209 20.4 15.7 *** 1.71 
(1.31, 2.24) 
663 61.3% 63.8 *** 2.17 
(1.79, 2.63) No  269 37.9 90 13.0 306 42.2% 




Table 7: Univariate associations between participants’ psychotropic medications and symptoms of sleep disturbance 
 Snore Pause Disruptive sleep 
N % X2   (p) OR (95% CI) N % X2   (p) OR (95% CI) N % X2   (p) OR (95% CI) 
Typical antipsychotics           
Yes  156 44.4 1.1 1.14 
(0.9, 1.44) 
63 18.4 0.3 1.1 
(0.8, 1.48) 
186 51.7 0.7 0.91 
(0.72, 1.14) No  579 41.3 236 17.2 783 54.1 
Atypical antipsychotics           
Yes  526 41.9 0.0 1.0 
(0.81, 1.23) 
203 16.5 2.3 0.81 
(0.62, 1.06) 
651 50.5 18.5 *** 0.63 
(0.52, 0.78) No  209 42.0 96 19.6 318 61.6 
Mood stabiliser             
Yes  237 50.7 20.3 *** 1.63 
(1.32, 2.02) 
92 20 3.9 * 1.32 
(1.0, 1.73) 
251 51.8 1.0 0.9 
(0.73, 1.11) No  498 38.7 207 16.3 718 54.4 
Antidepressant            
Yes  307 47.7 11.1 *** 1.39 
(1.15, 1.69) 
126 19.7 3.7 1.28 
(0.99, 1.65) 
405 60.1 17.9 *** 1.52 
(1.25, 1.84) No  428 38.9 173 16.1 564 49.8 
Clozapine             
Yes  118 41.7 0.0 1.0 
(0.76, 1.28) 
49 17.6 0.0 1.0 
(0.72, 1.42) 
126 42.6 17.5 *** 0.59 
(0.46, 0.75) 
No  617 42.0 250 17.4 843 55.8 




Table 8: Univariate associations between substance use and symptoms of sleep disturbance 
 Snore Pause Disruptive sleep 
N % X2   (p) OR (95% CI) N % X2   (p) OR (95% CI) N % X2   (p) OR (95% CI) 
Alcohol risk (AUDIT)         
 Low 496 41.7 0.1 1.03 
(0.84, 1.26) 
185 15.9 5.5 * 1.36 
(1.05, 1.76) 
627 51.1 9.7 ** 1.37 
(1.12, 1.68)  High 239 42.5 114 20.5 342 59 
Current smoker         
 No 242 42.2 0.0 0.99 
(0.81, 1.21) 
75 13.2 10.8 *** 1.6 
(1.21, 2.13) 
297 49.6 5.6 * 1.27 
(1.04, 1.54)  Yes 490 42.0 223 19.6 663 55.5 
Cannabis use - past year         
 <monthly 304 40.6 0.0 1.02 
(0.8, 1.3) 
136 18.7 0.0 1.0 
(0.75, 1.38) 
391 51.0 9.8 ** 1.46 
(1.15, 1.86)  ≥monthly 176 41.1 79 18.9 264 60.4 
Amphetamine use - past year         
 <monthly 256 41.6 0.6 0.84 
(0.54, 1.31) 
130 21.7 6.3 * 0.43 
(0.22, 0.84) 
347 54.8 2.5 1.42 
(0.92, 2.2)  ≥monthly 36 37.5 10 10.5 62 63.3 
Tranquilizers use - past year         
 <monthly 77 45.6 2.2 0.6 
(0.3, 1.19) 
43 26.1 0.0 0.95 
(0.44, 2.03) 
108 62.1 5.8 * 2.58 
(1.17, 5.68)  ≥monthly 15 33.3 11 25.0 38 80.9 
Caffeine (mg/day)          
 <200mg 252 37.3 9.8 ** 1.37 
(1.15, 1.67) 
95 14.3 7.4 ** 1.44 
(1.11, 1.88) 
372 53.6 0.0 1.0 
(0.83, 1.21)  ≥200mg 483 44.8 204 19.4 597 53.7 
OR – odds ratio; CI - confidence interval;  AUDIT - Alcohol Use Disorders Identification Test ; *, p<0.05; **, p<0.01; ***, p<0.001.   
 
 
Table 9: Logistic regression model for the relationship between subjects’ OSA symptoms and disease factors 
 Snore Pause 
 Unadjusted OR 
(95% CI) 
P Adjusted OR 
(95%CI) 
P Unadjusted OR 
(95% CI) 
P Adjusted OR 
(95%CI) 
P 
Physical Health         































Physical activities         





























Social function          


































 Snore Pause 
 Unadjusted OR 
(95% CI) 
P Adjusted OR 
(95%CI) 
P Unadjusted OR 
(95% CI) 
P Adjusted OR 
(95%CI) 
P 
Substance abuse         
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Objectives: Obstructive sleep apnoea (OSA) may be more common in people with 
schizophrenia compared to the general population, but the relative prevalence is unknown. 
Here, we determine the relative prevalence of severe OSA in a cohort of men with 
schizophrenia compared to representative general population controls and investigate the 
contribution of age and body mass index (BMI) to differences in prevalence.  
Methods: Rates of severe OSA (apnoea–hypopnoea index > 30) were compared between male 
patients with schizophrenia and controls from a representative general population study of 
OSA. 
Results: The prevalence of severe OSA was 25% in the schizophrenia group and 12.3% in the 
general population group. In subgroups matched by age, the relative risk of severe OSA was 
2.9 (p = 0.05) in the schizophrenia subjects, but when adjusted for age and BMI, the relative 
risk dropped to 1.7 and became non-significant (p = 0.17).  
Conclusions: OSA is prevalent in men with schizophrenia. Obesity may be an important 
contributing factor to the increased rate of OSA.  
Keywords: schizophrenia, psychosis, obstructive sleep apnoea, obesity, BMI, apnoea–





Obstructive sleep apnoea (OSA) may be more prevalent in people with schizophrenia 
compared to the general population, given the high rates of risk factors for OSA such as obesity, 
tobacco smoking, alcohol consumption and sedative medication use.1 Studies assessing OSA 
in people with schizophrenia provide prevalence estimates between 13.5 and 57.1%,2–4 which 
is higher than the general population.5 However, these studies may not provide generalisable 
or consistent data due to biases in recruitment and variability in assessment measures and 
diagnostic thresholds for OSA. There is no literature reporting the comparative prevalence of 
OSA in people with schizophrenia with matched general population controls.  
Analysis of registry data suggests that diagnosis of a psychotic illness is predictive of OSA.6 
Similarly, Rishi et al.7 reported an increased prevalence of severe OSA in a cohort exposed to 
atypical antipsychotic drugs compared to controls (odds ratio = 1.9, 95% confidence interval 
(CI) 1.1–3.3). Causes of these associations are unclear. The most important risk factor for OSA 
is obesity, which is highly prevalent in people with schizophrenia.1 Whilst obesity ostensibly 
increases the risk of OSA in this group, pharmacological factors such as hypnotic and central-
apnoeic effects of antipsychotics8 or sleep architecture changes intrinsic to schizophrenia9 may 
independently increase the risk of OSA beyond traditional risk factors. Furthermore, 
determining whether, and to what extent, OSA is over-represented in people with schizophrenia 
would help enhance clinical awareness and recognition, and enable evidence-based provision 
of treatment services.  
To further explore the relationship between OSA and schizophrenia, we aimed to determine 
the relative prevalence of OSA in men with schizophrenia taking clozapine compared to a 
general population control group matched for age and body mass index (BMI). We 
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hypothesised that rates of OSA would be higher in men with schizophrenia when matched for 
the traditional risk factors of increased age and BMI.  
Methods  
Population  
The data compared two cohorts: a community sample of men with stable schizophrenia (the 
Assessing Sleep in Schizophrenia and Evaluating Treatment (ASSET) study); and a 
comparison cohort of male general population controls (the Men Androgen Inflammation 
Lifestyle Environmental and Stress (MAILES) study).  
The ASSET subjects were recruited between 2015–2016 from a psychiatric outpatient clinic in 
Adelaide. Inclusion criteria included a current diagnosis of schizophrenia or schizoaffective 
disorder, age 18–64 years and current treatment with Clozapine as an outpatient. Ethics 
approval was provided by The Queen Elizabeth Hospital Human Research Ethics Committees 
(HREC). All participants gave written informed consent.  
Control subjects were drawn from the MAILES database, the details of which have been 
previously described.10 The cohort consisted of randomly selected community dwelling men 
aged at least 40 years residing in Adelaide, who were recruited between 2000–2002. The study 
was approved by the North West Adelaide Health Service and the Royal Adelaide HREC.  
Measures  
For both cohorts, height, weight and BMI were recorded. Subjects underwent home 
multichannel polysomnography (PSG), using an Embletta X100 (Embla Systems, Broomfield, 
CO) or a Somte (Compumedics, Abbotsford, VIC) portable sleep recorder in the schizophrenia 
cohort and the Embletta X100 in the control group. A sleep technician performed manual 
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scoring according to the American Academy of Sleep Medicine 2007 alternate criteria to derive 
an apnoea–hypopnoea index (AHI).11  
The primary outcome was a diagnosis of severe sleep apnoea defined as an AHI of ≥ 30. The 
prevalence of severe OSA in the ASSET and MAILES groups was determined. ASSET and 
MAILES subjects were then matched for age and BMI, and the prevalence in the two groups 
was compared, controlling for these factors.  
Statistical methods  
Relative risks were estimated directly using Poisson regression with sandwich estimated 
covariance matrix,12 and using propensity score matched conditional logistic regression. In 
both models, severe OSA was considered an event. Age, separately and with BMI, was adjusted 
for in the Poisson regression and propensity score matching. Due to the imbalance in age 
distribution between the two cohorts, the Poisson regression was repeated in the subgroup of 
individuals with ages between 41 and 61 that spans the age range of both cohorts. The 
propensity score matching attempted to match 25 controls for each case. Analyses were 
performed in R (version 3.3.1) using statistical, survival, non-random and splines packages.  
Results  
The ASSET group consisted of 24 men with schizophrenia who had undertaken home PSG 
recording. Six (25%) participants had severe OSA (AHI > 30). The MAILES sample consisted 
of 837 men who had been randomly selected for home PSG. The MAILES cohort was older (p 
< 0.001) and less obese (p < 0.001) than the ASSET subjects. The median age of the MAILES 
subjects was 59 years (range 41–88), median BMI was 28 (range 27–47) and median AHI was 
11 (range 1–109). One-hundred and three (12.3%) MAILES participants had severe OSA (AHI 
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> 30). The unadjusted comparison of the prevalence of severe OSA indicates a significantly 
higher rate in the ASSET population (p = 0.05).  
When adjusting for age alone in the unrestricted sample, the relative risk of severe OSA was 
2.9 (95% CI 1.0–8.1, p = 0.05). When adjusting for age and BMI in the unrestricted sample, 
the relative risk of severe OSA was reduced to 1.7 (95% CI 0.8–3.7) and became non-
significant p = 0.17.  
Restrictions and matching were performed to test the statistical robustness of the results. When 
restricting for age, there were 15 participants included in the ASSET and 569 participants 
included in the MAILES, and when using the propensity scoring matching there were 13 
participants included in the ASSET and 325 participants included in the MAILES (see Table 
1). The sample composition for each analysis is outlined in Figure 1.  
Discussion  
This study demonstrates that severe OSA is highly prevalent in men with schizophrenia, 
occurring at a rate of approximately 25%. However, we were unable to demonstrate an 
increased risk of OSA in men with schizophrenia compared to general population controls 
when adjusting for age and BMI. This finding refutes our hypothesis of an independent OSA 
risk factor intrinsic to schizophrenia and indicates that high rates of severe OSA in men with 
schizophrenia are driven primarily by obesity.  
The high rates of OSA in men with schizophrenia reported here add to substantial literature 
reporting a link between major mental illness, disproportionate cardiometabolic risk and death 
related to premature cardiovascular dis- ease.13 OSA is likely to play an additive role in driving 
cardiovascular risk in a significant number of men with schizophrenia. OSA is associated with 
hypertension, insulin resistance and increased cardiovascular mortality, and treatment with 
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nocturnal continuous positive airway pressure improves these risk factors and quality of life, 
and reduces direct and indirect healthcare costs.14 Men with schizophrenia should be 
considered at high risk of OSA with early identification and treatment a clinical priority.  
The non-significant odds of OSA in men with schizophrenia compared to the general 
population cohort when matching for age and BMI argues against a psychiatric disease-specific 
or antipsychotic medication-associated risk factor. This finding is unsurprising given that 
obesity and increased neck circumference are known to be directly causative of OSA, but does 
contrast with previous literature describing an association between second-generation 
antipsychotics and OSA independent of BMI.7 Whilst we can provide no evidence to support 
such an association, the link between psychotic illness, antipsychotic medications and OSA is 
likely to be complex. Antipsychotic medications do confer a predictable risk of weight gain,15 
ostensibly contributing to an increased risk of OSA in some patients. However, the impact of 
neurobiological changes affecting sleep architecture described in schizophrenia,16 how these 
are modified by antipsychotic drugs and how this influences sleep disordered breathing remain 
to be defined.  
Although our dataset is limited by not addressing the prevalence of OSA in women with 
schizophrenia, previously published epidemiological data suggest that they have similar rates 
of obesity and smoking1 and, as such, it is likely that women are similarly predisposed to 
developing OSA. A further limitation was insufficient power to perform multivariate 
regression analysis to identify other factors associated with the increased prevalence of OSA. 
Additionally, all subjects included in our analysis were taking clozapine, which may influence 
the generalisability of our results. It is possible that non-clozapine antipsychotics influence 
OSA risk through other factors, which may account for our finding that contradicts previous 




Our data suggest that OSA is highly prevalent in men with schizophrenia. Given that up to one-
quarter of men with schizophrenia may have severe OSA and that effective treatment exists, it 
is imperative that OSA be incorporated into cardiometabolic monitoring for people with 
schizophrenia. Future research should be directed towards determining the relative prevalence 
in women with schizophrenia and investigating the role of disease-specific factors in driving 










Table 1: Relative risk estimates 
 
Cohort E (N) Prevalence Unadjusted Age adjusted Age & BMI adjusted 
 
   RR [95% CI] p-value RR [95% CI] p-value RR [95% CI] p-value 
All S 6 (24) 25% [9.8, 46.7] 2.0 [1.0, 4.2] 0.05 2.9 [1.0, 8.1] 0.05 1.7 [0.8, 3.7] 0.17 
 
M 103 (837) 12.3% [10.2, 14.7]  
     
Age restricted S 4 (15) 26.7% [7.8, 55.1] 2.5 [1, 5.9] 0.04 4.5 [1.6, 12.7] 0.004 2.6 [1.3, 5.4] 0.008 
 
M 61 (569) 10.7% [8.3, 13.6]  
     
PS matched S 4 (13) 30.8% [9.1, 61.4]1  
 
4.0 [1.2, 13.8] 0.03 2.2 [0.6, 8.6] 0.25 
 
M 32 (325) 9.8% [6.8, 13.6] 1  
     
Event and prevalence rate reported for age matched cohorts. For the age and BMI matched schizophrenia and MAILES cohorts the prevalence rates were 23.1% [5, 53.8] & 
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Objectives: We aimed to assess the incidence of Obstructive Sleep Apnoea (OSA) in people 
with schizophrenia, to explore clinical associates with OSA and how well OSA screening tools 
perform in this population. 
Methods: All patients registered in a community outpatient Clozapine clinic, between January 
2014 and March 2016 were consecutively approached to participate. Participants were screened 
for OSA using at home multichannel polysomnography (PSG) and were diagnosed with OSA 
if the apnoea-hypopneoa index (AHI) was >10 events/hr. Univariate comparison of participants 
to determine whether AHI >10 events/hr was associated with demographic factors, 
anthropometric measures and psychiatric symptoms and cognition, were performed. The 
sensitivity, specificity, positive predictive value and negative predictive value of the commonly 
used sleep symptoms scales and OSA screening tools were also determined. 
Results: Thirty participants were recruited, 24 (80%) men and six (20%) women. Mean age 
was 38.8 (range: 25-60), mean BMI was 35.7 (range 19.9-62.1).  The proportion of participants 
with OSA (AHI >10 events/hr) was 40%; 18 (60%) had no OSA, four (13%) had mild OSA 
(AHI 10.1-20) and eight (27%) had severe OSA (AHI>30).  Diagnosis of OSA was 
significantly associated with increased weight, BMI, neck circumference and systolic blood 
pressure. Diagnosis of OSA was not significantly associated with PANSS, MADRS, PSP or 
BACS scores. All OSA screening tools demonstrated poor sensitivity and specificity for a 
diagnosis of OSA.  
Conclusion: OSA was highly prevalent in this cohort of people with schizophrenia and 
occurred at a high severity based on AHI. Diagnosis of OSA was associated with increased 




Obstructive sleep apnoea (OSA) is a reversible breathing disorder characterised by obstruction 
of the airway during sleep resulting in intermittent hypoxia and repeated arousals. The major 
risk factor for OSA is obesity and OSA can be contributed to by use of sedating medications. 
Untreated OSA results in non-restorative sleep and is associated with increased 
cardiometabolic risk, decrements in cognitive capacity, poorer occupational performance, 
daytime somnolence and depressive symptoms (Patil et al., 2007).  
OSA is likely to be highly prevalent in people with schizophrenia given the high rates of obesity 
in this population (Galletly et al., 2012). We conducted a systematic review of existing 
literature examining rates of OSA in cohorts of people with schizophrenia and identified four 
previous studies that reported OSA prevalence of between 19-57% (Myles et al., 2016), which 
is substantially higher than that seen in general population studies including a landmark 2015 
study that reported rates of severe OSA of 15% in men aged 40-60 years, and 1% in women 
aged 40-60. (Heinzer et al., 2015). However, no previous literature reports the prevalence of 
OSA in unselected cohorts of people with schizophrenia using gold-standard diagnostic 
methods. Similarly, only one previous study examined the diagnostic performance of general 
population OSA screening tools in this cohort and this study was confounded by a 
heterogeneity of diagnoses with a cohort with “mental illness”, 48% of which had a diagnosis 
of schizophrenia or schizoaffective disorder (Anderson et al., 2012). The result of this study 
suggests that OSA screening tools perform poorly in people with schizophrenia and comorbid 
OSA. Optimal identification of OSA in people with schizophrenia is an unmet clinical need 
and requires further clarification given the availability of effective treatment that may modify 
cardiovascular risk, which remains the main determinant of premature mortality in people with 
schizophrenia (Laursen et al., 2012). 
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The impact of untreated OSA on cognitive performance and psychiatric disease symptoms in 
people with schizophrenia also requires further clarification. People with schizophrenia 
consistently perform 1.5 standard deviations below population means in standardized cognitive 
assessments (Keefe et al., 2008). Disease-related cognitive decrements are generally treatment-
resistant to antipsychotic medications and are associated with poorer functional and social 
recovery (Fett et al., 2011). Untreated OSA has a well-established association with impaired 
cognitive function and poorer occupational performance (Patil et al., 2007) which is reversible 
with continuous positive airway pressure (CPAP) treatment (Matthews and Aloia, 2011). As 
such it is possible that co-morbid OSA may worsen negative and cognitive symptoms in people 
with schizophrenia. This association has not been previously investigated and if demonstrated 
may offer a novel means to modify treatment-resistant symptoms and improve functional 
recovery. 
We conducted a prospective pilot cohort study to determine the prevalence of OSA in an 
unselected group of community patients with schizophrenia prescribed clozapine. Our aims 
were to determine whether diagnosis of OSA was associated with anthropometric measures, 
psychiatric symptoms, medication use and cognitive performance. Further, we aimed to 
ascertain whether the existing OSA screening tools were useful in predicting OSA in people 
with schizophrenia.  
Methods  
Population 
Subjects were recruited from a clozapine outpatient clinic with 104 registered patients in 
Adelaide, South Australia. The “clozapine clinic” provides weekly and monthly reviews of 
people with treatment resistant schizophrenia or schizoaffective disorder taking clozapine. 
Inclusion criteria included males and females aged 18-64 years, a current clinical diagnosis of 
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schizophrenia or schizoaffective disorder and currently prescribed clozapine. Exclusion criteria 
included inability to provide informed consent and a diagnosis of sleep disordered breathing, 
as defined by a partial or complete cessation of breathing occurring many times throughout the 
night, resulting in daytime sleepiness or fatigue that interferes with a person's ability to 
function. Every patient registered in the clinic between January 2014 and March 2016 was 
approached to participate in the study. Ethics approval was provided by The Central Adelaide 
Local Health Network Human Research Ethics Committee. All participants gave written 
informed consent. 
Measures 
Baseline demographic and anthropometric data were recorded including age, sex, medical 
history, prescribed medications, height, weight, waist and neck circumference, body mass 
index (BMI) and blood pressure. Abdominal obesity was defined as a waist circumference ≥ 
94 cm for men and ≥ 80 cm for women. Hypertension was diagnosed if the person had a systolic 
blood pressure ≥ 130 mmHg and/or a diastolic pressure ≥ 85 mmHg. Psychopathological 
measures included the Positive and Negative Symptoms Scale (PANSS) (Kay et al., 1987), 
Montgomery Asperger’s Depression Rating Scale (MADRS) (Williams and Kobak, 2008) and 
Personal and Social Performance scale (PSP) (Morosini et al., 2000).  Standardised cognitive 
assessment was undertaken using the Brief Assessment of Cognition for Schizophrenia 
(BACS) (Keefe et al., 2008). Subjective sleep quality was assessed with the Pittsburg Sleep 
Quality Inventory (PSQI) (Buysse et al., 1989),  subjective daytime sleepiness with the 
Epworth Sleepiness Scale (ESS), severity of insomnia with Insomnia Severity Index (ISI) 
(Morin et al., 2011) and sleep related quality of life with Functional Outcomes of Sleep 
Questionnaire (FOSQ) (Weaver et al., 1997). Patients were assessed with standard OSA 
screening questionnaires including the OSA50 (Chai-Coetzer et al., 2011), and the STOP-
BANG questionnaire (Ong et al., 2010).   
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Following recruitment and baseline measures subjects underwent at-home multichannel 
polysomnography (PSG) using an Embletta X100 (Natus Medical Inc, USA) or Somte 
(Compumedics, Australia) portable sleep recorder administered in the participants home. PSG 
data were manually scored using the 2007 AASM alternate criteria to obtain an apnoea-
hypopnoea index (AHI) (Iber et al., 2007). A diagnosis of OSA was determined as an AHI >10 
events/hr and categorised as moderate if AHI was 20.1-30 or severe if AHI was >30 (Ruehland 
et al., 2009).  
Statistical Methods 
Statistical analyses were performed using SPSS 24 (IBM, New York). Univariate analysis was 
performed using chi-squared tests, independent samples t-tests for parametric data, Mann-
Whitney U tests for non-parametric data and Pearson’s test for linear correlation. Logistic 
regression was performed to determine the predictive value of diagnostic screening tests and 
diagnosis of severe OSA (AHI >30). A p-value of <0.05 was considered the threshold for 
statistical significance. 
Results  
104 patients enrolled in the clozapine clinic were approached for inclusion. 30 patients 
undertook study measures (see diagram 1). The other 74 patients satisfied inclusion criteria but 
did not give their consent to participate in the research project.  No participants had previously 
been assessed for OSA using PSG. All patients tolerated PSG and provided diagnostic quality 
sleep studies, one patient repeated the study due to an equipment error. The demographic and 
anthropometric data of the 30 patients are presented in table 1. The majority of the sample was 
overweight (27% BMI 25-30) or obese (63% BMI>30). 90% of subjects either lived alone or 
had no bed partner to corroborate the presence or absence of snoring or apnoeas. 77% of 
participants were prescribed clozapine as their only antipsychotic medication, 20% one 
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additional antipsychotic medication and 3% two additional antipsychotic medications. 27% of 
participants were prescribed clozapine as their only psychotropic medication, 43% were 
prescribed one additional psychotropic medication and 30% were prescribed two or more 
additional psychotropic medications. 
Table 1: Demographic and anthropometric data 
 All: N=30 Men: N=24 (80%) Women N=6 (20%) 
Mean age (range) 38.8 (25-60) 39.5 (25-60) 36.0 (30-42) 
Mean BMI (range) 35.7 (19.9-62.1) 34.4 (19.9-62) 40.6 (25.8-48.5) 
BMI categories 
Normal (BMI 18.5-25) 10% (n=3) 12.5% (n=3) - 
Overweight (BMI 25.1-30) 27% (n=8) 29% (n=7) 17% (n=1) 
Obese (BMI >30) 63% (19) 58% (n=14) 83% (n=5) 
Mean neck circumference cm (range)  43.15 (35-53) 41.2 (39-43) 
Mean waist circumference cm (range)   117.3 (85-162) 125.9 (100-140) 
 
OSA defined as an AHI >10 was present in 12 patients or 40% (95%CI = [23, 59]) of the 
cohort. The cohort mean AHI was 21.1 (SD 35) with a range of 0-134 (see table 2).  
Table 2: PSG data 
OSA categories  Total (n=30) Men (n=24) Women (n=6) 
AHI 0-10 (normal) 60% (n=18) 58% (n=14) 67% (n=4) 
AHI 10.1-20 (mild) 13% (n=4) 17% (n=4) - 
AHI 20.1-30 (moderate)  - - - 
AHI >30 (severe) 27% (n=8) 25% (n=6) 33% (n=2) 
*The DSM-V and AASM classifies mild OSA from an AHI>5, however Australian guidelines use AHI>10.  If 
we had used the international standard of AHI>5 there may have been greater ‘mild OSA’ diagnoses.  
Diagnosis of OSA (AHI >10) was significantly associated with higher weight, BMI, waist 
circumference, neck circumference and systolic blood pressure. Diagnosis of OSA was not 
significantly associated with age or heart rate (see table 3). Dose of clozapine was not 
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significantly associated with diagnosis of OSA (mean dose AHI <10 406mg, mean dose AHI 
10 399mg, p=0.91). 
Table 3: AHI associations with mean anthropometric measures 
 AHI <10 (n=18) AHI 10 (n=12) Mean difference [95%CI] p-value* 
Age years (SD) 37.9 (7.4) 40.2 (12.0) 2.4 [-10.6, 5.9] 0.92 
Weight kg (SD) 95.5 (27.3) 128.5 (34.8) -33.0 [-56.3, -9.8] <0.01 
BMI kg/m2 (SD) 32.0 (9.0) 41.2 (8.9) -9.2 [-16.1, -2.3] 0.01 
Waist circumference cm 
(SD) 
109.8 (18.2) 132.8 (14.8) -23.0 [-35.9, -10] <0.01 
Neck circumference cm (SD) 40.0 (2.7) 46.6 (4.2) -6.6 [-9.4, -4] <0.01 
Systolic BP mm/Hg (SD) 121.8 (12.9) 132.7 (14.2) -10.8 [-21.1, -0.25] 0.04 
Heart rate b/min (SD) 97.7 (11.7) 99.1 (10.2) -1.4 [-9.9, 7.1] 0.73 
*Independent sample t-test  
Mean ESS, PSQI and ISI scores for the entire cohort were 4.4 (SD=3.3), 5.0 (SD=2.0) and 7.9 
(SD=6.1) respectively. There was no detectable difference between mean ESS, PSQI and ISI 
scores in those with AHI 10 and those with AHI <10 (see table 4). 93% of the cohort (28 
subjects) had ESS scores within the normal range (score <10) and of the two subjects with 
elevated ESS (score 10) one was diagnosed with OSA. 63% of the cohort (19 subjects) had 
PSQI scores within the normal range (score <5), of the 11 subjects with an elevated PSQI 
(score 5) two (18%) were diagnosed with OSA. 83% of the cohort (25 subjects) had ISI scores 
within the normal range (score <15) and of the five subjects with an elevated ISI (score 15) 
one (20%) was diagnosed with OSA. There was no association found between sleep quality 
measures and AHI scores.  Total ESS did not correlate with total AHI (r=0.07, p=0.73), global 





Table 4: Associations between OSA and mean symptom severity scores 
 AHI <10 (n=18) AHI 10 (n=12) p-value * 
Mean ESS (SD) 4.0 (3.5) 5.2 (3.1) 0.34 
Mean PSQI (SD) 5.4 (2.2) 4.3 (1.8) 0.16 
Mean ISI (SD) 9.1 (6.7) 6.0 (3.5) 0.15 
*Mann-Whitney U test 
The OSA50 score (using a cut-off score of 5) correctly classified six subjects with OSA and 
eleven subjects without OSA. Sensitivity of OSA50 was 50%, specificity was 61%, (positive 
predictive value) PPV was 46% and negative predictive value (NPV) was 64%. The STOP-
BANG score (using a cut-off score of 3) correctly classified eleven subjects with OSA and 
five subjects without OSA. Sensitivity of STOP-BANG was 92%, specificity 28%, PPV was 
46% and NPV was 83%. In a logistic regression for predicting severe OSA (AHI >30) there 
was no detectable association with OSA50 total score and outcome (p=0.26) and only a low 
discriminatory ability (ROC-AUC=0.62). In contrast the association with STOP-BANG total 
score was weakly detectable (p=0.02) and had moderately higher discriminatory value (ROC-
AUC=0.77) (see figure 1, supplementary appendix). 
There were no significant associations between diagnosis of OSA and measures of 
psychopathology using the total PANSS, MADRS and PSP, nor was there a significant 
association between diagnosis of OSA and mean BACS z-score (see table 5). 
Table 5: Associations between OSA and mean psychopathology and cognitive scores 
*Mann-Whitney U test.  
 AHI <10 (n=18) AHI 10 (n=12) Mean difference (95% CI) p-value* 
Total PANSS (SD) 61.8 (15.8) 66.4 (21.3) - 4.6 [-18.7, 9.5] 0.51 
MADRS (SD) 5.9 (4.1) 4.8 (2.9) 1.1[-1.7, 3.9] 0.43 
Total PSP (SD) 56.4 (13.9) 49.5 (14.0) 6.9 [-4.1, 17.9] 0.21 




This pilot study indicates that OSA is highly prevalent in stable community dwelling people 
with schizophrenia, occurring at a rate of approximately 40%. These rates are substantially 
higher than those seen in the general population (Heinzer et al., 2015) reflecting the excess of 
obesity seen in our cohort and populations with major mental illness more generally (Galletly 
et al., 2012). Diagnosis of OSA was significantly associated with weight, BMI and neck 
circumference indicating these are clinically relevant predictors of OSA similar to general 
populations. Our results align with estimates reported in previous literature of between 19-57% 
(Myles et al., 2016), however are comparatively more robust due to our use of an unselected 
cohort, a cohort that contains only people with schizophrenia and diagnostic methods that have 
not been used in prior studies.  
Despite the high incidence of OSA in our pilot, sleep symptom scores were not substantially 
increased. The ESS and PSQI, which are validated in general populations as measures of sleep 
symptom severity (Buysse et al., 1989; Johns, 1991), were within the normal range in the 
majority of people diagnosed with OSA, were not significantly higher in people with OSA and 
did not correlate with AHI. These findings are similar to previous literature (Anderson et al., 
2012) and suggest that the ESS and PSQI should not be used as a means of identifying patients 
with schizophrenia at high risk of sleep-disordered breathing. The current Australian 
assessment for rebatable PSGs requires an above threshold score on the ESS.  Given the high 
prevalence of OSA in this population, we suggest that this should not be a restriction for people 
with Schizophrenia.  
Similarly, population screening tools performed poorly for the identification of OSA in our 
cohort. The STOP-BANG and OSA-50 scores have reasonable sensitivity and specificity in 
primary care populations (Ong et al., 2010;Chai-Coetzer et al., 2011) and are useful as a means 
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of identifying patients at risk of OSA requiring further diagnostic assessment. However, neither 
have been validated in people with major mental illness. In our cohort, the OSA-50 
demonstrated a sensitivity of 50% and specificity of 61% whilst the STOP-BANG 
demonstrated a sensitivity of 92% and specificity of 28%, which is lower than that 
demonstrated in a general population validation cohort (Ong et al., 2010). This lack of 
diagnostic accuracy may reflect the scores’ reliance on observed sleep symptoms, which are 
likely to be under-recognised in our cohort given 90% of subjects lacked a bed partner. The 
superior sensitivity of the STOP-BANG questionnaire reflects this scores’ reliance on 
anthropometric measurements such as weight, waist circumference, neck circumference and 
blood pressure. As such the STOP-BANG is a preferable tool for the identification of OSA in 
people with schizophrenia at the expense of a high false positive rate given the ubiquitous 
burden of obesity in this population that make the majority of patients high risk. 
We were unable to demonstrate a significant association between OSA and psychopathology 
scores or standardized measures of cognition in our cohort. OSA is known to be associated 
with poorer occupational performance, cognitive decrements and depression in general 
populations (Patil et al., 2007), which are reversible with CPAP treatment (Sánchez et al., 
2009;Pan et al., 2015). It is plausible, due to the high prevalence of sleep disordered breathing 
in this population, that co-morbid OSA could contribute to or worsen negative symptoms of 
schizophrenia in some people. Unfortunately, our study is insufficiently powered to detect a 
difference in psychopathology or cognitive measures. Future research in larger samples are 
required to definitively explore this possible association given treatment of OSA may 
potentially modify overlapping cognitive decrements which tend to be treatment resistant, and 
correlate with functional outcomes. 
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Whilst our study is the first to report prevalence of OSA in an unselected community cohort of 
people with schizophrenia using gold-standard diagnostic measures, there are a number of 
limitations to our analysis that warrant discussion. Firstly, our data is derived from a pilot 
cohort study and the sample size was underpowered to detect a significant association for a 
number of outcomes. This is a limitation of the literature more broadly, with the largest 
previous cohort reporting OSA prevalence in people with schizophrenia having a sample size 
of 24 (Anderson et al., 2012). Further research is required in larger cohorts to examine whether 
OSA is associated with poorer psychopathological and cognitive outcomes. Similarly, due to 
our sample size we were unable to perform meaningful multivariable analysis. Further 
evaluation of factors predictive of OSA in people with schizophrenia would be valuable to 
develop specific screening tools given the poor performance of existing tools we report here. 
Secondly, our cohort existed entirely of people exposed to clozapine which is associated with 
the highest risk of obesity compared to other antipsychotic agents. Given OSA in people with 
schizophrenia is primarily driven by obesity (Myles et al., 2018) and that clozapine use has 
previously been demonstrated to be associated with risk of OSA (Alam et al., 2012), our results 
may be biased to a higher prevalence of OSA compared to people with schizophrenia more 
generally. Thirdly, our data is observational and does not determine whether treatment of OSA 
co-morbid with schizophrenia improves cognitive measures, psychopathological outcomes, 
quality of life outcomes or cardiovascular risk factors. However, in an extension of this pilot 
study we monitored the response to CPAP and found CPAP improved obesity and cognition 
when used in people with schizophrenia and severe OSA (Myles et al., 2019).  Given the high 
prevalence of OSA in our pilot and because CPAP treatment modifies these outcomes in 
general populations further intervention studies are required to determine whether OSA 
treatment has any role in improving outcomes in this population. 
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This study indicates that OSA is highly prevalent in people with schizophrenia and is likely to 
be substantially under-recognised given that no subject diagnosed with OSA in our cohort had 
previously undergone diagnostic assessment for OSA. These results suggest OSA screening 
and diagnostic assessment should form part of routine metabolic evaluation in people with 
schizophrenia given subjects are able to tolerate PSG assessment and effective treatment exists. 
Our results also suggest general population sleep symptom tools and diagnostic screening 
questionnaires are unlikely to reliably identify people at risk and that obesity and increased 
neck circumference remain the best predictors of OSA in this population. Further research in 
larger samples is required to determine more accurate predictors of OSA in this population and 
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Previous studies have shown that people with schizophrenia have high rates of Obstructive 
Sleep Apnoea (OSA). Despite this, intervention studies to treat OSA in this population have 
not been undertaken. The ASSET (Assessing Sleep in Schizophrenia and Evaluating 
Treatment) pilot study investigated Continuous Positive Airway Pressure (CPAP) treatment of 
severe OSA in participants recruited from a clozapine clinic in Adelaide. Participants with 
severe untreated OSA (Apnoea-Hypopnoea Index (AHI) > 30), were provided with CPAP 
treatment, and assessed at baseline and six months across the following domains: physical 
health, quality of sleep, sleepiness, cognition, psychiatric symptoms and CPAP adherence. Six 
of the eight ASSET participants with severe OSA accepted CPAP. At baseline, half of the 
cohort had hypertension, all were obese with a mean BMI of 45, and they scored on average 
1.47 standard deviations below the normal population in cognitive testing. The mean AHI was 
76.8 and sleep architecture was markedly impaired with mean rapid eye movement (REM) 
sleep 4.1% and mean slow wave sleep (SWS) 4.8%. After six months of treatment there were 
improvements in cognition (BACS Z score improved by an average of 0.59) and weight loss 
(mean weight loss 7.3 ± 9 kg). Half of the participants no longer had hypertension and sleep 
architecture improved with mean REM sleep 31.4% of the night and mean SWS 24% of the 
night. Our data suggests CPAP may offer novel benefits to address cognitive impairment and 




1. Introduction  
Obstructive sleep apnoea (OSA) is a nocturnal breathing disorder caused by repeated collapse 
of the upper airway during sleep, resulting in repetitive arousal. OSA is associated with poor 
cardiovascular health due to physiological changes related to intermittent hypoxia, and reduced 
quality of life due to sleep disturbance (Al Lawati et al., 2009). Continuous positive airway 
pressure (CPAP) reverses these pathophysiological changes and improves quality of life. (Jing 
et al., 2008). OSA is prevalent in people with schizophrenia due to high rates of obesity 
(Galletly et al., 2012) and men with schizophrenia are 2.9 times more likely to have OSA than 
age matched general population controls (Myles et al., 2018). A recent systematic review 
estimated that 19–57% of people with schizophrenia suffer comorbid OSA (Myles et al., 2016); 
these rates are much higher than that seen in the general population (Heinzer et al., 2015). 
Despite this, there is minimal literature reporting outcomes following treatment of OSA in this 
population.  
The standard treatment for OSA is nocturnal CPAP which involves wearing a face or nasal 
mask that applies a continuous pressure to splint the upper airway during sleep. Effective CPAP 
treatment prevents obstructive events that cause repetitive hypoxia and arousals; and restores 
normal sleep architecture. In general population studies, not all people with OSA can tolerate 
CPAP, and the duration of CPAP use per night impacts on the clinical efficacy (Weaver et al., 
2007). Mean CPAP adherence of four hours per night is considered the minimum required for 
efficacy. Treatment outcomes and adherence rates for CPAP in people with schizophrenia have 
not been reported previously and would be valuable in determining whether treatment of OSA 
in this population is efficacious.  
In the general population CPAP reverses morbidity associated with OSA including impaired 
cognition and vigilance, insulin resistance, and hypertension (Al Lawati et al., 2009; Jing et 
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al., 2008; Patel et al., 2003). Ratings of quality of life, daytime sleepiness, depression and 
anxiety also improve with CPAP. Thus, treatment of OSA in people with schizophrenia could 
potentially improve not only cardiometabolic risk factors, but also neurocognitive and 
functional outcomes. OSA and schizophrenia (Afonso et al., 2011) are associated with 
disruptions to sleep architecture, as such it is also important to determine whether sleep 
architecture is normalized to the same extent in people with schizophrenia compared to the 
general population.  
This pilot study examined subjects diagnosed with schizophrenia and comorbid OSA. Subjects 
undertook psychiatric, cardiometabolic, cognitive and quality of life assessments prior to 
undergoing treatment with CPAP. The participants were then followed longitudinally during 6 
months of CPAP treatment to determine adherence, efficacy and acceptability of treatment, 
and changes in baseline measures. To our knowledge this is the first prospective assessment of 
CPAP usage in people with schizophrenia and comorbid OSA.  
Specifically, we aimed to determine:  
1. The efficacy of and adherence to CPAP treatment in people with schizophrenia and 
comorbid OSA.  
2. Changes in anthropometric measurements before and following six months of CPAP 
treatment  
3. Changes in psychiatric symptoms, quality of life measures, sleep quality measures and 
cognitive measures before and during CPAP treatment.  
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2. Materials and methods  
2.1. Population  
Subjects were recruited from a psychiatric outpatient clinic in Adelaide, South Australia. 
Inclusion criteria included males and females aged 18–64 years, a current clinical diagnosis of 
schizophrenia or schizoaffective disorder, currently prescribed clozapine and a diagnosis of 
severe OSA made during assessment in the ASSET study. Exclusion criteria included inability 
to provide informed consent and a diagnosis of sleep disordered breathing made prior to 
enrolment in the ASSET study. Subjects were recruited between January 2015 and March 
2016. Ethics approval was provided by The Queen Elizabeth Hospital Ethics Committee. All 
participants gave written informed consent.  
2.2. Measures  
A trained research nurse collected data on each participant at baseline at the Lyell McEwin 
Hospital Research Department, South Australia. Demographic and anthropometric data was 
recorded on the day prior to or the day following at-home diagnostic polysomnography (PSG) 
and included age, sex, medical history, prescribed medications, height, weight, waist and neck 
circumference, body mass index (BMI) and blood pressure. Waist circumference was measured 
to the nearest 0.5cm at the level of the iliac crest following two normal breaths. Abdominal 
obesity was defined as a waist circumference ≥ 94 cm for men and ≥80 cm for women. 
Hypertension was diagnosed if the person had a systolic blood pressure ≥ 130 mm Hg and/or 
a diastolic pressure ≥ 85 mm Hg. Psychopathological measures included the Positive and 
Negative Symptoms Scale (PANSS) (Kay et al., 1987), Montgomery Asperger's Depression 
Rating Scale (MADRS) (Williams and Kobak, 2008) and Personal and Social Performance 
Scale (PSP) (Morosini et al., 2000). Cognition was assessed using the Brief Assessment of 
Cognition for Schizophrenia (BACS) (Keefe et al., 2008). The results of the BACS were 
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recorded as Z scores across individual domains and as a total score for Verbal Memory (VM), 
Digit Sequencing (DIGI), Token Motor Task (TMT), Verbal Fluency (Fluency), Symbol 
Coding (SC), the Tower of London (TL) and Total z score (Total). A score of zero indicates 
that the participant is on par with the general population mean. Scores in the negative range 
indicate cognitive decrements and are presented as standard deviations below the normal 
population means. Validation studies in people with schizophrenia score 1.5 standard 
deviations below the normal population mean. Subjective sleep quality was assessed with the 
Pittsburg Sleep Quality Inventory (PSQI) (Buysse et al., 1989), severity of insomnia with 
Insomnia Se- verity Index (ISI) (Morin et al., 2011), Restless Legs Scale (RLS) (Group, 2003), 
and sleep related quality of life with Functional Outcomes of Sleep Questionnaire (FOSQ) 
(Weaver et al., 1997).  
Following recruitment and baseline measures subjects underwent at-home eight channel PSG 
performed using an Embletta ×100 (Natus Medical Inc., USA) or Somte (Compumedics, 
Australia) portable sleep recorder administered in the participants home by a trained psychiatric 
registrar. PSG data were manually staged by a BRPT registered Sleep Technician supervised 
by a board registered sleep physician at the Adelaide Institute for Sleep Health (ASIH) using 
the 2007 AASM al- ternate criteria to obtain an Apnoea-Hypopnoea Index (AHI) (Iber et al., 
2007).  
Eight subjects had an AHI > 30 events/h and were considered to have severe OSA, all were 
offered and accepted CPAP titration. We targeted an AHI > 30 events/h because this severity 
of OSA has been associated with a higher risk of cardiovascular events. Five of the participants 
then underwent laboratory-based CPAP titration overnight with additional PSG recording and 
one underwent at-home APAP titration using a Respironics REMstar Auto System (Philips, 
Netherlands). One subject underwent at-home APAP titration at their request. One subject 
 
174 
failed CPAP titration due to discomfort in the laboratory setting and one developed nausea 
when using the mask. Both of these subjects declined at-home titration. The remaining six 
formed the cohort reported in this paper. These six subjects were provided with CPAP 
machines from the Adelaide Institute for Sleep Health and received routine clinical care from 
this service consisting of an initial physician review and a one-hour education session with a 
trained CPAP nurse. Ongoing care included physician follow up with an associated nurse 
review every three months and phone contact from the nurse between reviews.  
The PSG data provided a range of sleep measures including AHI, mean apnoea/hypopnea 
duration, longest apnoea duration, number of desaturations < 90%, total sleep duration, sleep 
latency, duration of each stage of sleep, duration of slow wave sleep (SWS), total sleep time, 
duration of non-rapid eye movement (non-REM) and rapid eye movement (REM) sleep, sleep 
efficiency, number of arousals and REM latency.  
Participants were followed up after six months of CPAP use using the same anthropometric, 
psychopathological, cognitive and sleep quality measures as at baseline.  
CPAP usage was determined by analyzing subject specific CPAP telemetry recorded using 
Encore Anywhere (Philips, Netherlands) software. Recorded CPAP adherence data included 
mean daily CPAP usage, percentage usage of > 4 h, mean hourly usage on days used, average 
usage across all days, percentage of night with large leaks, average AHI and average snoring 
index.  
2.3. Outcomes  
The primary outcome was efficacy of CPAP treatment determined by changes in sleep 
architecture and AHI, and adherence to CPAP. Secondary outcomes were changes in 
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anthropometric measures, psychopathological measures, sleep quality measures and cognition 
at six-month follow-up.  
2.4. Statistical methods  
Statistical analyses were performed using SPSS 24 (IBM, New York). We present descriptive 
statistics including frequencies, means and standard deviations. No inferential statistics were 
performed due to the small sample size.  
3. Results  
104 subjects were approached for at-home PSG screening as part of the ASSET pilot study. 30 
subjects were recruited and underwent baseline study measures of whom 8 were diagnosed 
with severe OSA. Reasons for declining participation in at-home PSG screening were not 
collected in these non-consenting patients. Eight subjects from the ASSET study with severe 
OSA (AHI > 30 events/h) were offered CPAP, six (5 male, 1 female) of whom successfully 
underwent CPAP titration and completed six months of treatment (see Fig. 1).  
The sample was young and had high rates of obesity and hypertension. Mean age of the sample 
was 37.4 years (SD 12.3years), mean BMI was 45 (SD 9.6 range: 36.4–62.1), mean waist 
circumference was 137.4cm (SD 9.8cm range: 126cm–154cm), mean neck circumference was 
47.7 cm (SD 4.5 cm, range: 44 cm–53 cm), and mean AHI was 76.8 (SD 45, range: 40.2–
134.5).  
3.1. CPAP acceptability and sleep architecture pre and post-CPAP introduction  
Five CPAP titrations occurred in the laboratory setting, allowing PSG to be recorded 
throughout CPAP initiation. PSG measures of sleep architecture at baseline and after CPAP of 
the five subjects are presented in Table 1. At baseline the sample had extremely severe OSA 
with AHIs that ranged from 37.6–134.5 (mean 83.3), and associated disruption of normal sleep 
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architecture. The proportion of restorative SWS and REM sleep were reduced across the 
sample with mean time in SWS at baseline of 4.8% and mean time in REM of 4.1%. There was 
consistent improvement across these sleep domains with treatment, with REM sleep 
rebounding to 31.4% of the night and SWS 24% of the night.  
3.2. CPAP adherence  
CPAP usage was assessed using Philips Encore Anywhere software. This allowed 
determination of residual AHI with treatment, mask leakage, snoring, and percentage of the 
night CPAP was being used. Usage data for the first month is presented in Table 2, and usage 
data for the first six months of treatment is presented in Table 3. CPAP use of > 4 h per night 
is considered adequate adherence and is sufficient to substantially reverse levels of sleepiness 
(Weaver et al., 2007). In the six months of treatment the mean proportion of nights when CPAP 
was used for ≥4 h was 60%, and mean usage was 7.6 h/night, indicating adequate adherence. 
Mask leak and residual AHI are indicators of the effectiveness and proficiency with using 
CPAP. The average residual AHI across the first six months of treatment was 3.6events/h and 
percentage of the night in large leak 9.7%, indicating adequate treatment effect.  
3.3. Physical health  
Height, weight, body mass index (BMI), waist circumference (WC), and neck circumference 
(NC) before and during treatment are presented in Table 4, blood pressure and heart rate before 
and during treatment are presented in Table 5. The participants had high rates of obesity and 
hypertension (100%) for such a young sample after six months of CPAP treatment, with no 
other interventions, five participants lost weight and three no longer had hypertension.  
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3.4. Psychiatric symptom scales  
Psychiatric symptom measures were recorded at baseline and after six months of CPAP therapy 
and are presented in Table 6. Higher scores on the PANSS indicates more severe psychosis, 
higher scores on the MADRS indicates more severe depression and higher scores on the PSP 
indicate better overall functioning. There were no observable changes in psychopathology 
scales in these participants. The baseline scores were below diagnostic and clinically 
significant ranges.  
3.5. Sleep quality scales  
Sleep quality measures were recorded at baseline and after six months of CPAP therapy and 
are presented in Table 7. Higher scores on the PSQI, FOSQ, ESS, ISI and RLS indicate worse 
sleep quality in those domains. Sleep quality and functional consequences of poor sleep did 
not consistently change with CPAP. Insomnia severity reduced consistently, but the threshold 
for clinical insomnia is a score of 15, and as such the baseline results were not within the 
diagnostic range for most participants.  
3.6. Cognition  
Cognition was recorded at baseline and after six months of CPAP therapy using the BACS, the 
results are presented in Table 8. At baseline the mean BACS total Z score was −1.47 and Verbal 
memory (short term memory) −1.89. CPAP demonstrated improvements across several 
domains including Verbal memory 0.55 and the overall change was 0.59 (SD 0.25).  
4. Discussion  
This pilot study demonstrates CPAP treatment is effective at normalizing sleep architecture 
disturbances in subjects with schizophrenia and comorbid severe OSA. Average measures of 
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CPAP use were adequate at one month and were sustained over a six-month follow-up period. 
Average daily usage stabilized between 5 and 6 h on average whilst percentage of days with 
usage > 4 h a night was maintained at or above 60% for the duration of follow-up. This latter 
criterion is the threshold for adequate CPAP adherence for clinical efficacy. CPAP adherence 
has not been investigated previously in schizophrenia, and our results indicate that this 
treatment is acceptable, and usage is sustained in the long term. After six months treatment, 
the AHI remained sup- pressed, indicating effective reversal of obstructive apnoea, and there 
was a reduction in time spent with mask leakage, indicating that subjects became more 
proficient at fitting their masks correctly.  
Treatment with CPAP normalized sleep architecture with a rebound in REM sleep from an 
average of 4.1% to 31.4%, and a tripling of slow wave sleep. This may be important clinically 
as slow wave sleep is associated with rejuvenation and neuroendocrine homeostasis. 
Interestingly at follow-up after CPAP and in spite of substantial improvement in sleep 
architecture, there was little change in patient reported subjective sleep quality scales. There 
was a slight improvement in ISI scores, no change in FOSQ scores and a trend towards 
worsening of PSQI scores. A disconnect between objective functional outcomes and subjective 
impairment indicators have been previously noted in people with schizophrenia (Strassnig et 
al., 2018), our data similarly suggests subjective self-ratings are not an accurate reflection of 
objective sleep quality in people with schizophrenia.  
Participants treated with CPAP had an average 7.3 kg weight loss at 6 months with an average 
2.5 point reduction in BMI and an average 4.5 cm reduction in waist circumference. This is a 
novel finding that warrants further evaluation. Obesity is highly prevalent in people with 
schizophrenia and weight loss is difficult to achieve and maintain. All of our participants were 
taking clozapine, the most obesogenic anti- psychotic drug. In the general population, treatment 
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with CPAP is not associated with weight loss (Redenius et al., 2008). The loss of weight in our 
subjects may reflect improved vitality and an increase in physical activity; future studies should 
include objective measures of activity such as actigraphy to explore this possibility. In addition, 
restoration of normal oxygenation during sleep may be associated with a normalization of 
insulin resistance, which might advantageously influence macronutrient metabolism.  
Hypertension also improved, with a mean reduction of 12.1 mm Hg in systolic blood pressure 
and 4.8 mm Hg in diastolic blood pressure. All six participants met criteria for hypertension at 
baseline, but only three met these criteria at six months. These changes are consistent with 
general population studies of CPAP treatment in OSA (Martínez-García et al., 2013). At 
baseline all of our participants met criteria for obesity, all had at-risk waist circumference, and 
all had hypertension. People with schizophrenia have much higher rates of metabolic syndrome 
than the general population (Galletly et al., 2012), and our findings indicate improvement in 
some of the components of metabolic syndrome. 
Our subjects were relatively young (mean age 37.4 years, range 26 to 57). The early onset of 
obesity and metabolic disturbances in people with schizophrenia has been documented 
previously (Foley et al., 2013; Galletly et al., 2012). Our findings emphasize that OSA, like 
obesity and metabolic syndrome, can occur early in this population. Young people with the 
risk factors for OSA (obesity, elevated waist and neck circumference, smoking, alcohol abuse, 
sedating medications) should be screened using an objective measure such as home PSG, as 
they may well have undiagnosed OSA. 
OSA is associated with cognitive deficits, particularly: attention, vigilance, short term/working 
memory, executive functioning and motor functioning. People with normal or low baseline 
cognitive function are more vulnerable to the cognitive deficits of OSA, and these deficits have 
been found to normalize with CPAP treatment (Barnes et al., 2004; Matthews and Aloia, 2011; 
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Pan et al., 2015). The mechanisms underlying the cognitive deficits caused by OSA are poorly 
understood but may be explained to some degree by sleep fragmentation, sleep deprivation, 
hypoxia, chronic inflammation and cerebellar vascular damage. CPAP treatment improves 
performance across multiple cognitive domains (Pan et al., 2015) resulting in improved 
functional and occupational outcomes in the general population (Tregear et al., 2010). 
Translation of this benefit to people with schizophrenia and comorbid OSA would be an 
innovative means of modifying cognitive symptoms and real-world functional outcomes: 
currently an area of unmet clinical need. Our pilot results indicate that treatment of severe OSA 
with CPAP improves cognition in people with schizophrenia. Cognitive function improved 
with an average overall Z score improvement on the BACS of 0.59. Cognitive impairment is a 
major determinant of functional outcome in Schizophrenia (Green et al., 2000) and has been 
identified as a crucial target for treatment (MATRICS) (Green et al., 2004) but, as with obesity, 
achieving meaningful change has been difficult.  
This study provides proof of concept that treatment of OSA with CPAP is feasible in people 
with schizophrenia and offers insight into the novel benefits treatment may have on sleep 
quality, cardiometabolic outcomes and cognition in this population. The diagnostic measures 
and treatment interventions undertaken in this study are standard practice, not investigational 
and importantly are broadly available and easily accessible in most public health services. We 
have demonstrated that the investigation and treatment of OSA is well tolerated and acceptable 
in a population of subjects with serious mental illness, thus indicating that stable schizophrenia 
itself is neither a barrier to effective treatment nor an excuse for clinical apathy when a sleep 
disorder is suspected. Furthermore, highly powered randomized trials should be performed in 
the future to determine whether CPAP treatment of OSA comorbid with schizophrenia has a 
clinically relevant effect on cognitive and psychopathological symptoms.  
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4.1. Limitations  
Whilst our results are important and encouraging, several limitations to our study should be 
acknowledged. Firstly, the small numbers and observational nature of the study do not allow 
causal inferences to be made from the follow-up data presented and are hypothesis generating 
only. Similarly, the absence of a control group makes it difficult to determine whether changes 
in cognition are independently associated with CPAP treatment, further controlled studies are 
required to validate our results. Measures of fasting blood sugar, cholesterol and triglycerides, 
and insulin resistance were not recorded and should be included in future studies of CPAP 
treatment of OSA in schizophrenia. Secondly, whilst our data does support the acceptability of 
PSG and CPAP these results may not be broadly generalisable to typical populations of people 
with psychotic ill- ness. Whilst consecutive recruitment was undertaken, subjects refusing to 
participate in screening for OSA may have introduced selection bias where those less likely to 
adhere to CPAP were self-excluded from screening. Recruitment was also from a clozapine 
clinic, potentially representing a population where psychotic symptoms may be better 
controlled and thus adherence to treatment more likely. Similarly, universal clozapine exposure 
may have biased results in our cohort as the effect of clozapine on sleep architecture is poorly 
understood. Clozapine is highly sedating and may confound interpretation of objective daytime 
sleepiness measures that have been validated in general populations. Thirdly, the study 
interventions and follow-up may have introduced bias in that subjects may have felt more 
encouraged to participate and adhere to treatment. We consider this unlikely however as the 
majority of the study was undertaken using pre-existing sleep services and standard follow-up.  
5. Conclusion  
People with schizophrenia commonly suffer lifetime disability due to severe, chronic 
functional impairment. Our pilot data indicates that effective treatment of OSA with CPAP 
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therapy is achievable and well tolerated in people with schizophrenia and may improve 
cognition, sleep architecture and cardiometabolic measures, including blood pressure and 
weight. There is no previous published literature on the cognitive and physical outcomes before 
and after CPAP. Further re- search such as a randomized controlled trial of CPAP in people 
with schizophrenia and OSA, to determine whether CPAP leads to cognitive enhancement, 
improves functional outcomes and reduces cardiovascular disease (CVD) risk factors would 









Table 1: Sleep Architecture at baseline and immediately after CPAP initiation  
 AHI % Non-REM (stage 1&2 plus SWS) % Slow wave sleep (SWS) % REM sleep 
ID Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP 
1 73.4 1.1 97.6 84.6 4 20.4 2.4 15.4 
2 130.7 7.9 98.8 66.5 .2 21.6 1.2 33.5 
3 134.5 3.7 98.9 54.7 7.9 32.8 1.1 45.3 
4 37.6 4.4 84.4 76.6 12.1 17.5 15.6 23.4 
5 40.2 10.7 100 60.7 0 28.1 0 39.3 





Table 2: CPAP usage during the first month of treatment 
 Days used Percentage of days 
≥4 hr 
Average usage in hours on 
days used 
Average usage in hours 
on all days 
Average % of the night 
in large leak 
Average AHI 
1 24 61.3 6.1 4.7 .3 2.2 
2 19 35.5 4.4 2.8 1.4 8.5 
3 30 96.8 9.2 8.9 4.4 4.8 
4 29 84.4 7.75 7 21.7 1.7 
5 14 37.5 9.5 4 6.7 4.4 
6 29 80.6 8.75 8.15 35.2 7.3 
Mean (SD)  24 days (6.5 days) 66% (25%) 7.6hrs (2hrs) 5.9hrs (2.4hrs) 11.6% (14%) 4.8 (2.7) 




Table 3: CPAP usage during the first six months of treatment 
 Days used Percentage of days 
≥4 hr 
Average usage in hours on 
days used 
Average usage in hours 
on all days 
Average % of the night 
in large leak 
Average AHI 
1 148 67 6.85 5.5 1.7 1.6 
2 115 39.6 5.2 3.3 3.9 6.8 
3 177 89 8.7 8.5 6.8 1.9 
4 109 53.5 7.5 4.5 11.8 1.5 
5 72 34.6 8.8 3.5 8.4 2.7 
6 158 78.3 8.75 7.5 26 7.3 
Mean (SD) 130days (38days) 60.3% (21.5%) 7.6hrs  (1.4hrs) 5.4hrs (2.1hrs) 9.7% (8.7%) 3.6 (2.7) 




Table 4: Weight, BMI, WC and NC changes after 6 months treatment with CPAP 
ID Age Height Weight BMI WC NC 
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP 
1 26 176 192.5 183.3 62.14 59.79 154 151 53 missing 
2 40 170 136 125.3 47 43.01 135 133 53 46 
3 30 175 142.4 121.3 46.5 39.61 139.5 134 43 missing 
4 45 181 133.2 126 40.69 38 140 124 45 43 
5 26 186 125.8 131 36.4 37.86 130 134 44 44 
6 57 158 92.6 92 36.86 36 126 120 48 46 
Mean (SD) 137.1(32.3) 129.8 (29.7) 44.9 (9.5) 42.4 (8.9) 137.4 (9.7) 137.2 (10.7) 47.5 (4) 44.6 (1.5) 








Table 5: Blood pressure and HR changes after 6 months treatment with CPAP 
ID Systolic BP Diastolic BP Hypertension* 
Y v N 
Heart rate 
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP 
1 139 145 75 88 Y Y 95 106 
2 127 121 88 87 Y Y 88 93 
3 134 109 79 74 Y N 102 82 
4 153 120 92 84 Y N 90 92 
5 133 143 92 80 Y Y 116 102 
6 154 129 97 81 Y N 112 90 
Mean (SD) 140 (11.1) 127.8 (14.1) 87.2 (8.5) 82.3 (5.2) 50% reduction in hypertension 100.5 (11.6) 94.2 (8.6) 
Mean change (SD) -12.1 (18) -4.8 (10.2) -6.3 (14) 




Table 6: Psychiatric symptom scales before and after 6 months treatment with CPAP 
ID 
PANSS MADRS PSP 
Baseline CPAP Baseline CPAP Baseline CPAP 
1 73 62 4 Missing 49 60 
2 42 54 2 2 72 60 
3 86 92 12 4 33 37 
4 43 57 0 3 60 61 
5 63 67 6 10 60 60 
6 54 52 4 0 60 50 
Mean 60.2 (17.4) 64 (14.8) 4.8 (4.6) 3.8 (3.8) 55.6 (13.3) 54.7 (9.6) 
Mean change (SD) 3.8 (9.3) -1.0 (5.0) -1.0 (8.7) 
Abbreviations: Positive and Negative Symptom Scale (PANSS), Montgomery Aspergers Depression Rating Scale 
(MADRS), Personal and Social Performance Scale (PSP), Continuous Positive Airway Pressure (CPAP). 
 
 
Table 7: Sleep Quality measures before and after six months of CPAP 
ID PSQI FOSQ ISI RLS ESS 
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP 
1 7 11 30 35 11 6 7 0 4 4 
2 7 8 39 31 7 1 0 0 9 10 
3 4 4 19 27 16 7 11 14 11 3 
4 5 4 36 39 5 1 8 5 2 5 
5 8 6 31 32 12 8 0 12 3 5 
6 3 2 35 31 7 1 0 0 - - 
Mean 5.7 5.8 31.7 32.5 9.7 4 4.3 5.2 5.8 (4) 5.4 (2.7) 
Mean Change (SD) 0.16 (2.1) 0.83 (5.91) -5.6 (1.86) 0.83 (6.43) -0.4 (3.5) 
Abbreviations: Pittsburgh Sleep Quality Index (PSQI), Functional Outcomes of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), Restless Leg Scale (RLS), Epworth 





Table 8: Brief Assessment of Cognition for Schizophrenia (BACS) 
 
VM DIGI TMT Fluency SC TL Total 
 Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP 
1 -2.35 -1.63 -0.81 -2.08 -2.24 -0.52 1.05 0.55 0.03 0.34 0.07 0.07 -1.06 -0.81 
2 -1.31 -0.38 0.46 1.22 -0.52 -0.38 -0.35 0.22 0.74 0.34 0.35 0.62 -0.16 0.41 
3 -3.50 -2.46 -3.59 -2.58 -1.57 -0.38 -2.16 -2.33 -2.52 -2.2 -1.31 -1.03 -3.64 -2.73 
4 -0.69 0.66 -0.56 0.71 -1.18 -1.18 -0.19 0.22 -0.45 -0.29 1.17 1.45 -0.47 0.39 
5 -2.25 -2.35 -1.57 -0.05 -0.12 -0.38 -1.83 -1.5 -1.33 -0.69 -0.48 -0.75 -1.88 -1.43 
6 -1.21 -1.83 -1.82 -0.81 0.01 1.2 -0.52 -0.68 -1.4 -0.85 -1.58 -1.58 -1.62 -1.13 
Mean -1.89 -1.33 -1.32 -0.6 -0.93 -0.27 -0.67 -0.59 -0.82 -0.56 -0.3 -0.2 -1.47 -0.88 
Mean change (SD) 0.55 (0.75) 0.71 (1) 0.66 (0.8) 0.085 (0.41) 0.15(0.37) 0.09 (0.23) 0.59 (0.25) 
Abbreviations: verbal memory (VM), digit sequencing (DIGI), token motor task (TMT), verbal fluency (fluency), symbol coding (SC), Tower of London (TL).  
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Overview of thesis aims 
The aim of this thesis is to explore the relationship between schizophrenia and OSA to develop 
a translatable evidence base for improved clinical detection and treatment. This broad objective 
aligns with contemporary research efforts to improve the management of modifiable physical 
ill-health in people with major mental illness but is novel in the sense that prior to this thesis 
there was a dearth of evidence reporting on OSA comorbid with schizophrenia. This thesis was 
led by the following research questions: 
1. How prevalent is OSA in schizophrenia and is prevalence higher than in the general 
population? 
2. Is OSA comorbid with schizophrenia associated with poorer psychiatric, physical 
health and quality of life outcomes, compared to people with schizophrenia who do not 
have OSA? 
3. What risk factors or diagnostic tools are reliable for the clinical detection of OSA in 
people with schizophrenia? 
4. Is treatment for OSA tolerable and does it improve physical health and psychiatric 
outcomes in people with schizophrenia? 
The narrative arc of this thesis was firstly to report observational data on prevalence and clinical 
predictors of OSA in a cohort of people with schizophrenia and subsequently to prospectively 
determine whether CPAP treatment of diagnosed OSA is undertaken as prescribed and results 




1. Determine the prevalence of OSA using diagnostic PSG in an unselected 
psychiatrically stable, community dwelling cohort of people with treatment resistant 
schizophrenia, who were prescribed clozapine. 
2. Determine whether prevalence of OSA in this cohort is higher than a general population 
matched control cohort. 
3. Undertake exploratory analysis to determine whether or not OSA in people with 
schizophrenia is associated with physical health outcomes, psychiatric symptom 
severity, cognitive function, medication use and quality of life measures. 
4. Prospectively determine whether common sleep symptom scores and diagnostic 
screening tools developed for detection of OSA in general populations are accurate in 
people with schizophrenia. 
5. Determine if treatment of OSA comorbid with schizophrenia is undertaken as 
prescribed and whether it is associated with improvement in physical health, psychiatric 
disease and cognitive outcomes. 
Summary of research findings 
Paper 1 
Beginning this thesis with a systematic review allowed me to examine existing literature to 
determine what is already known in regard to my aims and to highlight clinically important 
deficiencies in the literature to explore in subsequent chapters. The review included studies 
that reported the prevalence of OSA in cohorts of people with schizophrenia and related 
disorders. Examining these studies allowed me to establish a putative baseline prevalence 
estimate of OSA in cohorts with schizophrenia and, in those studies reporting applicable 
clinical data, to determine whether specific physical health or psychiatric measures might assist 
as a means of clinical identification.  
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Unfortunately the included literature was heterogeneous and included samples that varied 
substantially in age, degree of obesity, psychiatric disease stability and diagnostic measures of 
OSA such that no single study was broadly generalizable. Importantly some studies were likely 
to have bias towards a higher prevalence of OSA because of convenience sampling of older 
patients or those referred for PSG because of clinical suspicion of OSA; whilst other studies 
may have been biased to lower rates because of low rates of obesity in the cohort which is not 
typical of people with schizophrenia generally. Regardless, this review found rates of OSA 
between 13.5 – 57.1%, which indicates that OSA is likely to be highly prevalent in people with 
schizophrenia. Only one study reported OSA prevalence in comparison to a general population 
control group and did not demonstrate a significant excess of OSA, however this result was 
likely to have been influenced by non-standard diagnostic measures and a very low BMI in the 
schizophrenia and control cohort.  
Increased age, BMI >25, male sex and neck circumference were the factors reported to be 
associated with a diagnosis of OSA across the studies. However, there was a lack of data 
reporting other clinical predictors or whether OSA diagnostic screening tools were valid in 
these cohorts. Importantly mean ESS and PSQI scores were low in people with schizophrenia 
and comorbid OSA in one study, indicating that sleep symptoms and daytime somnolence are 
less likely to be reported in this population. As such the clinical recommendations made in this 
paper emphasised the importance of anthropometric parameters and age and de-emphasised 
sleep symptom severity in identifying those patients suitable for further evaluation with PSG. 
At the time, this paper was the only published paper to report clinical guidelines for detection 
of OSA in people with schizophrenia. Outside of these findings, this paper did not provide any 
information on the physical health and psychiatric associations with a diagnosis of OSA nor 
did it provide information on treatment of OSA in schizophrenia. These deficits in knowledge 




This paper addressed whether symptoms of OSA were associated with physical health, 
psychiatric and quality of life outcomes in a large representative sample of people with 
schizophrenia. Whilst prior studies have reported prevalence of general sleep disturbance in 
schizophrenia (Serretti et al., 2004; Sweetwood et al., 1976), this paper is the first to report on 
sleep disturbances characteristic of OSA, and how these disturbances correlated with other 
clinical outcomes. In this sample sleep disturbance was common with 41.9% of people 
reporting snoring and 17.4% of people reporting respiratory pausing during sleep, making it 
likely that undiagnosed OSA was highly prevalent in this cohort, especially in those that 
reported pausing. This finding is perhaps unsurprising given that approximately 47% of the 
cohort were overweight or obese, putting them at especially high risk of OSA. 
Univariate exploratory analysis indicated that a number of adverse outcomes were associated 
with snoring and pausing. Salient positive findings included reduced odds of employment or 
study, increased odds of diagnosed cardiovascular disease, reduced odds of engaging in 
physical activity and, lower mean quality of life, independent living and psychological 
wellbeing scores. A multivariate logistic regression model adjusting for male sex, age and BMI 
indicated that history of cardiovascular disease and excessive alcohol consumption remained 
predictive of snoring and pausing. These findings support the hypothesis that OSA is a 
potentially modifiable cardiovascular risk factor in people with schizophrenia. Furthermore, 
the higher rate of unemployment and significant impairments in independent living and 
psychological wellbeing suggest that sleep disturbance may drive decrements in social 
participation and engagement in people with schizophrenia. As such these outcomes may also 
be modifiable with treatment of underlying co-morbid OSA. The caveat to these inferences is 
that this paper does not provide evidence of causal association; any presumed benefit from 
treatment of OSA requires prospective validation. Interestingly this paper was unable to 
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demonstrate an association between OSA symptoms and prescription of atypical antipsychotic 
drugs on univariate analysis. Comparative literature has not consistently reported an 
association between antipsychotic use and diagnosis of OSA (Rishi et al., 2010; Shirani et al., 
2011) and unfortunately this paper does not provide any definitive evidence as to whether an 
association exists. The obesogenic potential of some of these drugs may plausibly increase the 
risk of OSA in people with schizophrenia, however further evidence using multivariate analysis 
controlling for BMI and other traditional risk factors is required to more definitively evaluate 
this possible association. 
Overall this paper indicates that sleep disturbances typical of OSA are prevalent in 
schizophrenia and are associated with increased risk of cardiovascular disease and adverse 
socio-occupational and lifestyle outcomes. Whilst not demonstrating causality these findings 
further support the hypothesis that treatment of co-morbid OSA in schizophrenia may improve 
these outcomes.  
Paper 3 
The matched cohort study reported in this paper investigated whether the prevalence of OSA 
in people with schizophrenia is significantly higher than in the general population. The design 
allowed for multivariate analysis of factors predictive of a diagnosis of OSA. The cohorts were 
comprised of unselected groups screened for OSA using PSG: the first dataset (ASSET study) 
reported on a cohort of people with schizophrenia and the second dataset (MAILES study) a 
general population control group. The control group was comprised entirely of males and as 
such analyses were restricted to males only.  
This paper demonstrated that men with schizophrenia had significantly higher rates of OSA 
than the general population, with an approximately two-fold increase in risk. On multivariate 
analysis this relative risk became non-significant when adjusting for age and BMI. These 
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results confirmed my hypotheses that OSA is more prevalent in people with schizophrenia and 
that this risk is primarily driven by obesity (given the significantly lower mean age of the 
schizophrenia cohort). This is the first study to demonstrate an increased relative risk of OSA 
in people with schizophrenia and foregrounds the importance of improving detection in this 
population. Furthermore, the adjusted analysis provides robust evidence that this increase in 
risk is largely drive by obesity and as such argues against a specific antipsychotic medication 
associated risk factor beyond their obesogenic potential. 
Paper 4 
This paper reported the main results of the ASSET study which consecutively screened people 
with schizophrenia for OSA using PSG. It reported on 30 subjects with schizophrenia 
prescribed clozapine and is the first study in the literature to report the prevalence of OSA in 
an otherwise unselected psychiatrically stable cohort. The methods of this paper allowed for 
reporting of the prevalence of OSA, exploratory univariate analysis of factors associated with 
diagnosis of OSA and prospective evaluation of sleep symptom scores and OSA diagnostic 
tools. 
This paper indicated that OSA was highly prevalent in the cohort, occurring at a rate of 40% 
for any severity (AHI >10) and 27% for severe OSA (AHI >30). Similar to the results of paper 
3 anthropometric measures of elevated BMI, waist circumference and neck circumference were 
all significantly associated with diagnosis of OSA. Salient negative findings included no 
significant difference in mean dose of clozapine, mean scores on PANSS and MADRS, total 
Personal and Social Performance (PSP) scores and BACS total scores between those with and 
without a diagnosis of OSA. Analysis of sleep symptom scales indicated that there was no 
mean difference in mean ESS, PSQI or Insomnia Severity Index (ISI) between those with and 
without OSA. As a corollary a large proportion of the entire cohort had ESS (93%), PSQI 
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(63%) and ISI (83%) scores within the normal population range and none of the three symptom 
scales had a significant correlation with AHI. Similarly, the two diagnostic scoring tools 
assessed in this paper (OSA50 and STOP-BANG) were poorly discriminative for diagnosis of 
OSA in this cohort. Sensitivity and specificity for OSA50 was 50% and 61% respectively and 
for STOP-BANG 92% and 28% respectively. ROC curves also demonstrated low to moderate 
discriminatory value for the OSA50 (AUC=0.62) and STOP-BANG (AUC=0.77). 
In sum these findings confirm a high rate of OSA in people with schizophrenia and indicate 
that diagnosis is strongly associated with anthropometric factors. We were unable to detect an 
association with psychosis symptom severity (PANSS), depressive symptomatology 
(MADRS), social functioning (PSP) and cognitive decrements (BACS), which refutes the 
hypothesis that OSA compounds these negative outcomes of schizophrenia. Importantly, this 
paper demonstrates that sleep symptom scores are unreliable in people with schizophrenia and 
should not be used for identification of at-risk patients at the clinical level. It is interesting to 
note that the majority of people diagnosed with OSA in this cohort had ESS and PSQI scores 
within the normal population range which is indicative of how unreliable these tools are at 
identifying self-reported sleep pathology in people with schizophrenia. Similarly, this study 
indicates that general population OSA screening tools perform poorly in people with 
schizophrenia. Whilst the STOP-BANG was marginally superior to the OSA50 because of a 
better sensitivity, neither tool was sufficiently accurate to be recommended for clinical use in 
this population.  
Paper 5 
The final paper of this thesis was an extension of paper 4 reporting a small prospective single-
arm intervention trial of CPAP treatment in subjects of the ASSET trial who were diagnosed 
with severe OSA (AHI >30). This paper addressed the final aim the thesis, namely whether 
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CPAP treatment was effective at treating OSA and to prospectively determine whether 
treatment was associated with improvement in physical health, psychiatric and cognitive 
outcomes. Eight subjects of the ASSET trial were eligible for inclusion. Six underwent 
successful CPAP titration and completed six months of treatment and had follow-up measures 
performed. To our knowledge this is the first CPAP intervention trial in people with 
schizophrenia co-morbid with OSA. 
This paper indicated that CPAP treatment was effective at normalising AHI in all participants 
and improving sleep architecture with substantial rebound REM sleep and tripling of SWS 
observed across the cohort. Importantly, adherence to CPAP treatment was good with four of 
the six participants utilising CPAP for >4 hours per night. Mean usage per night across the 
entire group of 5.9 hours which is consistent with adequate usage for treatment effect (Weaver 
et al., 2007). Interestingly we did not observe change in subjective sleep quality scores (as 
measured by ESS and PSQI), despite objective improvements in AHI and sleep architecture. 
This observation confirms that for people with schizophrenia, subjective self-ratings are not 
useful in measuring or monitoring symptoms of sleep disturbance.  
In regard to physical health outcomes CPAP treatment at six months was associated with mean 
weight loss of 7.3kg which was an unexpected finding given that OSA treatment in general 
populations is usually associated with modest weight increase (Redenius et al., 2008). CPAP 
treatment was also associated with modest improvement in mean systolic blood pressure and 
effectively reversed a diagnosis of hypertension in three participants. This finding is consistent 
with CPAP treatment effect in general populations (Martinez-Garcia et al., 2013). Consistent 
with the results of paper 4, we were unable to detect change in PANSS, MADRS or PSP scores 
with CPAP treatment which was probably a reflection of these scores being below the 
diagnostic range at baseline in all participants. Importantly, we were able to demonstrate an 
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improvement in cognition at follow-up with mean change in BACS total Z-score of 0.59, which 
supports our hypothesis that comorbid OSA is a modifiable cause of cognitive decrements in 
people with schizophrenia. Despite the small sample size, this paper provides a proof-of-
concept that CPAP treatment is feasible and effective in people with schizophrenia and is likely 
to have novel benefits in terms of cardiometabolic and cognitive outcomes.  
Theoretical implications of main findings and future directions 
The five papers presented in this thesis substantially expand and improve on literature 
describing the relationship between, outcomes of and treatment for OSA comorbid with 
schizophrenia. More broadly this thesis also contributes incremental evidence to improve the 
physical health and cognitive outcomes of people with schizophrenia, which is the overarching 
aim of this work. Taken together the data in this thesis demonstrates clearly that OSA is highly 
prevalent in schizophrenia, is likely to be poorly recognised using general population 
screening/symptom tools and is associated with adverse physical health outcomes. Perhaps of 
more importance and novelty, however, is that this thesis provides preliminary evidence that 
people with schizophrenia undertook CPAP when it was prescribed, and that CPAP was 
effective at normalising objective measures of sleep disturbance and architecture and is 
associated with positive physical health and cognitive outcomes. The implications of these 
findings are services should consider incorporating OSA screening into routine physical health 
assessments in people with schizophrenia; further research is required to develop robust clinical 
tools for accurate identification of OSA; and treatment with CPAP should be undertaken in 
people with OSA comorbid with schizophrenia because it may result in positive clinical 
outcomes. 
In regard to the first two aims of this thesis, the results presented here confirm that OSA is 
highly prevalent in schizophrenia occurring at a rate of approximately 40% which is double 
 
206 
that seen in general male populations. This result falls within the higher range of estimated 
prevalence in the systematic review presented in chapter 2. Furthermore, this result is likely to 
be more robust and generalisable to typical populations of people with schizophrenia than 
previous literature, because of the unselected recruitment method that avoids the demographic 
biases inherent in previous studies. The high risk of OSA in people with schizophrenia, the fact 
that no subjects in the ASSET trial had been previously assessed for OSA and the poor 
correlation of sleep symptoms with diagnosis confirm that OSA is under-diagnosed in 
schizophrenia. One important implication is that screening for OSA should be incorporated 
into routine physical health assessment for people with schizophrenia. Importantly, the results 
of this thesis have been incorporated into updated clinical practice guidelines for schizophrenia 
that have been published during my doctoral candidature (Galletly et al., 2016) which indicates 
the impact my research has had.  
Because OSA is prevalent in schizophrenia the elucidation of clinical associations is important 
to identify predictors to enhance diagnosis of OSA at the clinical level. This thesis 
demonstrates that obesity is the main contributing factor to risk of OSA which is perhaps 
unsurprising given the excess rates of obesity in people with schizophrenia compared to the 
general population and because obesity is the strongest predictor of OSA generally. Of 
potentially more importance, however, are the negative findings of this thesis. Paper 2 indicated 
that prescription of atypical antipsychotic drugs was not associated with symptoms of OSA; 
paper 3 found that relative risk of OSA in people with schizophrenia became non-significant 
when controlling for age and BMI arguing against atypical antipsychotic medications (as a 
drug class) as an independent predictor of OSA; and paper 4 did not demonstrate an association 
between mean dose of clozapine and diagnosis of OSA. These results indicate that 
antipsychotic drugs are unlikely to play an aetiological role in OSA independent of their 
obesogenic effect. This thesis also demonstrates that common sleep symptom scores (ESS and 
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PSQI) and OSA diagnostic tools (OSA50 and STOP-BANG) perform poorly in people with 
schizophrenia. This may be because people with schizophrenia are unaware of subjective sleep 
disturbance, do not participate in activities queried in these questionnaires and lack a partner 
to report observed snoring during the night or tiredness during the day. As such, an important 
finding of this thesis is that these general population tools should generally be avoided for 
stratifying risk of OSA at the clinical level. Future research is required in larger cohorts to 
develop and validate population-specific tools which reliably identify those at risk of OSA in 
whom further diagnostic testing is warranted. 
Clinical outcomes associated with OSA were also explored in this thesis to identify adverse 
outcomes that may be amenable to treatment. Paper 2 indicated that symptoms of OSA were 
associated with reduced odds of employment, lower mean quality of life and psychological 
wellbeing scores and increased odds of cardiovascular disease. Although self-reported sleep 
symptoms and daytime somnolence are low in people with schizophrenia, it is possible that 
these adverse psychosocial outcomes are driven by sleep disruption intrinsic to OSA that may 
go unrecognised by patients or clinicians. The significance of increased odds of cardiovascular 
disease is difficult to interpret because of the shared risk factor of obesity. It is plausible 
however, that OSA may exacerbate insulin resistance and hypertension in some people and 
exacerbate the risk of developing cardiovascular disease. This thesis was not able to validate 
the hypothesis that OSA is associated with adverse psychiatric outcomes in schizophrenia. 
Paper 4 did not demonstrate any significant difference in mean PANSS, MADRS or PSP scores 
in people diagnosed with OSA and those who were not. These findings suggest that OSA does 
not directly exacerbate psychopathology intrinsic to schizophrenia, however further research 
in larger cohorts is required to definitively explore this possibility. 
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The final and perhaps most important part of this thesis was demonstrating that CPAP treatment 
of OSA is effective in people with schizophrenia. The single arm intervention trial presented 
in paper 5 demonstrated that CPAP titrations were achievable and that adherence to CPAP 
treatment was adequate to achieve therapeutic efficacy in the majority of participants. Effects 
of CPAP treatment at six-month follow-up included significant weight loss, improvement in 
systolic blood pressure and improvement in cognitive scores. These findings suggest treatment 
of OSA comorbid with schizophrenia should be a priority in improving both physical health 
and cognitive outcomes in people with schizophrenia. Due to the small sample size these results 
can only be considered hypothesis generating and as such further randomised trials with larger 
numbers are required to definitively confirm these exciting early findings. 
Limitations  
Whilst this thesis fills substantial gaps in existing research, there are a number of limitations 
inherent to the experiments reported here that warrant consideration. Firstly, although the 
dataset reported in paper 2 was large, it utilised OSA specific sleep symptoms as the dependent 
variable to explore possible associations with putative diagnosis of OSA. As previously 
discussed and as shown by our prospective validation of the PSQI and ESS, self-reported sleep 
symptom scores are likely to perform poorly in people with schizophrenia. This is particularly 
true for witnessed apnoeas during sleep as most people in this cohort lacked a bed partner who 
could have observed this symptom. As such this experiment may have misclassified a 
proportion of subjects as not having OSA because of unrecognised symptoms and biased the 
reported associations. Furthermore, whilst this paper did identify significant associations 
between OSA symptoms and adverse outcomes, these may have been confounded by other co-
occurring factors such as obesity, physical health comorbidity and smoking which may explain 
part of these findings.  
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In regard to paper 3, the main limitation of our findings is that the results are only applicable 
to men due to the lack of female general population controls. There is evidence of substantial 
difference in sex-specific risk factors for OSA [9] and as such it is possible that the association 
we observed for men does not hold true for women. More generally this experiment is also 
limited by the small sample size of the schizophrenia cohort which precluded powered analysis 
of other OSA risk factors. 
Whilst the experiment reported in paper 4 is the first to report OSA prevalence using diagnostic 
measures in a psychiatrically stable cohort of people with schizophrenia, it is limited by 
recruitment factors that may impact on the generalisability of our results. Firstly, all subjects 
included in this experiment were prescribed clozapine. Because clozapine is the most 
obesogenic antipsychotic drug it is plausible that our estimate of prevalence is an overestimate 
in comparison to non-clozapine populations who may be less obese. In addition it is possible 
that clozapine may be an independent risk factor for OSA because of its sedative qualities or 
possible effect on reducing sensitivity to hypoxaemic drive during sleep. Whilst we were not 
able to demonstrate any significant difference in mean dose of clozapine in people with OSA, 
this does not preclude clozapine as confounding factor in our prevalence estimate. Clozapine 
is also the most effective agent for treatment refractory schizophrenia and it is possible the 
cohort analysed in this experiment are more psychiatrically stable than more general 
populations of people with schizophrenia. As such our reported success with PSG and CPAP 
compliance may not be generalizable to less psychiatrically stable populations. 
Finally, the main limitation of paper 5 is the small sample size of participants undertaking 
CPAP and the single arm nature of the intervention. Whilst this case series does report exciting 
results it can only be considered hypothesis generating. Further randomised intervention trials 




This thesis expands broadly on previous literate and provides novel insights into the 
relationship between OSA and schizophrenia. Our results indicate that OSA is highly prevalent 
in schizophrenia, is driven mainly by excess rates of obesity in this population and is associated 
with poor physical health outcomes, reduced quality of life and poorer psychological 
wellbeing. Detection and treatment of OSA should be incorporated into the routine physical 
healthcare of people with schizophrenia and our results go some way to providing practical 
evidence to develop screening tools. Importantly this thesis indicates that CPAP treatment of 
OSA in people with schizophrenia may be beneficial in facilitating weight loss, improving 
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Background: Many risk factors for obstructive sleep apnoea (OSA) are commonly found in 
people with schizophrenia. Identification and treatment of OSA may improve physical health 
in this population; however there are no guidelines to inform screening and management. 
Objectives: Systematic review to determine, in people with schizophrenia and related 
disorders, (1) the prevalence of OSA; (2) the physical and psychiatric correlates of OSA; (3) 
the health impact of treatment of OSA in terms of measures of psychiatric and physical health, 
and quality of life; (4) the diagnostic validity of standard OSA screening tools.  
Data Sources: Medline, EMBASE, ISI Web of Science and PsycINFO electronic databases 
were searched. Cohort, case-control or cross-sectional studies or RCTs reporting on prevalence 
of OSA in subjects with schizophrenia and related disorders were reviewed. 
Results: The prevalence of OSA varied between 13.5% and 52%. Diagnosis of OSA was 
associated with larger neck circumference, BMI >25, male sex and older age. There were no 
data on physical or psychiatric outcomes following treatment of OSA. Diagnostic applicability 
of screening tools for OSA was not investigated. 
Conclusion: OSA is prevalent in people with schizophrenia and related disorders, and is 
potentially under-recognised. Further research is required to determine utility of OSA 
screening tools, the relationships between antipsychotic medications and OSA and the benefits 
of treating OSA. We propose a strategy for the identification of OSA in people with 
schizophrenia and related disorders. 




1. Introduction  
Schizophrenia is a chronic psychotic disease with peak onset in adolescence and early 
adulthood. Whilst negative symptoms, psychotic relapses and chronic socio-occupational 
impairment are common, cardiovascular disease is recognised as the primary cause of 
morbidity and mortality in this population and is responsible for a 16-18 year reduction in life-
expectancy (Laursen, 2011). Obstructive sleep apnoea (OSA) is independently associated with 
heightened risk of hypertension, diabetes, stroke, heart failure and cardiovascular disease, thus 
comorbid OSA may be an additive and modifiable risk factor for cardiovascular disease in 
people with schizophrenia (Epstein et al., 2009).  
OSA is likely to be prevalent in people with schizophrenia given the high rates of obesity, 
metabolic syndrome (Galletly et al., 2012; Mitchell et al., 2013), tobacco smoking (Myles et 
al., 2012), alcohol consumption (Moore et al., 2012), and sedative medication use, all of which 
are recognised risk factors in the general population (Al Lawati et al., 2009; Galletly et al., 
2012).  Whilst recent reviews have reported on OSA in schizophrenia (Alam and Chengappa, 
2011; Gupta and Simpson, 2015; Kalucy et al., 2013) and in general psychiatric populations 
(Gupta and Simpson, 2015) they do not provide guidance regarding screening strategies for 
OSA in people with schizophrenia. A clinically focussed review of available literature could 
provide evidence for cost-effective application of OSA screening in this population.  
Currently, screening for OSA is not recommended in any current physical health guidelines for 
schizophrenia. OSA may be less easily recognised among people with schizophrenia, where 
sleep disturbance, daytime somnolence and cognitive impairment are potentially mistaken for 
negative symptoms of schizophrenia or medication side effects.  It is also unclear whether 




We performed a systematic review to determine, in cohorts of people with a current diagnosis 
of schizophrenia or schizoaffective disorder: (1) the prevalence of OSA; (2) the physical and 
psychiatric correlates of OSA; (3) the health impact of treatment of OSA in terms of 
psychiatric, physical health and quality of life measures and; (4) the diagnostic validity of 
standard OSA screening tools and standardised measures of daytime sleepiness.  
2. Materials and methods  
The methods are based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) (Moher et al., 2009). 
2.1 Searches 
Online searches of the electronic databases Medline (1966 to April 2015), EMBASE (1988 to 
April 2015), ISI Web of Science (1900 to April 2015) and PsycINFO (1967 to April 2015) 
were undertaken using the search terms (psychosis OR schizophrenia OR OR psychotic OR 
schizoaffective disorder) AND (sleep apnoea OR sleep apnea OR sleep disordered breathing 
OR parasomnia* OR hypersomnia* OR circadian rhythm sleep disorder*) IN (title AND 
abstract AND keyword).  The search was limited to English language publications. Studies not 
published in peer-reviewed journals were not considered for inclusion. Study methodologies 
acceptable for inclusion were retrospective or prospective cohort studies, cross-sectional 
studies, case-control studies or randomised-controlled trials. Case series and reports were not 
considered for inclusion. HM performed the electronic searches. The abstracts of all identified 
papers were reviewed, and HM and NM reviewed in full-text any article appearing to report 
on schizophrenia and OSA in the title or abstract.  
2.2. Inclusion criteria 
Papers were considered for inclusion if they reported on: 
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1. Subjects with current diagnosis of a schizophrenia, schizoaffective disorder, or 
schizophreniform disorder; 
2. Prevalence of OSA based on formal overnight diagnostic testing, not specifically 
limited to multichannel polysomnography (PSG).  
Papers were considered for assessment for each objective if they individually reported on 
either: 
1. The prevalence of OSA in the cohort 
2. Psychiatric disease, physical health or anthropometric measures and quantitative 
assessment of how these related to a current diagnosis of OSA including; 
a. Quantitative measures of sedative, hypnotic or antipsychotic medication use 
b. Positive or negative symptom scores  
c. Body mass index (BMI), neck circumference, sex, age, weight, blood pressure 
(BP) 
d. Cognitive function   
e. Quality of life 
f. Social and occupational function 
3. Prospective assessment of any OSA or daytime sleepiness screening tools used for the 
identification of subjects subsequently diagnosed with OSA 
4. Physical health or psychiatric disease measures before and after treatment of OSA 
2.3. Definition of psychiatric disease and OSA measures 
A diagnosis of each psychotic illness was defined according to the primary research. We 
included studies that specified the proportion of participants within the cohort with a diagnosis 
of either: schizophrenia, schizoaffective disorder, or schizophreniform disorders. Studies 
generally defined these diagnoses according to DSM or ICD criteria with or without validation 
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according to specified diagnostic interviews. No study included people diagnosed with 
schizophreniform disorder. 
The gold standard for diagnosis of OSA is overnight multichannel PSG (Epstein et al., 2009). 
However we included broader definitions of diagnosis including at-home PSG, and overnight 
oximetry monitoring. This was used as the measure of defining a case, due to the paucity of 
literature. We felt that an inclusive strategy would be beneficial despite the trade-off of reduced 
accuracy. The diagnostic measures specific to each study were identified in the results. 
2.4. Outcome and data reporting 
Two authors, HM and NM, examined the full text of each paper to identify aims, methodology 
and outcomes (see table 1). The following data relevant to each study was extracted: 
1. Study name, date of data collection and population demographics 
2. Study design 
3. Diagnostic tool and criteria used to define a diagnosis of OSA 
4. Number of subjects enrolled in each study 
5. Outcome measures specific to the four analyses listed above 
Narrative review of the data is outlined in the results and discussion. No further statistical 
analyses were undertaken. 
3. Results  
The details of the search strategy are outline in figure 1. Electronic searches identified 817 
articles excluding duplicates. Review of title or abstract yielded 129 articles, which were 
reviewed in full text.  Four original articles reporting applicable data were identified (see table 
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1). (Poulin et al., 2003)(Poulin et al., 2003)(Poulin et al., 2003)(Poulin et al., 2003)(Poulin et 
al., 2003)The specific results for each objective are outlined below. 
3.2. Prevalence of OSA  
Four studies determined the prevalence of OSA in cohorts of subjects with schizophrenia using 
overnight multichannel PSG (Anderson et al., 2012; Winkelman, 2001) modified PSG (Ancoli-
Israel et al., 1999) or overnight oximetry (Takahashi et al., 1998). The prevalence of diagnosed 
OSA varied between 13.5% and 57.1% across the four studies (see table 1).  
The available studies varied in subject demographics. Winkelman (Winkelman, 2001) 
recruited subjects based on suspicion of OSA, which may underlie the higher prevalence in 
that cohort. Anderson (Anderson et al., 2012) included a proportion of patients who did not 
have schizophrenia or a related disorder and excluded subjects with previously diagnosed OSA, 
thereby  reducing the reported prevalence.  Ancoli-Israel (Ancoli-Israel et al., 1999) studied an 
older age group (mean age 59.6 years). The low rates reported by Takahashi (Takahashi et al., 
1998) may be as a result of the low mean BMI  (of 23.9) in this Japanese cohort, which is not 
typical of people with schizophrenia generally.  
The diagnostic criteria for OSA differed significantly across the studies. Overnight 
multichannel PSG is considered to be the gold standard for diagnosis of OSA with the Apnoea 
Hypopnea Index (AHI) from PSG being the most reproducible diagnostic measure. Anderson 
et al (2012) was the only study to conduct multichannel PSG and report an AHI, whilst 
Winkelman (2001) reported Respiratory Disturbance Index (RDI) and Ancoli-Israel et al 
(1999) reported RDI with modified polysomnography. Whilst RDI is recognised as a measure 
of sleep disordered breathing it is considered to underestimate severity of disease because it 
measures events across total recording time rather than more specifically across sleep time, 
potentially reducing the accuracy of these studies (Epstein et al., 2009). Takahashi (1998) 
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reported Oxygen Desaturation Index (ODI) and therefore it could not be determined whether 
unstable breathing events were obstructive or central in nature. The distinction is important 
given the possibility that antipsychotic medications may induce central apnoea (Rishi et al., 
2010).(Sharafkhaneh et al., 2005) 
One study (Takahashi et al., 1998) reported prevalence of OSA based on ODI in a group of 
inpatients with schizophrenia matched with a group of healthy control recruited from staff at 
the same hospitals. The prevalence was 18.1% in the schizophrenia group and 22.9% in the 
control group, a difference that was not statistically significant. The absence of a difference in 
this case-control study is possibly attributable to the low mean BMI across the two groups and 
may reflect shared risk factors between the groups. 
3.3. Physical and psychiatric correlates of OSA  
Two studies (Anderson et al., 2012; Winkelman, 2001) report data on physical health and 
demographic predictors of OSA and three studies report data on the associations between 
antipsychotic medication use and OSA (Anderson et al., 2012; Takahashi et al., 1998; 
Winkelman, 2001). No studies report on measures of quality of life, psychiatric symptoms, 
cognitive function, or social and occupational function, and how these correlate with OSA 
diagnosis.  
Anderson et al. (2012) reported correlations between diagnosis of OSA (based on AHI) and 
age, sex, weight, BMI, neck circumference and blood pressure. Age (r=0.47, p=0.001) and 
neck circumference (r=0.311, p=0.028) were positively correlated with AHI whilst the other 
measures were not correlated with AHI in univariate analyses. Binary logistic regression 
revealed male sex (OR=21.9, 95%CI 1.3-370.3) and BMI >25 (OR 36.1 95%CI 1.3-990.1) as 
significant predictors of OSA using AHI >5 as the dependent variable. Winkelman (2001) 
employed stepwise multiple logistic regression relating age, BMI and sex to OSA, using an 
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RDI >10 as the dependent variable. This analysis demonstrated significant associations for 
male sex (OR=5.76 95%CI 2.08-15.27), age (OR=1.03 95%CI 1.00-1.06) and BMI (OR=1.14 
95%CI 1.08-1.21). 
The three studies reporting on antipsychotic medications (Anderson et al., 2012; Takahashi et 
al., 1998; Winkelman, 2001) demonstrated conflicting results, likely as a result of 
methodological differences in assessment of antipsychotic use. Takahashi et al (1998) reported 
no significant correlation between dose of antipsychotic medication (expressed as mg 
equivalent dose of haloperidol) and ODI.  Winkelman (2001) demonstrated no significant 
association between antipsychotic use (defined categorically as present or absent) and an RDI 
>10 using multiple logistic regression., However, the association was significant at a higher 
RDI cut-off of >20 (OR=5.02, 95%CI 1.44-17.56). Anderson et al (2012) reported a negative 
correlation between quantitative measures of antipsychotic use (expressed as percentage of 
maximum dose) and AHI> 5 (r=-0.382, p=0.014), however no significant association was 
demonstrated between the number of prescribed antipsychotic medications and AHI >5 as the 
dependent variable on binary logistic regression.  
Benzodiazepine use was examined in two studies (Takahashi et al., 1998; Anderson et al., 
2012) with conflicting results. Takahashi (1998) reported a positive correlation between 
hypnotic medications (expressed as number of pills per day) and DI in women included in that 
study, whilst Anderson (2012) reported no significant interaction between categorical 
benzodiazepine use and AHI on binary logistic regression.  
3.4. Diagnostic utility of OSA screening tools or measures of daytime sleepiness  
No study examined the utility of available OSA screening tools in predicting a diagnosis of 
OSA in this population. Anderson et al (2012), in a cohort that included people with diagnoses 
other than schizophrenia or schizoaffective disorder, examined measures of daytime sleepiness 
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and sleep disturbance by prospectively recording Epworth Sleepiness Score (ESS) (Johns, 
1991) and Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989)  scores in subjects who 
subsequently underwent PSG.   This study defined diagnosis of OSA as an AHI >5. An 
abnormal ESS was defined as a score ≥10 whilst an abnormal PSQI was defined as a score >5. 
The prevalence of OSA was 52% in this study. The mean ESS was 5.6 (SD=5.04) and the mean 
PSQI was 6.5 (SD=3.5) across the cohort. 15% of subjects had an ESS >9 whilst 56% of 
patients had a PSQI >5. ESS and PSQI scores were moderately correlated (r=0.38, p=0.007).  
3.5. Physical health and psychopathological measures following OSA treatment  
No study reported treatment of OSA in people with schizophrenia or schizoaffective disorder, 
thus no primary evidence exists evaluating the acceptability of CPAP treatment or its efficacy 
on measures of physical health, psychopathology or functioning.  
4. Discussion 
This review suggests that OSA is common in people with schizophrenia and schizoaffective 
disorder with rates reported between 13.5% and 57.1%. The disparity in prevalence estimates 
across the included studies reflects variations in patient populations including age, selection 
bias, degree of obesity and the diagnostic measures used. It is likely that acute changes in 
mental state in inpatient studies negatively affect compliance with PSG, whilst increased use 
of sedating medications could exaggerate the severity of OSA. The prevalence of OSA in stable 
community patients with schizophrenia and schizoaffective disorder and the influences of 
obesity, sedative medication use, alcohol abuse, smoking and antipsychotic medication remain 
to be determined. 
The prevalence of OSA reported in the included studies is substantially higher than general 
population prevalence estimates of between 3-4% in men and around 2% in women (Young et 
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al., 2008). However, only one included study (Takahashi et al., 1998)examined the relative 
prevalence of OSA in people with schizophrenia compared to general population controls using 
a case-control methodology. This study reported no difference in relative prevalence, but was 
potentially confounded by the low mean BMI in both groups. Interestingly the general 
prevalence of OSA in the control group was 22.9%, which is substantially higher than would 
be expected in the general population. Another study, not included in this review, examining 
case records in a large cohort of US veterans (Sharafkhaneh et al., 2005) reported a significant 
odds ratio of OSA in a psychosis cohort of 1.49 compared to other patients without psychosis. 
However, this study did not base a diagnosis of OSA on PSG, utilised opportunistic screening 
and did not include information on non-Veteran’s Health Administration healthcare contact, 
potentially reducing the observed prevalence of OSA (1.6% in that study) given that up to 80% 
of OSA remains undiagnosed despite adequate access to healthcare (Kapur et al., 2002; Young 
et al., 1997). Further evaluation of the relative prevalence of OSA in future research would be 
valuable as a means of clarifying the extent to which OSA is driven by shared risk factors 
between people with schizophrenia and the general population. 
Age, BMI >25 and male sex were significantly associated with OSA in people with 
schizophrenia or schizoaffective disorder in two studies (Anderson et al., 2012; Winkelman, 
2001) and an association with neck circumference was reported in one study (Anderson et al., 
2012).These findings are consistent with American Academy of Sleep Medicine general 
population guidelines,(Epstein et al., 2009) that identify BMI and increased neck 
circumference as primary predictors of OSA. Similarly the STOP-BANG questionnaire 
(Chung et al., 2008) utilises criteria of BMI >35, age >50 years, neck circumference >40cm 
and male sex, along with observed apnoeas, hypertension, snoring, and symptoms of daytime 
sleepiness, with a reported sensitivity of 70.9% for OSA in the general population. This 
provides indirect evidence that general screening tools and guidelines would be useful in 
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identifying at-risk patients at the clinical level, with the caveat that as yet such screening tools 
have not yet been specifically validated in this population.  The literature reviewed here also 
suggests BMI at a lower cut-off of >25 constitutes a risk factor in comparison to the general 
population where BMI >35 is considered to confer increased risk.  
Interestingly the one study (Anderson et al., 2012) that examined measures of daytime 
sleepiness using the ESS and PSQI reported lower levels of daytime sleepiness in people with 
schizophrenia compared with general population controls (Johns, 1991). This observation is 
supported by other literature (Rishi et al., 2010) reporting that a minority of patients with 
schizophrenia and comorbid OSA reported sleeping difficulties or snoring prior to diagnosis. 
These findings lend weight to the suggestion that OSA may be particularly under-recognised 
in schizophrenia. People with schizophrenia are less likely to have an intimate partner 
observing nocturnal symptoms (given just 10.9% of community patients are in de-facto or 
married relationships, (Morgan et al., 2011)). Partner reports of snoring, pausing and daytime 
somnolence may therefore be less useful for developing a risk profile for OSA in people with 
schizophrenia, compared to the general population.  People with schizophrenia and related 
disorders have high rates of unemployment, which may limit witnessed daytime somnolence 
(Waghorn et al., 2012). Furthermore clinicians or patients may discount sleep symptoms as a 
side effect of antipsychotic medication. The evidence suggests an emphasis be placed on 
physical risk factors rather than symptoms such as daytime sleepiness for identification of OSA 
in people with schizophrenia. 
The literature reports an inconsistent association between antipsychotic and hypnotic use, and 
OSA, which is likely confounded by variability in measures of medication use across the 
available studies. Antipsychotic medications possess sedative and hypnotic properties that may 
superficially improve insomnia in some patients but could potentially contribute to daytime 
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somnolence and negatively impact sleep-wake cycle regulation.  Previous literature 
demonstrating patients taking antipsychotic medications have higher prevalence (Shirani et al., 
2011) and severity of OSA (Rishi et al., 2010) suggests antipsychotic medications could play 
an aggravating role in people with schizophrenia and comorbid OSA.  Similarly no clear 
association was reported between hypnotic use and OSA in the included studies potentially as 
a result of inconsistent and clinically non-relevant measures of medication use. However there 
is a recognised association between benzodiazepine use and OSA in the general population 
(Dolly and Block, 1982; Hanly and Powles, 1993).  Prescription of hypnotic medication is 
common in schizophrenia however the degree to which this increases risk or severity of OSA 
is yet to be determined.  Whilst physiological sleep changes are recognised in schizophrenia 
(Cohrs, 2008; Keshaven et al., 1995; Monti and Monti, 2004; Wilson and Argyropoulos, 2012), 
the aetiological role of neurobiological determinants and antipsychotic or hypnotic treatment 
effects on the development of OSA are as yet unclear and require further evaluation.   
No study was identified that assessed patients before and after treatment of OSA to determine 
impact on physical health, psychopathology or other domains of function in people with 
schizophrenia. In the general population OSA is associated with depression, anxiety, reduced 
quality of life and decrements in daytime work performance owing to fatigue or sleepiness (Lal 
et al., 2012; Patil et al., 2007); whilst treatment of OSA with CPAP has demonstrated efficacy 
in improving quality of life (Rizzi et al., 2014). OSA could potentially compound the negative 
symptoms of amotivation, apathy and social withdrawal in schizophrenia and could contribute 
to poorer prognostic outcomes. In people with OSA, treatment with CPAP might therefore 
improve negative symptoms, mood, cognition, and functional capacity. Investigating this 
hypothesis, and the acceptability of, and adherence to CPAP treatment in this population should 
also be a research priority.  
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We suggest that OSA screening be considered as part of the physical health assessment of 
people with schizophrenia. OSA is potentially under-recognised, may be an additive risk factor 
for poor physical health in this population and treatment has the potential to improve 
cardiovascular risk and quality of life. Based on the available literature OSA screening should 
be conducted with emphasis on neck circumference >40cm, obesity, male sex, age >50, loud 
snoring, and apnoeas.  The OSA50 (Chai-Coetzer et al., 2011) is an appropriate tool for this 
purpose and has been validated in the general population in a primary care setting. An OSA50 
score ≥5 should prompt referral for PSG as the preferred diagnostic test. We propose sleep 
symptoms as a subordinate criterion for consideration for referral for PSG, given patients with 
schizophrenia are unlikely to report symptoms of daytime sleepiness, these symptoms may be 
confounded by medication side effects or psychiatric symptoms, and most lack partners to 
report snoring or nocturnal apnoeas. 
The available evidence suggests that OSA is more prevalent in people with schizophrenia than 
in the general community, but may be under-recognised. Screening for OSA should be included 
in the physical health assessment of people with schizophrenia. It is possible that treatment is 
a means of modifying cardiovascular risk and improving symptoms and psychosocial 
functioning.  Further research should be directed towards estimates of OSA prevalence in 
community samples with stable schizophrenia, validation of OSA screening tools in this 
population and investigation of OSA treatment outcomes specifically focussing on whether 









Table 1: Studies reporting prevalence of OSA in populations of patients with 
schizophrenia 
Study Population Diagnostic measure OSA criteria Prevalence 
Anderson et al. 
2012 
52 outpatients with 
major mental illness, of 




Polysomnography Severity based 
on AHI 
Mild – AHI 5-15 
Moderate – AHI 
15-30 







46 inpatients with 
schizophrenia or 
schizoaffective disorder 
considered at high risk of 
OSA referred to sleep 
disorders clinic 
Polysomnography RDI >10 57.1% in males 
46.2% in females 
Ancoli-Israel et 
al. 1999 
52 geriatric outpatients 
(mean age 59.6 years) 




RDI >10 48% prevalence 
Takahashi et al. 
1998 
101 inpatients with 
schizophrenia 
Overnight oximetry DI 21.9% in males 
13.5% in females 
Abbreviations: AHI apnoea-hypopnoea index as defined by AASM (Kushida et al., 2005); RDI respiratory 
desaturation index defined as defined by ASDA criteria (ASDA, 1992) (Timms RM, 1988), DI desaturation index 
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